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Parkinson’s disease 
Idiopathic Parkinson’s disease (PD) is the second most common neurodegenerative 
disorder after Alzheimer’s disease. The first symptoms usually become manifest 
between 50 and 60 years of age (Wolters, van Laar, & Berendse, 2007). In general, the 
incidence and prevalence rates rise with increasing age, with males being more 
affected than females (females ≥40 years 37.55 per 100.000 person-year, males ≥40 
years 61.21 per 100.000 person-year) (Hirsch, Jette, Frolkis, Steeves, & Pringsheim, 
2016; Pringsheim, Jette, Frolkis, & Steeves, 2014). The prevalence of Parkinson’s 
disease worldwide is 315 per 100.000 persons (Pringsheim et al., 2014). 
The clinical presentation of PD is predominantly characterised by motor 
symptoms, such as bradykinesia (slowness and diminished amplitude of movement), 
akinesia (loss of movement), resting tremor, rigidity and postural instability (Jankovic, 
2008). However, also a variety of non-motor symptoms such as cognitive 
impairments, neuropsychiatric symptoms (e.g. depression, hallucinations), autonomic 
dysfunctions (e.g. orthostatic hypotension), sleep disorders and fatigue can occur in 
PD (Lohle, Storch, & Reichmann, 2009). Non-motor symptoms may disproportionately 
magnify disability, increase the need for supervision, and affect emotional aspects of 
the relationship with a caregiver (Mosley, Moodie, & Dissanayaka, 2017). The PD 
symptoms are especially caused by a progressive degeneration of dopamine 
producing neurons in the substantia nigra and the ventral tegmentum, which belong 
to the basal ganglia (Wolters et al., 2007; Zgaljardic et al., 2006). Also, alterations in 
the noradrenergic, serotonergic and cholinergic transmitter systems play a role in the 
etiology of the disease. 
The substantia nigra and ventral tegmentum are key elements of the 
frontostriatal circuits. The dopamine driven frontostriatal circuits in PD can be divided 
in a “sensorimotor circuit”, an “associative, cognitive circuit” and a “limbic circuit” 
(see figure 1). In each of these circuits, specific parts of the frontal cortex (motor and 
premotor frontal areas, dorsolateral prefrontal cortex and orbitofrontal cortex) are 
connected to specific parts of the striatum and subsequently to functionally 
segregated parts of other structures within the basal ganglia (e.g. pallidum, 
subthalamic nucleus and thalamus) in a topographical manner. The sensorimotor 
circuit is important for motor behaviour, the associative, cognitive circuit is involved in 
cognitive and executive functions (such as initiative and drive) and the limbic circuit is 
related to regulation of emotional and decision-making aspects of behaviour 
(Zgaljardic et al., 2006). Thus, if the dopaminergic input is decreased over time in 
patients with PD, this will have an impact not only on motor function, but also on 
cognition and behaviour. However, Bohnen and colleagues (2018a; 2018b) 
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demonstrated that cognitive decline is more severe when there is also disintegration 
of the cholinergic system.  
 
 
Figure 1. Functional organisation of the basal ganglia. The basal ganglia are divided into motor 
(A), associative (B), and limbic (C) subregions, which are topographically segregated, as 
highlighted by areas coloured in red (motor cortex), green (prefrontal cortex), and blue 
(anterior cingulate cortex). Figure reprinted from Obeso and colleagues. GPe=globus pallidus 
pars externa. GPi=globus pallidus pars interna. STN=subthalamic nucleus. (Rodriguez-Oroz et al., 
2009). 
Cognitive impairments in Parkinson’s disease 
In patients with PD about 25% show mild cognitive impairment (MCI) at onset, with 
increasing frequency rates (39.4%) as disease severity progresses (Kalbe et al., 2016). 
The presence of MCI is of clinical relevance, since it has been found to predict the risk 
of developing PD dementia (Domellof, Ekman, Forsgren, & Elgh, 2015). According to 
the Movement Disorders Task Force criteria, MCI is defined as 1) a gradual decline in 
cognitive ability reported by either the patient or informant or observed by the 
clinician, 2) cognitive impairments on neuropsychological testing or a screening of 
global cognitive abilities and 3) cognitive impairments that are not sufficient to 
interfere significantly with daily life functioning (Litvan et al., 2012). MCI can be 
subdivided into single versus multiple domain MCI and amnestic versus non-amnestic 
MCI, based on the specific profile of cognitive impairments within the domains of 
memory, executive functions (EF), attention, visuospatial functions and language. In 
the study of Kalbe et al. (2016), MCI single domain was operationalised as one 
impaired test result (i.e. at least 1.5 SD < normative mean) within one cognitive 
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domain and MCI multiple domain as at least one affected test result in at least two 
domains. If impairments were found related to memory tests, MCI was defined as 
amnestic. Findings showed that 39.4% of the MCI subtypes were non-amnestic single 
domain, 30.5% amnestic multiple domain, 23.4% non-amnestic multiple domain and 
6.7% amnestic single domain. Thus, findings indicate that the MCI non-amnestic 
subtype is more frequently found than the amnestic subtypes. EF appeared to be the 
most affected cognitive domain (Kalbe et al., 2016), which is in line with previous 
findings (Moustafa & Poletti, 2013; Muslimovic, Post, Speelman, & Schmand, 2005).  
Executive functions 
Given that the dopaminergic frontostriatal networks become dysfunctional in PD, it is 
not surprising that impairments in executive functions (EF), which are predominantly 
regulated by prefrontal areas, are frequently observed in PD (Jurado & Rosselli, 2007; 
Zgaljardic et al., 2006). These impairments are frequently present in the early stages 
of the disease and are even observed in newly diagnosed patients (Dirnberger & 
Jahanshahi, 2013; Elgh et al., 2009; McKinlay, Grace, Dalrymple-Alford, & Roger, 2010; 
Muslimovic et al., 2005). 
EF enable us to behave in a goaldirected way, to set and achieve realistic life 
goals and to adapt our behaviour to changing conditions (Burgess & Simons, 2005; 
Lezak, 1982). EF are mainly required in new, non-routine and complex situations. EF is 
an umbrella term encompassing several aspects, but to date still no consensus has 
been reached on which specific functions are defined as EF (Jurado & Rosselli, 2007). 
There is no uniformity of the concept EF, as shown in a review which detected 68 
different definitions of subcomponents of EF in 60 different studies (Packwood et al. 
(2011). 
However, we will use in this thesis a more condensed definition of EF, which 
distinguishes eight essential and clinical relevant aspects of EF: self-awareness of 
strengths and needs, realistic and concrete goal-setting, planning the steps to these 
goals, self-initiating these plans, self-monitoring and evaluating performance 
according to plan and goal, self-inhibiting behaviour not leading to the goals set, 
flexibility and problem solving when situations cannot be dealt with according to plan 
and strategic behaviour (Ylvisaker, (1998).  
Neuropsychological assessment of executive functions 
Measurement of EF is quite challenging, using either objective and/or subjective 
methods. Neuropsychological tests are commonly used to measure impairments in EF 
in an objective way, as opposed to questionnaires, that can be considered as more 
subjective. A neuropsychological test setting is a standardised environment which 
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offers structure by administering neuropsychological tests in a fixed order and 
providing patients with detailed instructions (including cues to initiate behaviour). 
Also, external distractions are minimised in order to optimize patients’ focused 
attention on task execution. In case of measuring EF this is disadvantageous, since EF 
are especially required in non-routine, complex and unstructured situations, in which 
one needs to make a plan of action and self-initiate this plan. Standard 
neuropsychological tests, such as the Trail Making Test and Stroop Color-Word test 
might therefore not tap the aspects of EF in the same way as they are tapped in 
everyday life situations. This implies that the ecological validity of standard 
neuropsychological tests might be rather low (Burgess et al., 2006; Manchester, 
Priestley, & Jackson, 2004). The Behavioural Assessment of the Dysexecutive 
Syndrome (Wilson, Alderman, Burgess, Emslie, & Evans, 1996b) has been specifically 
designed as a test battery for EF with a higher ecological validity. Its predictive value 
for functioning in everyday life is still limited, although higher than using standard 
tests (Norris & Tate, 2000; Wood & Liossi, 2006).  
Questionnaires (e.g. Dysexecutive Syndrome (DEX)) measure the extent to 
which patients and/or their significant others actually experience executive 
impairments in everyday life and to what extent they experience this as burdensome. 
Although these measures are subjective, they might give a better view of EF problems 
in everyday life than is provided by neuropsychological tests. However, a general 
problem of this subjective method is, that in case patients have impaired self-
awareness (which is part of EF dysfunctions and common among neurological patient 
groups) they tend to underestimate their executive problems and as such are not able 
to give an accurate representation of their actual functioning. Proxy-reports of 
patients’ significant others are in this case essential. In a previous study no evidence 
was found that impaired self-awareness played a role in the assessment of EF in 
patients with PD, since no significant difference was found between patient and proxy 
reports of the DEX (Koerts et al., 2012).  
Impact of EF on everyday life functioning and QoL of 
patients with PD 
Previous studies have shown that in patients with PD several executive dysfunctions 
can occur. Deficits in internal control of attention, set shifting (i.e. flexibility), 
planning, inhibition, conflict resolution (i.e. problem solving), impairments in dual task 
performance (i.e. multitasking) and impairments on a range of decision-making and 
social cognition tasks are being most frequently reported (Dirnberger et al., 2013). 
These EF are essential for performing goal-directed behaviour in daily life. Therefore it 
is not surprising that patients with PD and executive dysfunctions become increasingly 
529605-L-sub01-bw-Vlagsma
Processed on: 11-3-2019 PDF page: 12
 
chapter 1 
 
12 
impaired in planning, organizing and executing daily life activities (Bronnick, 2006). 
Patients need to plan and execute daily task more sequentially and controlled, 
because the required capacities for parallel and automatic processes of multitasking 
become impaired (Koerts et al., 2011). For example, walking while performing another 
task (e.g. phone someone), managing medication intake at fixed time intervals in 
relation to eating and drinking or driving (Bronnick et al., 2006; Manning et al., 2012; 
Wu, Hallett, & Chan, 2015) can become very challenging activities. Patients with PD 
also reported themselves that impairments in EF contribute significantly to a 
decreased independence in everyday life activities (E. Foster & Hershey, 2011) and 
subsequently to a lower Quality of Life (QoL) (Kudlicka, Clare, & Hindle, 2014; Lawson 
et al., 2014a).  
Neuropsychological rehabilitation  
According to the World Health Organization’s International Classification of 
Functioning, Disability and Health (ICF), a disease can affect patients’ functioning on 
different levels: on the functional level (i.e. cognitive or physical impairments), on the 
activity level and on the patients’ level of participation in societal domains (i.e. work, 
social relations, leisure and mobility) (Heerkens, Hirs, de Kleijn-de Vrankrijker, van 
Ravenberg, & ten Napel, 2002). Neuropsychological rehabilitation aims to help 
patients and their relatives to cope with the cognitive, emotional, social and 
behavioural consequences of (acquired) brain injury and, if possible, to improve these 
problems. As shown in figure 2, cognitive rehabilitation is part of the broader field of 
neuropsychological rehabilitation and is specifically aimed at the cognitive 
consequences of brain injury and disease. Cognitive rehabilitation consists of psycho-
education, making practical adjustments to patients’ living environment and cognitive 
training. Cognitive training can aim at improvement at different levels of functioning, 
which are consistent with the levels of functioning as distinguished by the WHO. 
Cognitive training on the functional level (defined as “cognitive training” in chapter 6) 
aims at recovery of underlying cognitive functions by repetitive practise of 
(computerised) tasks that require the use of specific cognitive functions that are 
impaired. Skills training focuses on repetitive training of specific activities in everyday 
life in which patients encounter cognitive impairments. Strategy training involves 
learning cognitive strategies by making use of intact cognitive functions in order to 
help patients compensate for their cognitive impairments in everyday life. Compared 
to function and skills training, strategy training aims to improve patients’ level of 
participation more in general and exceeds the level of improving only specific 
activities in everyday life. 
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Figure 2. Framework of neuropsychological interventions that are used in clinical 
neuropsychology (Kessels, Eling, Ponds, Spikman, & van Zandvoort, 2017).  
In recent literature reviews, cognitive rehabilitation and in particular strategy training 
has been proven beneficial and is recommended as treatment option for executive 
impairments in patients with different types of acquired brain injury (e.g. traumatic 
brain injury and stroke) (Cicerone et al., 2011; Krasny-Pacini, Chevignard, & Evans, 
2013). These treatment programmes include generally session of 1 to 2 hours in 
length over a 3-6 month period, depending on the session frequency (usually once or 
twice a week) (Tate et al., 2014). In patients with neurodegenerative disorders such as 
PD, cognitive rehabilitation is not yet part of the standard therapy. 
Based on the aforementioned topics, the aim of this thesis was to answer 
two main questions. The first question was how impairments in EF in patients with 
Parkinson’s disease could be characterised related to their assessment and how these 
impairments interfere with everyday life. It was hypothesised that impairments in EF 
are mainly apathy driven and can be explained partly by underlying slowness of motor 
and cognitive processes. The other main question to answer was if cognitive 
treatment would improve impairments in EF of patients with PD in everyday life? Our 
hypothesis was that strategy training would be more effective as compared to 
computerised training of specific cognitive functions. 
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Thesis outline 
According to the main research questions, this thesis is divided into two sections. The 
first part, chapter two and three, focuses on the neuropsychological assessment of EF, 
slowness and their interrelationship in patients with PD. The other part (chapter four, 
five and six) centres around the topic of cognitive rehabilitation for impairments in EF 
in patients with PD. Most importantly, the effectiveness of ReSET; a Strategic 
Executive Treatment was evaluated in a group of patients with PD.  
In chapter two it was examined whether patients with PD show mental 
slowness apart from motor slowness. If this was the case, the secondary aim was to 
determine to what extent mental slowness affects patients’ performance on 
neuropsychological tests of attention, memory and EF. 
The first aim of the study in chapter three, was to examine whether 
impairments in EF as objectified with tests are associated with complaints about 
impairments in EF in everyday life, as reported on subjective questionnaires. The 
second aim was to determine to what extent level of participation and QoL of patients 
with PD can be predicted by impairments in EF as measured with objective 
neuropsychological test measures versus subjective questionnaires.  
The main question studied in chapter four is: are there reasonable arguments 
to assume that patients with PD cannot benefit from cognitive treatment programmes 
aimed to improve EF? PD patients’ profile of executive impairments on 
neuropsychological tests and a questionnaire (Dysexecutive Syndrome: DEX), and 
treatment goals related to executive impairments in everyday life were compared to 
the executive profile and goals of patients with ABI, for whom cognitive treatment for 
executive impairments is commonly accepted. 
Chapter five comprises a review of studies that have been conducted on 
cognitive rehabilitation in patients with PD so far (up to 2013). Herewith, we were 
specifically interested in the extent to which the studied cognitive treatment 
programmes focused on improving EF, in whether strategy training was applied and in 
methodological aspects (i.e. methodological quality and type of outcome measures 
that were used). 
Chapter six presents the results of our randomised controlled trial in which 
we investigated according to our hypothesis whether ReSET, a Strategic Executive 
Treatment, is more effective than a computerised function training for aspects of 
attention (Cogniplus) in improving executive impairments in daily life and level of 
participation in PD. 
A general discussion of the preceding chapters is presented in chapter seven. 
The focus is on interpreting the main outcomes of the RCT in terms of their clinical 
relevance. Recommendations for future research are discussed as well. 
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Abstract 
Introduction 
Motor slowness (bradykinesia) is a core feature of Parkinson’s disease (PD). It is often 
assumed that patients show mental slowness (bradyphrenia) as well, however 
evidence for this is debated. The aims of this study were to determine whether 
patients with PD show mental slowness apart from motor slowness and, if this is the 
case, to what extent this affects their performance on neuropsychological tests of 
attention, memory, and executive functions (EF). 
Methods 
Fifty-five nondemented patients with PD and 65 healthy controls were assessed with a 
simple information-processing task in which reaction and motor times could be 
separated. In addition, all patients and a second control group (N=138) were assessed 
with neuropsychological tests of attention, memory, and EF.  
Results 
While patients with PD showed significantly longer reaction times than healthy 
controls, their motor times were not significantly longer. Reaction and motor times 
were only moderately correlated and were not related to clinical measures of disease 
severity. Patients with PD performed significantly worse on tests of attention and EF, 
and for the majority of neuropsychological tests 11-51% of the patients showed a 
clinically impaired performance. Reaction times did not, however, predict patients’ 
test performance, while motor times were found to have a significant negative 
influence on tests of attention.  
Conclusions 
Patients with PD show mental slowness, which can be separated from motor 
slowness. Neuropsychological test performance is not influenced by mental slowness 
however, motor slowness can have a negative impact. When interpreting 
neuropsychological test performance of patients with PD in clinical practice, motor 
slowness needs to be taken into account. 
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Introduction 
The diagnosis of Parkinson’s disease (PD) is based on the presence of motor 
symptoms, with bradykinesia being the single most important diagnostic sign (Wolters 
et al., 2007). Bradykinesia manifests itself as visible slowness and diminished 
amplitude of movement (Hughes, Daniel, Kilford, & Lees, 1992). Slowness is, however, 
assumed to be associated not only with motor behaviour in PD, but with mental 
information processing as well. This mental equivalent of bradykinesia is called 
bradyphrenia or mental slowness (Revonsuo, Portin, Koivikko, Rinne, & Rinne, 1993; 
Wolters et al., 2007). 
The presence of mental slowness in patients with PD is, however, a subject of 
discussion. Several studies found evidence for the presence of mental slowness 
(Berry, Nicolson, Foster, Behrmann, & Sagar, 1999; Gauntlett-Gilbert & Brown, 1998; 
Hsieh, Chen, Wang, & Lai, 2008; Muslimovic et al., 2005; Revonsuo et al., 1993; 
Sawamoto, Honda, Hanakawa, Fukuyama, & Shibasaki, 2002), whereas other studies 
could not demonstrate mental slowness in PD (Duncombe, Bradshaw, Iansek, & 
Phillips, 1994; Helscher & Pinter, 1993; Phillips et al., 1999). A possible explanation for 
this lack of consensus is that a broad variety of measures is used to assess speed of 
information processing as an indication of mental slowness. Some measures also 
include the measurement of higher order cognitive functions such as memory or 
executive functions (EF) (Albinet, Boucard, Bouquet, & Audiffren, 2012). Furthermore, 
previously many studies aimed to assess speed of information processing as an 
indication of mental slowness, but used measures that also included a manual motor 
response. However, in terms of neural networks, a global distinction can be made 
between the central processes of planning, preparing, and initiating a motor response 
and the physical execution of that manual motor response (i.e. peripheral nervous 
system). The central processes primarily involve activity in the prefrontal cortex, the 
supplementary, premotor cortex and the primary motor cortex, whereas the actual 
motor response involves primarily muscle activity in the arm and hand (Wolters et al., 
2007). Since peripheral motor dysfunction is common in certain patient populations 
(e.g. patients with dystonia, Huntington’s disease, and PD), it is crucial to distinguish 
between the assessment of speed of mental information processing and motor speed 
(Salthouse, 1994; Salthouse, 1996) when determining actual mental slowness. For this 
purpose, information-processing tasks that allow differentiation between reaction 
time (i.e. measure of information processing speed as an indication of mental 
slowness) and motor time are preferred to more standard neuropsychological tests 
that include manual or verbal motor activity (e.g. Trail Making Test or Stroop), which 
do not allow disentanglement of both components. To our knowledge, such tasks 
have not yet been applied to study the concepts of mental and motor slowness in 
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patients with PD. Therefore, our main objective was to examine whether mental and 
motor slowness could be measured separately and consequently whether these can 
be differentiated from each other in patients with PD using such a paradigm. Based on 
the assumption that bradykinesia and bradyphrenia are characteristic clinical signs of 
PD, we expect this to be demonstrated by longer motor as well as longer reaction 
times of patients with PD than of healthy controls. On the other hand, since we 
assume bradykinesia and bradyphrenia to be distinguishable concepts, it is 
hypothesised that motor and reaction times can be correlated, but do not show a 
one-to-one relationship. 
Furthermore, if patients with PD exhibit mental slowness, the second aim is 
to determine to what extent this mental slowness influences the performance on 
neuropsychological tests. Neuropsychological tests are frequently used for the 
assessment of cognition in patients with PD and have demonstrated that cognitive 
impairments, especially within the domains of attention, memory, and EF, are 
common in this group (Elgh et al., 2009; Muslimovic et al., 2005). However, the 
majority of tests contain either a direct (outcome is measured as time of completion, 
e.g.: Trail Making Test) or an indirect (presentation of stimuli at a fixed pace, e.g.: Rey 
Auditory Verbal Learning Test) speed component. It seems therefore likely that 
impaired performances of patients with PD on such tests can, at least partially, be 
explained by their mental slowness. So far, only a small number of studies 
investigated the influence of mental slowness on cognitive test performance. Both 
Albinet et al. (2012) and Salthouse (1992) showed that mental slowness (partially) 
accounted for healthy participants’ age-related differences in cognitive test 
performance. Moreover, differences on tests for focused and divided attention 
between patients with traumatic brain injury and healthy controls disappeared when 
scores were controlled for mental slowness (Spikman, van Zomeren, & Deelman, 
1996). Only one study investigated the role of mental slowness in patients with PD 
and concluded that mental slowness was not related to executive functioning 
(Liozidou, Potagas, Papageorgiou, & Zalonis, 2012). Knowledge about the influence of 
slowness on neuropsychological tests performance is crucial in clinical practice, since 
it has to be determined whether impaired test performance can be interpreted as 
deficits of memory, attention and EF, or has to be attributed to slowness of 
information processing. Since most neuropsychological tests require also manual or 
verbal motor activity, the effect of motor slowness on neuropsychological test 
performance is examined as a subquestion. Finally, it is determined to what extent 
motor slowness, as measured with an information-processing task, and motor 
symptoms and disease severity, as measured with more clinical measures (Unified 
Parkinson’s Disease Rating Scale motor section UPDRS-III, and the Hoehn and Yahr 
scale H&Y) are associated. 
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Methods 
Participants 
Fifty-five patients with idiopathic PD who were diagnosed according to the UK 
Parkinson’s Disease Brain Bank Criteria were included. Exclusion criteria were 
dementia (i.e. SCales for Outcomes in PArkinson’s disease-COGnition, SCOPA-COG, 
score ≤17;) (Verbaan et al., 2011) and other severe neurological and psychiatric 
comorbid conditions. Patients were recruited at the Department of Neurology of three 
medical centres in The Netherlands. Neuropsychological assessment was conducted 
while patients were on their regular dopaminergic medication and in the on phase. 
Four patients were not on dopaminergic therapy, and two patients did not report 
their current medication use. Furthermore, five patients underwent Deep Brain 
Stimulation (targets: subthalamic nucleus N=3, globus pallidus N=1, thalamus N=1), 
which was performed more than one year prior to study inclusion. A Levodopa 
equivalent daily dose(LEDD) was calculated for all patients who were on dopaminergic 
medication (Esselink et al., 2004). The UPDRS-III and the H&Y scale were used to 
assess disease severity. Patients in H&Y stages 4 and 5 were not included in this study. 
The study was approved by the medical ethical committee and was conducted in 
accordance with the declaration of Helsinki. All patients gave written informed 
consent. 
In addition, data of two healthy control groups were used that came from 
several sources. Exclusion criteria were major neurological diseases and/or psychiatric 
disorders. One control group (HC1: N=65) was assessed with the simple information-
processing task (see below for a detailed description of this task); data were provided 
by Schuhfried GmbH test company, Vienna, Austria. PD patients’ performances on 
neuropsychological tests were compared to data of a second group of healthy 
controls (HC2), who were assessed with all neuropsychological tests that were used in 
the present study, except for the simple information-processing task. HC2 was 
composed out of healthy controls that were included in our previous studies. For tests 
of attention, memory and EF the number of controls with available data ranged from 
N= 77 (Stroop) to N= 136 (Zoo map). For the Rey Auditory Verbal Learning Test 
(RAVLT), data of 32 controls were available. Table 1 shows descriptive variables and 
disease characteristics of patients with PD and both healthy control groups. Level of 
education of all participants was classified on a 5-point scale ranging from (1) 
uncompleted or special education: < 9 years of education, to (5) completed university 
(of applied sciences).  
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Table 1. Descriptive and disease characteristics of PD patients and healthy control groups. 
 PD HC1 HC2 
 M (SD) Range M (SD) Range M (SD) Range 
Age in years 61.0 (9.5) 42 - 79 63.1 (5.1) 55 - 80 59.0 (7.6) 38 - 87 
Education 4.0 (1.0) 2 - 5 3.0 (1.0) 2 - 5 3.0 (1.0) 2 - 5 
Sex             
     Male n (%) 36 (65.5)   41 (63.1)   72 (52.2)   
     Female n (%) 19 (34.5)   24 (36.9)   66 (47.8)   
UPDRS-III 21.2 (8.2) 8 - 46         
H&Y 2.5 (0.5) 1 - 3         
LEDD 731.3 (457.8) 0 - 2080.0         
SCOPA-COG 28.8 (4.4) 19 - 37         
Note. Educational level was classified on a 5-point scale; 1= unfinished or special education, < 9 
years of education, 5= Bachelor or Master’s degree. PD = Parkinson’s disease; HC = healthy 
controls; UPDRS-III = Unified Parkinson’s Disease Rating Scale Part III, motor section, range = 0-
108 maximum; H&Y = Hoehn and Yahr scale, range = 0-5 maximum; LEDD = levodopa equivalent 
daily dose. SCOPA-COG= SCales for Outcomes in PArkinson’s Disease – COGnition, range = 0-43 
maximum.  
 
Neuropsychological assessment 
Speed of information processing 
The simple information-processing task (S1 condition) of the Vienna Test System 
(Prieler, 2008) was used to measure reaction time and motor time separately. During 
the task, the participants’ dominant index finger rested on a key (rest key). A black 
circle was constantly present in the middle of the lower half of the screen and as soon 
as this circle turned yellow, participants were instructed to lift their index finger and 
to press the response key as fast as possible. The distance between the rest key and 
the response key was 5.5 cm. The interstimulus interval ranged between 1.5 to 6.5 s, 
and the duration of the presentation of the yellow circle was 1 second. The task 
consisted of five practise trials and 28 test trials. For each participant, two scores were 
calculated: (a) mean reaction time (RT), that is, the mean time between the 
appearance of the target stimulus and lifting the dominant index finger over all 
correctly completed trials and (b) mean motor time (MT), i.e. the mean time between 
lifting the dominant index finger and pressing the response key over all correctly 
completed trials. Both reaction time and motor time were measured in milliseconds. 
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Neuropsychological tests of attention, memory, and executive functions 
The Trail Making Test part A (TMT; in seconds) (Reitan, 1958) and the Stroop Word 
Card (in seconds) (Stroop, 1935) were used to assess attention. Short-term verbal 
memory was measured with the Digit Span Forward (total score) (Wechsler, 1987). 
The Rey Auditory Verbal Learning Test (Dutch version; RAVLT) (Deelman, Brouwer, van 
Zomeren, & Saan, 1980) is a verbal memory test that was used to measure immediate 
recall (IR; max. score=75) and delayed recall (DR; max. score=15) of unrelated verbal 
information. EF were assessed with the TMT B/A ratio (Reitan, 1958) and Visual 
elevator (Test of Everyday Attention; TEA, max. score=10) (Robertson, Ward, & 
Ridgeway, V. & Nimmo-Smith, I., 1994), Stroop Color-Word/Color card ratio (Stroop, 
1935), and the subtest Zoo map (total score) of the Behavioural Assessment of the 
Dysexecutive Syndrome (BADS) (Wilson et al., 1996b).  
Statistical analyses 
IBM Statistical Package for the Social Sciences version 22 was used for data analysis. 
Analyses of covariance (ANCOVAs) with age, gender, and level of education included 
as covariates were used to compare the performances of patients with PD and healthy 
controls on the simple information-processing task and neuropsychological tests 
(Table 2 and 3). For statistical analysis an alpha of .05 was applied. In case of multiple 
comparisons (Table 3) a Bonferroni-corrected alpha was used per cognitive domain. 
Furthermore, effect sizes for group differences were calculated (Cohen’s d). 
Correlations were calculated to determine the associations between the RT, MT, 
UPDRS, neuropsychological tests (Pearson’s r), and H&Y (Spearman’s rs). 
Performances of patients with PD and controls on the simple information-processing 
task and other neuropsychological tests were also analysed from a clinical 
perspective, that is, performances on tests were compared to representative 
normative data as provided by the test developers. Performances that fell within the 
lowest 10% of the normative samples were considered as being impaired (Lezak, 
Howieson, Loring, Hannay, & Fischer, 2004). Finally, hierarchical linear regression 
analyses (method: enter) were used to study the influence of speed of information 
processing on patients’ performances on each neuropsychological test separately. The 
assumptions for regression analyses were met. MT (block 1) and RT (block 2) were 
respectively included as independent variables into each model. Scores on tests of 
attention (TMT A and Stroop Word Card), memory (Digit Span Forward and RAVLT), 
and EF (TMT B/A, Stroop ratio, Visual elevator and Zoo map) were dependent 
variables. 
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Results 
Demographic data  
No differences were found between HC1 and patients with PD with regard to age (t = -
1.46, p = .149), gender (χ2 = 0.07, p = .787) and level of education (Mann-Whitney U = 
1617.50, p = .342). Overall, there were also no differences between patients with PD 
and HC2 in age (t = 1.39, p = .167), gender (χ2 = 2.81, p = .093), and level of education 
(Mann-Whitney U = 3232.00, p = .086). The RAVLT subgroup of HC2 (N=32) did not 
differ from patients with PD with regard to age (t = -0.15, p = .878) and gender (χ2 = 
2.01, p = .156). However, level of education was significantly different between this 
subgroup and patients with PD (Mann-Whitney U = 585.50, p = .006). Because the 
results show some trend-level differences between patients and controls and since it 
is known that age, gender and level of education can be of influence on cognitive test 
performance, these demographic variables were included as covariates in further 
analyses. Demographic data are presented in Table 1.  
Simple information-processing task and neuropsychological test 
performance 
In comparison to healthy controls, patients with PD showed a significantly slower RT 
(medium effect size, see Table 2). No differences were found between groups with 
regard to MT. From a clinical perspective, the simple information-processing task 
revealed clinically impaired mental slowness in 11% of patients with PD and clinically 
impaired motor slowness in 7% of patients with PD (performance ≤ lowest 10% of 
normative sample). In the healthy control group, 5% of controls showed clinically 
impaired mental slowness and 6% impaired motor slowness. The percentage of 
impairments did not significantly differ between groups for both mental and motor 
slowness (RT: χ2 = 1.70, p = 0.192; MT: χ2 = 0.38, p = .536). 
 
Table 2. Performances of PD patients and healthy controls on the simple information-
processing task of the Vienna Test System.    
 PD HC1 ANCOVA Covariates ES 
 M (SD) M (SD) F (p) Age Sex Edu d 
Simple information-
processing task 
          
     Motor time 232.73 (78.64) 218.35 (72.19) 1.97 (0.163) ns ns ns 0.19 
     Reaction time 363.53 (84.67) 316.34 (75.93) 10.10 (0.002)* ns ns ns 0.60 
Note. PD = Parkinson’s disease; HC = healthy controls; ANCOVA = analysis of covariance; ES = 
effect size; Edu = education. Times in ms. *p<0.01; covariates. 
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A significant but moderate correlation was found between the RT and MT of the 
simple information-processing task (patients with PD: r = .40, p = .003; controls: r = 
0.41, p = .001). In addition, no significant associations were found between the scores 
on the UPDRS-III and H&Y and the RT and MT (RT and H&Y: rs = .11, p = .465, RT and 
UPDRS: r = .17, p = .227, MT and H&Y: rs = .09, p = .553, MT and UPDRS: r = .23, p = 
.108).  
Table 3 presents the average performance of patients with PD and healthy 
controls on tests of attention, memory and EF. Patients with PD performed 
significantly worse than healthy controls on tests of attention and on the Zoo map. 
Groups did not differ with regard to the performances on other tests of EF and 
memory. However, for six out of nine tests, 11 to 51% of PD patients’ test scores were 
considered as clinically impaired. 
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In Table 4 the univariate associations between MT, RT, and neuropsychological test 
performance of patients with PD are presented. A significant correlation was found 
between MT and the TMT A and Stroop ratio. RT also showed a significant correlation 
with the Stroop ratio. Consequently, hierarchical regression analyses were conducted 
to study whether neuropsychological test scores of patients with PD can be predicted 
from MT and RT. MT and RT were separately included (i.e. MT= block 1, RT= block 2) 
in the regression models to determine their individual contribution to the model.  
 
Table 4. Univariate Pearson’s correlations between MT, RT and 
neuropsychological tests in patients with PD. 
    MT    RT 
Attention   
     TMT A   0.31*   0.16 
     Stroop Word Card   0.25   0.26 
   
Memory   
     Digit Span forward -0.20 -0.02 
     RAVLT IR -0.25 -0.18 
     RAVLT DR -0.13 -0.10 
   
EF   
     TMT ratio   0.16   0.07 
     Stroop ratio    0.41*   0.36** 
     Visual elevator total score -0.10 -0.21 
     Zoo map total score -0.17 -0.05 
Note. PD = Parkinson’s disease; TMT = Trail Making Test; RAVLT = Rey 
Auditory Verbal Learning Test IR = immediate recall; DR = delayed 
recall; TMT ratio = TMT B/TMT A; Stroop ratio = Color-Word/Color 
card; MT = motor time; RT = reaction time; EF = executive functions. 
* p < 0.05, ** p < 0.01. 
Table 5 shows that MT alone appeared to be a significant predictor of performance on 
the TMT A (R2 = 0.09, F(1, 54) = 5.53, p = .022). However, when RT was included the 
model was no longer significant (R2 = 0.10, F(2, 54) = 2.77, p = .072). Furthermore, a 
different pattern was found for the complete model of the Stroop Color-Word/Color 
card ratio. The complete model (including MT and RT) explained a significant 
percentage of variance in the Stroop Color-Word/Color card ratio (R2 = 0.22, F(2, 54) 
=7.10, p = .002), however only MT was found to contribute significantly to the model 
(see Table 5). For the other neuropsychological tests, neither the combination of MT 
and RT nor MT or RT separately were significant predictors of PD patients’ 
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performances. The results of complete models were as follows: attention [Stroop 
Word Card: R2 = 0.09, F(2, 54) = 2.67 , p = .079], memory [Digit Span Forward: R2 = 
0.05, F(2, 54) = 1.24 , p = .298, RAVLT IR: R2 = 0.07, F(2, 54) = 2.00, p = .146 and RAVLT 
DR: R2 = 0.02, F(2, 54) = 0.52, p = .597], and EF [TMT B/A ratio: R2 = 0.02, F(2, 54) = 
0.64, p = .532, Visual elevator: R2 = 0.04, F(2, 51) = 1.12, p = .335 and Zoo map total 
score: R2 = 0.03, F(2, 54) = 0.82, p = .444]. 
Table 5. Predictors of PD patients’ performance on tests of attention and EF 
based on hierarchical linear regression analysis.   
 R
2 R2 change B β t p 
Attention        
     TMT A       
          Constant   31.187  5.80 <0.001** 
          Motor time 0.09  0.052 0.31 2.35 0.022* 
       
EF       
     Stroop ratio       
          Constant   1.093  6.88 <0.001** 
          Motor time  0.17  0.001 0.32 2.38 0.021* 
          Reaction time 0.22 0.05 0.001 0.23 1.74    0.089  
Note. PD = Parkinson’s disease; EF = executive functions; TMT = Trail Making 
Test. Regression analysis, method: enter. *p < 0.05, **p < 0.001 
 
Discussion 
To our knowledge, this is the first study that measures RT and MT separately in order 
to determine whether mental slowness can be differentiated from motor slowness in 
patients with Parkinson’s disease. Patients with PD showed on average a significantly 
longer RT on a simple information-processing task than healthy controls. Surprisingly, 
PD patients’ MTs were not significantly slower than healthy controls. This is 
remarkable since bradykinesia is a core feature of PD. These findings indicate that 
mental slowness can be present in patients with PD in the absence of motor slowness 
and strengthen findings of previous studies that demonstrated mental slowness in PD 
,even though these studies did not use tasks that allowed the differentiation of 
mental and motor slowness (Berry et al., 1999; Gauntlett-Gilbert & Brown, 1998; 
Hsieh et al., 2008; Muslimovic et al., 2005; Revonsuo et al., 1993; Sawamoto et al., 
2002). 
The finding that mental and motor slowness are distinctive constructs was 
also substantiated by the moderate correlations between RT and MT in both patients 
and controls, which indicates that RT and MT only share a relatively small amount of 
529605-L-sub01-bw-Vlagsma
Processed on: 11-3-2019 PDF page: 30
 
chapter 2 
 
30 
variance (i.e. 16%). Interestingly, clinical ratings of motor symptoms and disease 
severity (i.e. scores on UPDRS-III and H&Y scale) were related neither to RT nor to MT. 
A possible explanation for this finding is that standard clinical measures of motor 
symptoms in PD assess motor slowness (i.e. bradykinesia) in a different way from 
reaction time paradigms. The unexpected finding that patients did not show 
significantly slower MTs than healthy controls strengthens this interpretation. The 
UPDRS, for example, assesses motor slowness with several items that do not only ask 
the observer to evaluate the speed of a specific motor action, but also ask them to 
evaluate the amplitude, hesitations, and halts of the action per side of the body. Even 
though the bradykinesia subscale of the UPDRS is a valid measure of motor slowness 
(Buck, Wilson, Seeberger, Conner, & Castelli-Haley, 2011), to our knowledge the 
relation with reaction time paradigms has not been studied so far and may represent 
an interesting subject for future research. 
The second aim of the current study was to determine the influence of 
mental slowness on neuropsychological test performance of patients with PD. This is 
relevant, because the majority of neuropsychological tests include a speed 
component (i.e. in the outcome measure or paced presentation of stimuli). Hence, PD 
patients’ performances on these tests may be negatively influenced by disease-
related mental slowness, which may have consequences for the interpretation of test 
results in clinical practice. The group of patients with PD that was included in the 
present study showed a profile of cognitive impairments that was consistent with 
previous studies (Koerts, Tucha, Lange, & Tucha, 2013; Muslimovic et al., 2005; 
Watson & Leverenz, 2010), indicating that a representative group of patients with PD 
was included. Results of regression analyses showed that RT as an indication of 
mental slowness did not predict PD patients’ performances on any of the 
neuropsychological tests of attention, memory, and EF, which is in line with the 
findings of Liozidou et al. (2012). MT, on the other hand, was found to be a significant 
predictor of PD patients’ performance on TMT A and the Stroop Color-Word/Color 
card ratio. With regard to the TMT A this is not surprising, since this paper-and-pencil 
test involves manual motor activity because it requires patients to search and connect 
succeeding numbers as fast as possible by drawing a line. Regarding the Stroop Color-
Word/Color card ratio it seems that even though we used the ratio score that implies 
to control for the speed component (measured with the Color card), this measure still 
reflects motor behaviour that is, reading words out loud as fast as possible.  
The current study has a few limitations that need to be mentioned. First, the 
heterogeneity of the patient group with regard to treatment (dopaminergic treatment 
N=44; nondopaminergic treatment/treatment unknown N=6; deep brain stimulation, 
DBS, N=5) is a limitation, since dopaminergic treatment and DBS can have positive as 
well as negative effects on cognition (Cools, Barker, Sahakian, & Robbins, 2001; Cools, 
Barker, Sahakian, & Robbins, 2003; Cools, 2006). When comparing, however, the 
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results on descriptive measures and the RT and MT between patients on 
dopaminergic treatment and patients who received DBS or of whom the treatment 
strategies were unknown, no differences were found (data not shown). Furthermore, 
when analysing the MTs, we did not control for possible minor on-off fluctuations. 
Since there were no significant differences between patients and controls regarding 
the MTs of the simple information-processing task, we assume that the minor on-off 
fluctuations did not negatively influence test performance. Another limitation is the 
use of the UPDRS-III total score instead of a sum score of the individual bradykinesia 
items. Since the total score also includes the evaluations of rigidity and tremor, it is 
possible that the association between the UPDRS-III and RT and MT would have been 
different when these items were excluded. Also, the use of normative data, without 
adjustments for age, gender and education, when determining the percentage of 
impaired RTs and MTs in patients with PD and healthy controls can be considered a 
limitation. However, when for example an age-related norm group was used, the size 
of the normative sample would have been substantially smaller. Therefore the use of 
a general norm group was preferred. Since the percentage of impaired performances 
on the simple information-processing task did not significantly differ between patients 
and controls, the sensitivity of the paradigm appears to be insufficient and must be 
considered a limitation. A final limitation is that for patients with PD the exact disease 
duration was not reported in this study. The possible influence of disease duration on 
test performance could therefore not be analysed.  
In conclusion, patients with PD show mental slowness that can be separated 
from slowness of movement. However, this mental slowness did not have an 
influence on the performances of patients with PD on various neuropsychological 
tests for attention, memory and EF. Interestingly, patients showed no motor slowness 
on the simple information-processing task. Also, their MTs were not related to clinical 
measures of disease severity (including bradykinesia), indicating that both measures 
assess motor slowness in a different way. MTs did, however, determine patients’ 
performance on two test measures of which the outcome was measured in terms of 
speed. We tentatively conclude that these findings indicate that mental slowness is 
not a substantial factor that needs to be taken into account when interpreting results 
of patients with PD on these neuropsychological tests. PD patients’ motor speed, on 
the other hand, can be of influence on test performances and needs to be taken into 
consideration in clinical practice. 
Acknowledgements 
We are grateful to Schuhfried GmbH, in particular M. Vetter and R. Debelak, for the 
friendly cooperation and providing normative data for our analyses. 
529605-L-sub01-bw-Vlagsma
Processed on: 11-3-2019 PDF page: 32
 
chapter 2 
 
32 
References 
Albinet, C. T., Boucard, G., Bouquet, C. A., & Audiffren, M. (2012). Processing speed and executive 
functions in cognitive aging: How to disentangle their mutual relationship? Brain and 
Cognition, 79(1), 1-11. doi:10.1016/j.bandc.2012.02.001 [doi] 
Berry, E. L., Nicolson, R. I., Foster, J. K., Behrmann, M., & Sagar, H. J. (1999). Slowing of reaction time 
in parkinson's disease: The involvement of the frontal lobes. Neuropsychologia, 37(7), 787-795. 
doi:S0028-3932(98)00137-7 [pii] 
Buck, P. O., Wilson, R. E., Seeberger, L. C., Conner, J. B., & Castelli-Haley, J. (2011). Examination of the 
UPDRS bradykinesia subscale: Equivalence, reliability and validity. Journal of Parkinson's 
Disease, 1(3), 253-258. doi:10.3233/JPD-2011-11035 [doi] 
Cools, R. (2006). Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in 
parkinson's disease. Neuroscience and Biobehavioural Reviews, 30(1), 1-23. doi:S0149-
7634(05)00054-0 [pii] 
Cools, R., Barker, R. A., Sahakian, B. J., & Robbins, T. W. (2001). Enhanced or impaired cognitive 
function in parkinson's disease as a function of dopaminergic medication and task demands. 
Cerebral Cortex (New York, N.Y.: 1991), 11(12), 1136-1143.  
Cools, R., Barker, R. A., Sahakian, B. J., & Robbins, T. W. (2003). L-dopa medication remediates 
cognitive inflexibility, but increases impulsivity in patients with parkinson's disease. 
Neuropsychologia, 41(11), 1431-1441. doi:S0028393203001179 [pii] 
Deelman, B. G., Brouwer, W. H., van Zomeren, A. H., & Saan, R. J. (1980). Cognitive impairment after 
trauma capitis. In A. Jennekens-Schinkel, J. J. Diamant, H. F. A. Diesfelt & R. Haaxma (Eds.), 
Neuropsychologie in Nederland (pp. 253-282). Deventer: Van Loghum Slaterus. 
Duncombe, M. E., Bradshaw, J. L., Iansek, R., & Phillips, J. G. (1994). Parkinsonian patients without 
dementia or depression do not suffer from bradyphrenia as indexed by performance in mental 
rotation tasks with and without advance information. Neuropsychologia, 32(11), 1383-1396. 
doi:0028-3932(94)00071-9 [pii] 
Elgh, E., Domellof, M., Linder, J., Edstrom, M., Stenlund, H., & Forsgren, L. (2009). Cognitive function 
in early parkinson's disease: A population-based study. European Journal of Neurology : The 
Official Journal of the European Federation of Neurological Societies, 16(12), 1278-1284. 
doi:10.1111/j.1468-1331.2009.02707.x [doi] 
Esselink, R. A., de Bie, R. M., de Haan, R. J., Lenders, M. W., Nijssen, P. C., Staal, M. J., . . . Speelman, J. 
D. (2004). Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD: A 
randomised trial. Neurology, 62(2), 201-207.  
Gauntlett-Gilbert, J., & Brown, V. J. (1998). Reaction time deficits and parkinson's disease.  
Neuroscience and Biobehavioural Reviews, 22(6), 865-881. doi:S0149763498000141 [pii] 
Helscher, R. J., & Pinter, M. M. (1993). Speed and power of higher cerebral functions in parkinsonian 
patients. Journal of Neural Transmission. Parkinson's Disease and Dementia Section, 5(1), 35-
44.  
Hsieh, Y. H., Chen, K. J., Wang, C. C., & Lai, C. L. (2008). Cognitive and motor components of response 
speed in the stroop test in parkinson's disease patients. The Kaohsiung Journal of Medical 
Sciences, 24(4), 197-203. doi:10.1016/S1607-551X(08)70117-7 [doi] 
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992). Accuracy of clinical diagnosis of idiopathic 
parkinson's disease: A clinico-pathological study of 100 cases. Journal of Neurology, 
Neurosurgery, and Psychiatry, 55(3), 181-184.  
Koerts, J., Tucha, L., Lange, K. W., & Tucha, O. (2013). The influence of cognitive reserve on cognition 
in parkinson's disease. Journal of Neural Transmission (Vienna, Austria : 1996), 120(4), 593-
596. doi:10.1007/s00702-012-0916-6 [doi] 
529605-L-sub01-bw-Vlagsma
Processed on: 11-3-2019 PDF page: 33
 
Mental slowness in patients with Parkinson’s disease: associations with cognitive functions? 
 
33 
2 
Lezak, M. D., Howieson, D. B., Loring, D. W., Hannay, H. J., & Fischer, J. S. (2004). Neuropsychological 
assessment. New York: Oxford University Press. 
Liozidou, A., Potagas, C., Papageorgiou, S. G., & Zalonis, I. (2012). The role of working memory and 
information processing speed on wisconsin card sorting test performance in parkinson disease 
without dementia. Journal of Geriatric Psychiatry and Neurology, 25(4), 215-221. 
doi:10.1177/0891988712466456 [doi] 
Muslimovic, D., Post, B., Speelman, J. D., & Schmand, B. (2005). Cognitive profile of patients with 
newly diagnosed parkinson disease. Neurology, 65(8), 1239-1245. 
doi:10.1212/01.wnl.0000180516.69442.95 
Phillips, J. G., Schiffter, T., Nicholls, M. E., Bradshaw, J. L., Iansek, R., & Saling, L. L. (1999). Does old 
age or parkinson's disease cause bradyphrenia? The Journals of Gerontology.Series A, 
Biological Sciences and Medical Sciences, 54(8), M404-9.  
Prieler, J. (2008). Reaction test. Mödling: Schuhfried GmbH. 
Reitan, R. M. (1958). Validity of the trail making test as an indicator of organic brain damage. 
Perceptual and Motor Skills, 8, 271-276. doi:10.2466/PMS.8.7.271-276 
Revonsuo, A., Portin, R., Koivikko, L., Rinne, J. O., & Rinne, U. K. (1993). Slowing of information 
processing in parkinson's disease. Brain and Cognition, 21(1), 87-110. doi:S0278-
2626(83)71007-9 [pii] 
Robertson, I. H., Ward, T.,Ridgeway, V. & Nimmo-Smith, I. (1994). Manual: The test of everyday 
attention. Bury St. Edmunds, England: Thames Valley Test Company. 
Salthouse, T. A. (1994). The nature of the influence of speed on adult differences in cognition. 
Developmental Psychology, 30(2), 240-259.  
Salthouse, T. A. (1996). The processing-speed theory of adult age differences in cognition. 
Psychological Review, 103(3), 403-428.  
Sawamoto, N., Honda, M., Hanakawa, T., Fukuyama, H., & Shibasaki, H. (2002). Cognitive slowing in 
parkinson's disease: A behavioural evaluation independent of motor slowing. The Journal of 
Neuroscience : The Official Journal of the Society for Neuroscience, 22(12), 5198-5203. 
doi:22/12/5198 [pii] 
Spikman, J. M., van Zomeren, A. H., & Deelman, B. G. (1996). Deficits of attention after closed-head 
injury: Slowness only? Journal of Clinical and Experimental Neuropsychology, 18(5), 755-767. 
doi:10.1080/01688639608408298 
Stroop, J. R. (1935). Studies of interference in serial verbal reactions. Journal of Experimental 
Psychology,18, 643-662.  
Verbaan, D., Jeukens-Visser, M., Van Laar, T., van Rooden, S. M., Van Zwet, E. W., Marinus, J., & van 
Hilten, J. J. (2011). SCOPA-cognition cutoff value for detection of parkinson's disease dementia. 
Movement Disorders : Official Journal of the Movement Disorder Society, 26(10), 1881-1886. 
doi:10.1002/mds.23750 [doi] 
Watson, G. S., & Leverenz, J. B. (2010). Profile of cognitive impairment in parkinson's disease. Brain 
Pathology (Zurich, Switzerland), 20(3), 640-645. doi:10.1111/j.1750-3639.2010.00373.x [doi] 
Wechsler, D. (1987). Wechsler memory scale- revised. San Antonio, TX: The Psychological 
Corporation. 
Wilson, B. A., Alderman, N., Burgess, P. W., Emslie, H., & Evans, J. J. (1996). Behavioural assessment 
of the dysexecutive syndrome. Bury St. Edmunds: Thames Valley Test Company. 
Wolters, E. C., van Laar, T., & Berendse, H. W. (Eds.). (2007). Parkinsonism and related disorders (first 
ed.). Amsterdam: VU University press.  
529605-L-sub01-bw-Vlagsma
Processed on: 11-3-2019 PDF page: 34
 
 
 
 
 
 
 
  
529605-L-sub01-bw-Vlagsma
Processed on: 11-3-2019 PDF page: 35
 
 
 
 
 
Chapter 3 

	ǣ

ǫ
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Published as: Vlagsma, T. T., Koerts, J., Tucha, O., Dijkstra, H. T., Duits, A. A., van Laar, 
T., & Spikman, J. M. (2017). Objective Versus Subjective Measures of Executive 
Functions: Predictors of Participation and Quality of Life in Parkinson 
Disease?. Archives of physical medicine and rehabilitation, 98(11), 2181-2187. 
529605-L-sub01-bw-Vlagsma
Processed on: 11-3-2019 PDF page: 36
 
chapter 3 
 
36 
Abstract 
Objectives 
To determine whether objective (neuropsychological tests) and subjective measures 
(questionnaires) of executive functions (EF) are associated in patients with Parkinson’s 
disease (PD),  and to determine to what extent level of participation and quality of life 
(QoL) of patients with PD can be predicted by these measures of EF. 
Methods 
Design: Correlational research design (case-control and prediction design).  
Setting: Departments of neuropsychology of three medical centres in The 
Netherlands.  
Participants: A sample (N=136) of patients with PD (N=42) and their relatives, and 
controls without PD (N=94). 
Main Outcome Measures: A test battery measuring EF. In addition, patients, their 
relatives, and controls completed the Dysexecutive Questionnaire, Brock Adaptive 
Functioning Questionnaire, and Barkley Deficits in Executive Functioning Scale-time 
management questionnaires measuring complaints about EF. Participation and QoL 
were measured with the Impact on Participation and Autonomy scale and the 
Parkinson’s Disease Questionnaire-39, respectively. 
Results 
Patients with PD showed impairments in EF on objective tests and reported 
significantly more complaints about EF than did controls without PD. No associations 
were found between patients’ performances on objective and subjective measures of 
EF. However, both objective and subjective measures predicted patients’ level of 
participation. In addition, subjective measures of EF predicted QoL in patients with 
PD.  
Conclusions 
These findings show that objective and subjective measures of EF are not 
interchangeable and that both approaches predict level of participation and QoL of 
patients with PD. However, within this context, sex needs to be taken into account.  
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Introduction 
Cognitive impairments, including impairments in executive functions (EF), are 
frequently found in patients with Parkinson’s disease (PD) (Kudlicka, Clare, & Hindle, 
2011; McKinlay et al., 2010). Impairments in EF can already be present in newly 
diagnosed patients with PD and have a negative influence on patients’ level of 
participation (Klepac, Trkulja, Relja, & Babic, 2008; Vlagsma et al., 2015) and quality of 
life (QoL) (Kudlicka et al., 2014; Lawson et al., 2014b). EF is an umbrella term that 
encompasses several higher-order capacities important for adequate and 
independent daily living, because they enable us to adapt to new, nonroutine 
situations and to act in a goal-oriented way (Burgess & Simons, 2005).  
Neuropsychological tests are used to measure impairments in EF objectively. 
However, these tests are usually administered in a standardised setting offering a 
large amount of structure; that is, detailed instructions are given and external 
distractions are minimised. Consequently, performances on objective basic 
neuropsychological tests (e.g. Trail Making Test, (Reitan, 1958)) might not reflect 
complex unstructured daily life situations that require higher-order aspects of 
executive functioning (Lezak, 1982), such as goal setting and planning. Therefore, the 
ecological validity of many standard tests of EF is considered to be low (Burgess et al., 
2006; Manchester et al., 2004). The Behavioural Assessment of the Dysexecutive 
Syndrome (BADS, (Wilson, Alderman, Burgess, Emslie, & Evans, 1996a) is a 
neuropsychological test battery consisting of six subtests that is within the field of 
neuropsychology considered to be the most valid ecological measure for EF. The 
predictive value for the BADS for daily life functioning is higher than that for the 
regular EF tests, but still limited (Norris & Tate, 2000; Wood & Liossi, 2006). An 
example of a task that better resembles daily life executive functioning is the 
Executive Secretarial Task (EST) which is performance-based task as it was designed to 
be a simulation of a job assessment procedure (Lamberts, Evans, & Spikman, 2010). 
Also in the field of occupational therapy, performance-based assessments resembling 
daily life tasks (i.e. performance of daily life activities, such as cooking) are performed 
to measure EF in an ecologically valid way (Poulin, Korner-Bitensky, & Dawson, 2013). 
A large drawback of this kind of measures is that their assessment is more time-
consuming than is the case for regular neuropsychological tests; for instance, the 
administration of the EST takes three hours. This makes this kind of performance-
based measures less suitable for use in regular neuropsychological assessment.  
 In contrast to neuropsychological tests that allow objective measurement, 
questionnaires can be used to measure the subjective experience of EF problems as 
well as patients’ and their relatives’ burden related to these EF problems in daily life 
(Koster, Higginson, MacDougall, Wheelock, & Sigvardt, 2015). However, if patients 
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have impaired self-awareness, which is common in neurological disorders, self-report 
questionnaires might not give an accurate representation of patients’ functioning. 
This problem can be partly overcome by using proxy versions, which may also give an 
indication of patients’ self-awareness by comparing judgments of patients and their 
relatives. Furthermore, various other factors might influence self-reports of patients. 
For example, in patients with PD the presence of depression or anxiety has been 
found to have a negative influence on the number and severity of complaints (Koerts 
et al., 2012; Lehrner et al., 2014). The objective and subjective approaches thus 
measure problems in EF from a different perspective, and therefore it is important to 
study their mutual relation. 
Previous studies showed that correlations between impairments in EF, 
measured with objective measures, and complaints about EF, reported on subjective 
measures, are weak in populations of patients with neurological disorders (Chaytor, 
Schmitter-Edgecombe, & Burr, 2006; Fuermaier et al., 2015). For instance, patients 
with PD who report complaints about EF do not necessarily show impairments on 
tests of EF and vice versa (Koerts, Van Beilen, Tucha, Leenders, & Brouwer, 2011; 
Koerts et al., 2012; Kudlicka, Clare, & Hindle, 2013; Lanni et al., 2014). One 
explanation for this weak association is that neuropsychological tests and 
questionnaires measure EF at different levels, because objective tests assess EF in a 
standardised environment and require patients to show an optimal performance, 
whereas questionnaires do not focus on performance, but ask for normal functioning 
in everyday life (Toplak, West, & Stanovich, 2013).  
According to the World Health Organization’s International Classification of 
Functioning, Disability and Health (ICF), (Heerkens et al., 2002), a disease can 
influence a patient’s life on several hierarchical and interrelated levels:  functional 
level (i.e. cognitive or physical impairments), daily life activity level, and participation 
level (i.e. involvement in societal domains such as work and mobility). In this context, 
QoL, defined as the subjective evaluation of various aspects (e.g. health or social 
functioning) of life in the context of one’s needs and expectations, is an important 
concept (Kudlicka, Clare, & Hindle, 2014). Currently not much is known about the 
extent to which ICF levels and QoL are interrelated in PD; for example, to what extent 
do impairments in EF (i.e. functional level) have an influence on level of participation 
and QoL of patients? Therefore, this study aims to determine whether level of 
participation and QoL of patients with PD can be predicted by impairments at a 
functional level, as measured with both objective and subjective measures. It is 
expected that especially the combination of both objective and subjective measures, 
instead of using these approaches separately, will be of added value in predicting 
patients’ level of participation and QoL.  
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Methods 
Participants 
Forty-two patients with idiopathic PD were included, who were diagnosed according 
to the UK Parkinson’s Disease Brain Bank Criteria. Patients were recruited at the 
departments of neurology of three medical centres in the Netherlands. Patients were 
selected by a neurologist during regular consultation hours and were considered 
eligible for participation in this study when they reported problems in EF in daily life 
and had a mild disease severity (Hoehn and Yahr scale (H&Y), stage I-III). Severe 
neurological and psychiatric comorbidities, including dementia (i.e. SCOPA-COG: 
SCales for Outcomes in PArkinson’s disease-COGnition score ≤17) (Verbaan et al., 
2011) formed exclusion criteria. Disease severity was determined with the Unified 
Parkinson’s Disease Rating Scale motor part (part-III) and H&Y. Patients in H&Y stage 4 
and 5 were not included in this study. A Levodopa equivalent daily dose (LEDD) score 
(Esselink et al., 2004) was calculated for all patients receiving dopaminergic 
treatment. Five patients were not on dopaminergic treatment, two patients did not 
report medication use, and two received Deep Brain Stimulation (DBS) which was 
performed at least one year before study inclusion. Patients receiving dopaminergic 
treatment were assessed in the on phase. Furthermore, at the time of inclusion, 11 
patients were employed (of which 5 patients had made adjustments to their work 
activities or hours) and 31 patients were unemployed, either because they reached 
the age of retirement (n=24) or they had decided to quit their jobs before retirement 
age because of their disease (n=7). With regard to the data that were collected from 
proxies, 2 patients were unable to find a life partner or relative willing to participate, 
one daughter of a patient participated, and the other 39 patients found their life 
partner willing to fill out questionnaires.  
In addition, 94 healthy controls were included. No significant differences 
were found between groups with regard to age and level of education, but the groups 
did significantly differ in sex (table 1). This study obtained approval of a medical 
ethical committee in the Netherlands and was conducted in agreement with the 
Declaration of Helsinki. All participants signed an informed consent.  
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Table 1. Descriptive and disease characteristics of patients with PD and healthy controls.  
 PD (n=42) HC (n=94)   
 M (SD) Range M (SD) Range t/U/X
2 P 
Age in years 60.8 (9.9) 42 - 77 58.5 (6.8) 38 - 84 1.31 0.197 
Education  ⱡ 5.6 (1.1) 3 - 7 5.3 (0.9) 3 - 7 1663.50 0.082 
Gender  ≠           3.98 0.046 
     Male  n (%) 27 (64.3)    43 (45.7)      
     Female  n (%) 15 (35.7)    51 (54.3)      
UPDRS III 20.3 (9.5) 8 - 59  -      
H&Y 2.1 (0.6) 1 - 3  -      
LEDD 718.3 (622.3) 0 - 3020.0  -      
SCOPA-COG 29.1 (4.5) 19 - 37  -      
HADS score             
     Anxiety 6.7 (3.3) 2 - 15 4.0 (2.7) 0 - 12   
     Depression 6.1 (3.0) 0 - 13 2.6 (2.6) 0 - 11   
Note. ⱡMann-Whitney U test; ≠ χ2 test; PD=Parkinson’s disease patients; HC=Healthy 
Controls, M=Mean; SD=Standard Deviation; Educational level was classified based on a 7-
point scale; 1=<6 years primary school and 7=university degree; UPDRS motor part 
III=Unified Parkinson’s Disease Rating Scale part III: range 0-108 max.; H&Y scale=Hoehn and 
Yahr scale: range 1-5; LEDD=Levodopa Equivalent Daily Dose; SCOPA-COG=SCales for 
Outcomes in PArkinson’s Disease – COGnition; HADS=Hospital Anxiety and Depression Scale. 
Neuropsychological assessment 
Procedure 
Before the neuropsychological assessment was administered, patients received the 
questionnaires at home. They were asked to fill them out and bring the 
questionnaires with them to their appointment. To minimise the chance that on-off 
fluctuations would occur during the neuropsychological assessment, patients were 
asked beforehand about their medication use and at what time they needed to take 
their medication. The test assistant reminded patients, if necessary, at these time 
points to take their medication to prevent them from going to an off phase, which 
affects cognitive performance. The time from taking dopaminergic medication to the 
start of the tests varied slightly; however, given that all patients were assessed at the 
same time in the morning at the neuropsychology departments of the respective 
hospitals and that patients usually take their first medication when they get up from 
bed, the time between intake of medication and start of the tests was minimised.  
Objective measures of EF  
EF were assessed with the Trail Making Test (TMT) B/A ratio, Stroop Color-Word/Color 
card ratio, Visual Elevator Test total score (a subtest of the Test of Everyday Attention; 
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TEA); total score), Verbal Fluency Test: (total score of 3 letters) and Zoo Map (subtest 
of the Behavioural Assessment of the Dysexecutive Syndrome; BADS): total score.  
Subjective measures of EF  
The Dysexecutive Questionnaire (DEX; total score) was used to assess problems in 
executive functioning in daily life. The “time management” scale of the Barkley 
Deficits in Executive Functioning Scale (BDEFS; total score) was used to measure 
patients’ time management capacities. The scale also includes questions about taking 
initiative and distractibility, because these aspects can influence the time 
management capacities. The Brock Adaptive Functioning Questionnaire (BAFQ; mean 
total score of 12 scales) was used to measure cognitive and behavioural aspects of 
adaptive functioning. All questionnaires consisted of self-rating and proxy-rating 
versions (e.g. completed by the partner). Controls completed only self-rating versions 
of the questionnaires. On all questionnaires, higher scores represent more 
complaints.  
Level of participation and QoL  
The Impact on Participation and Autonomy (IPA) scale (total score on the subscales 
“activities in or around the house” and “social relations”) was used to assess patients’ 
level of participation. Health-related QoL was measured with the Parkinson’s Disease 
Questionnaire-39 (PDQ-39; total score). On both questionnaires higher scores 
represent lower levels of participation or QoL.  
Anxiety and depression 
Symptoms of anxiety and depression were measured with the Hospital Anxiety and 
Depression Scale (HADS; total score and separate scores anxiety and depression 
subscales). 
Statistical analyses 
Analyses of covariance were conducted to compare the groups on neuropsychological 
test measures and questionnaires of EF. Because patients showed significantly higher 
scores on both subscales of the HADS and more men were included in the patient 
group (anxiety subscale: t=4.67, p<0.001; depression subscale: t=6.87, p<0.001) (see 
table 1), HADS scores and sex were included as covariates. Test performances of all 
participants were also analysed from a clinical perspective, that is test scores were 
compared with normative data and considered as being “impaired” when a score fell 
within the lowest 10% of the normative sample (Lezak et al., 2004). Paired-samples t-
tests were used to compare evaluations of patients and their relatives on 
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questionnaires of EF. Furthermore, effect sizes (Cohen’s d) were calculated. 
Associations between objective and subjective measures of EF and measures of 
participation and QoL were analysed using Pearson’s correlations within the patient 
group. Finally, two multiple regression analyses (method: enter) were used to 
determine whether objective and subjective measures can predict level of 
participation (dependent variable: IPA scale) and QoL (dependent variable: PDQ-39) in 
patients. To reduce the number of independent variables, the objective and subjective 
measure of EF showing the highest mean correlation with the dependent variables 
(i.e. IPA scale and PDQ-39) were included in the model. Moreover, the descriptive 
variables age, sex, UPDRS part III total score, and HADS total score (sum score of 
anxiety and depression subscales) were included as predictors. Statistical significance 
was reached at α<.05. In case of multiple comparisons, a Bonferroni correction was 
applied. 
Results 
Performance on objective measures  
Patients with PD performed significantly worse than controls on the Visual Elevator 
Test, when corrected for sex and HADS scores (table 2). No significant differences 
were found between groups on the other test measures of EF, which is consistent 
with the marginal to medium effect sizes. However, from a clinical perspective, 
patients showed a significantly higher percentage of impaired performances than did 
controls on 3 of 5 neuropsychological tests (TMT B/A ratio: χ2=7.61, p=0.006; Visual 
Elevator Test: χ2= 4.09, p=0.043; BADS Zoo Map subtest: χ2=6.33, p=0.012).  
Performance on subjective measures  
Patients with PD reported significantly more problems in EF on the DEX, BAFQ, and 
BDEFS-time management questionnaires than did controls, which is consistent with 
the large effect sizes (see table 2). Comparison of patients’ evaluations with those of 
their relatives showed that patients reported significantly more complaints on the 
BDEFS-time management questionnaire (table 3). Differences between patients and 
relatives on the other questionnaires were not significant. Furthermore, all subjective 
measures of EF were moderately to strongly interrelated (DEX and  BDEFS-time 
management: r=0.45, p=0.004; DEX and BAFQ: r=0.79, p<0.001; BDEFS-time 
management and BAFQ: r=0.57, p<0.001).  
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Table 3. Scores on questionnaires of patients with PD and their relatives (proxy-rating).  
 
Self-rating (n=42) Proxy-rating (n=41) 
Paired samples t-
test 
Effect size 
M (SD) M (SD) t p d 
DEX      26.29 (10.82) 22.02 (13.59) 2.18 0.035 0.35 
BAFQ   2.26 (0.39) 0.51 (0.51) 2.33 0.026 0.31 
BDEFS   45.21 (12.24) 40.29 (14.96) 2.82 0.008* 0.36 
Note. PD=Parkinson’s disease; M=Mean; SD=Standard Deviation; DEX=Dysexecutive 
Questionnaire; BAFQ=Brock Adaptive Functioning Questionnaire; BDEFS=Barkley Deficits in 
Executive Functioning Scale – time management scale; *p < Bonferroni corrected alpha. 
Association between objective and subjective measures of EF 
No significant correlations were found between any of the performances on the 
objective and subjective measures of EF (table 4).  
Contribution of objective and subjective measures of EF to level 
of participation and QoL 
Within the patient group, no significant correlations were found between the 
objective test measures and the IPA scale and PDQ-39. The subjective measures DEX, 
BDEFS and BAFQ, however, were all significantly related to the PDQ-39 (see table 4). 
Furthermore, the scores on the IPA were significantly associated with the scores on 
the BDEFS- time management and BAFQ (see table 4). For subsequent regression 
analyses, the objective and subjective measures that showed the highest mean 
correlation with the dependent variables (i.e. IPA and PDQ-39) were included as 
independent variables (i.e. BADS Zoo Map subtest and BAFQ) in the model (see table 
4 ).  
The regression model explained 78% of variance of the total score on the IPA 
scale (F=7.06, p<0.001). Age, sex, Zoo Map total score, and BAFQ total score were 
significant predictors (table 5). Hence, for patients with PD a combination of a higher 
age, being female, a better Zoo Map score, but more complaints as measured using 
the BAFQ were related to a higher IPA scale score (i.e. a lower level of participation). 
For the PDQ-39, the results showed that the model explained 68% of variance (F=4.13, 
p=0.004). Significant predictors were sex, UPDRS part III total score, and BAFQ score 
(see table 5). Hence, the combination of being female, showing more severe PD 
related motor symptoms, and reporting more problems on the BAFQ was related to a 
higher score on the PDQ-39 (i.e. a reduced QoL) in patients with PD.  
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Table 4. Pearson’s correlations between objective and subjective measures of EF and 
measures of participation and QoL.  
 DEX p Bdefs p BAFQ p IPA p PDQ-39 p 
Objective           
     TMT B/A -0.03 0.856 0.20 0.222 0.14 0.381 0.17 0.314 -0.04 0.793 
     Stroop 3/2 -0.32 0.042 -0.22 0.185 -0.30 0.062 -0.04 0.825 -0.09 0.566 
     Visual elevator -0.04 0.804 -0.08 0.623 -0.05 0.781 -0.03 0.880 -0.15 0.361 
     Verbal fluency 0.02 0.908 0.07 0.692 -0.18 0.280 0.04 0.834 0.03 0.878 
     BADS Zoo Map 0.23 0.140 0.15 0.368 0.15 0.350 0.34 0.033 -0.18 0.262 
Subjective           
     DEX       0.32 0.045 0.39 0.011* 
     Bdefs       0.42 0.007* 0.47 0.003* 
     BAFQ       0.51 0.002* 0.42 0.008* 
Note. TMT B/A = Trail Making Test B/A ratio; Stroop 3/2 ratio = Stroop Color-Word/Color card 
ratio; BADS Zoo map = Behavioural Assessment of the Dysexecutive Syndrome Zoo map subtest; 
DEX = Dysexecutive Questionnaire; BAFQ = Brock Adaptive Functioning Questionnaire;  BDEFS = 
Barkley Deficits in Executive Functioning Scale – time management scale; IPA = Impact on 
Participation and Autonomy, PDQ-39 = Parkinson’s Disease Questionnaire-39; *Significant p-
value < Bonferroni corrected alpha. 
 
Table 5. Results of the multiple regression analyses for the prediction of 
level of participation (IPA) and QoL (PDQ-39) in patients with PD. 
 B β t p 
IPA      
     Constant -30.81  -3.28       0.003** 
     Age 0.22 0.35 2.68       0.012* 
     Gender 6.59 0.52 3.72       0.001** 
     UPDRS part III score -0.01 -0.02 -0.16       0.874 
     HADS total score 0.01 0.01 0.07       0.944 
     BADS Zoo Map total score 0.46 0.37 2.92       0.007** 
     BAFQ 10.81 0.73 3.61       0.001** 
PDQ-39     
     Constant -40.42  -1.11       0.275 
     Age -0.16 -0.08 -0.52       0.606 
     Gender 18.63 0.43 2.72       0.011* 
     UPDRS part III score 0.70 0.32 2.25       0.032* 
     HADS total score 0.24 0.06 0.30       0.767 
     BADS Zoo Map total score -1.00 -0.24 -1.66       0.107 
     BAFQ 28.27 0.57 2.44       0.021* 
Note. IPA=The Impact on Participation and Autonomy; QoL=Quality of Life; 
PDQ-39=Parkinson’s Disease Questionnaire-39; UPDRS = Unified Parkinson’s 
Disease Rating Scale-part III; HADS = Hospital Anxiety and Depression Scale; 
BADS = Behavioural Assessment of the Dysexecutive Syndrome; BAFQ = 
Brock Adaptive Functioning Questionnaire; *p<0.05, **p<0.01.  
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Discussion  
The objective and subjective measures of EF are each good predictors of level of 
participation in daily life and QoL in patients with mild to moderate PD. Both types of 
measurement indicate that patients with PD show difficulties in EF, but without being 
significantly related to each other. On subjective measures, patients reported 
significantly more complaints than did healthy controls, which is in line with previous 
studies (Koerts et al., 2011; Koerts et al., 2012; Koster et al., 2015). Compared with 
relatives, patients reported more problems in executive functioning related to time 
management (BDEFS-time management). Because the BDEFS-time management 
questionnaire includes questions related to time management, initiation of behaviour 
and distractibility, this suggests that patients are bothered with time management 
issues, initiation difficulties, and feelings of distraction that are not (yet) observed by 
their relatives, a finding that is consistent with the study of Lanni et al. (2014). With 
regard to all the other EF questionnaires, no differences were found between self- and 
proxy ratings. Thus, patients and their relatives in general agree on the EF problems as 
experienced by patients in daily life. This has also been found in recent studies and 
supports the idea that patients with PD do not have impaired self-awareness, which is 
usually indicated by lower scores of patients compared to their relatives and thus 
underestimation of problems (Koerts et al., 2011; Koerts et al., 2012; Vlagsma et al., 
2016).  
With regard to objective neuropsychological tests, patients with PD showed a 
higher percentage of impairments than controls on 3 out of 5 tests of EF, which is 
consistent with the fact that impairments in EF occur in PD (Elgh et al., 2009; McKinlay 
et al., 2010; Muslimovic et al., 2005). However, when directly comparing patients with 
PD with healthy controls, patients with PD performed significantly worse only on the 
Visual Elevator Test, but not on other neuropsychological tests. In this context, a 
relatively mild group of patients with PD was included in the present study.  
Notwithstanding these findings, we found no significant associations 
between objective and subjective measures of EF, replicating previous studies (Koerts 
et al., 2011; Koerts et al., 2012; Lanni et al., 2014; Rabin et al., 2006). Apparently, test 
results do not correspond to complaints about EF, indicating that objective and 
subjective assessments measure performance at different levels. A possible 
explanation for this discrepancy is that standard neuropsychological tests of EF have a 
limited ecological validity, because these tests are structured, are standardised, and 
have clearly defined start and endpoints that are not available in daily life. This 
argument cannot, however, explain the nonsignificant association between the Zoo 
Map score (BADS) and the scores on the other questionnaires, because the BADS is 
considered to have a relatively high ecological validity. A better explanation might be 
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that in addition to aspects of EF such as planning and monitoring of behaviour that are 
measured with neuropsychological tests, questionnaires measure behavioural and 
social-emotional aspects. For instance, self-initiation of behaviour, empathy, impulsive 
behaviour, and social monitoring are hard to objectify with neuropsychological tests, 
but can be assessed with questionnaires. Finally, the fact that both approaches 
measure EF at different levels might also be of influence; objective tests target 
patients’ optimal performance, whereas questionnaires ask patients to give their view 
on normal functioning in daily life (Heerkens et al., 2002).  
To determine to what extent objective and subjective assessments of EF can 
predict level of participation and QoL in patients with PD, regression analyses were 
conducted. The combination of a higher age, being female, a better performance on 
an objective test of EF (BADS Zoo Map subtest), and reporting more complaints about 
EF in daily life was related to a significant reduction in level of participation (within the 
domains of household activities and social relations). Higher age having a negative 
influence on patients’ level of participation might be explained by aging usually 
involving a reduction of social relations and increase in health problems, which can 
hamper, for example, the performance of household activities.  
In previous studies on sex in relation to participation and QoL, female 
patients with PD tend to report greater disability, a stronger reduction in social 
functioning and, a lower perceived QoL as compared with male patients (Behari, 
Srivastava, & Pandey, 2005; Heller, Dogan, Schulz, & Reetz, 2014), which is in line with 
our findings. Furthermore, our results show that EF were associated with patients’ 
participation level. However, contrary to what might be expected, we found that a 
better performance of objectively measured impairments in EF was associated with a 
lower level of participation. Even though the contribution of the performance of the 
objective test of EF to the level of participation should be considered in the context of 
all other variables, there is no clear explanation for this finding. It could be that 
patients with a sufficient score on the BADS Zoo Map subtest (that is not indicative of 
impairment) have an intact self-awareness and therefore tend to notice more 
problems in daily life functioning, which, in turn, leads to a lower level of participation 
(Lezak, 1982); however, this finding might also be based on chance. Level of 
participation was also predicted by subjective complaints (BAFQ). Reported 
complaints about EF are thus related to a decreased participation in PD patients’ daily 
life, which supports the conclusions of a previous study (Foster & Hershey, 2011).  
The combination of being female, showing more severe PD related motor 
symptoms, and reporting more complaints about EF was associated with a reduced 
QoL in patients. Interestingly, disease severity appeared to be a significant predictor 
of QoL, which is in line with a previous study (Appleman, Stavitsky, & Cronin-Golomb, 
2011), but it was not related to participation. In addition, just as for participation 
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level, sex differences and subjective complaints about EF were found to be significant 
predictors of QoL. It is not surprising that subjective complaints were a significant 
predictor of QoL, because these also reflect the burden associated with impairments 
in EF, which, in turn, will negatively influence the QoL of patients. This strengthens the 
idea that sex differences and subjective complaints about EF are important aspects 
that need to be taken into account when determining patients’ level of participation 
and QoL. 
Study limitations 
A limitation of the present study is that more severely affected patients with PD (i.e. 
H&Y stage 4 and 5) were not included. It could be that more severely affected patients 
show and report more or other EF impairments and that their level of participation 
and QoL are predicted by different aspects. Furthermore, the heterogeneity of the 
patient group with regard to treatment (i.e. dopaminergic treatment and DBS (n=2)) is 
a limitation. Regarding dopaminergic treatment, this is inherent to PD, and on ethical 
grounds it was not possible to adjust patients’ medication for research purposes. 
Furthermore, recent literature states that there is no convincing evidence for the 
assumption that DBS leads to impairments in cognitive functioning (Mehanna, 2014). 
Given that patients with severe cognitive impairments were excluded, including two 
patients who underwent DBS most likely did not influence the results. 
Conclusions 
Impairments in EF that patients with mild to moderate PD show during the objective 
assessment are not related to complaints about EF in daily life. Both objective and 
subjective measures can, however, predict patients’ level of participation. In addition, 
subjective measures explained a significant part of QoL. These findings indicate that 
the objective and subjective approaches are not interchangeable and each has a 
unique contribution to the assessment of problems in executive functioning and to 
the prediction of participation and QoL of patients with PD. Moreover, sex differences 
need to be taken into account. On the basis of these findings, we suggest to include 
one or more objective and subjective measures of EF as a standard part of assessment 
in patients with PD so as to recognize even mild deficits in EF early and to allow 
offering patients early interventions for these problems. This may foster maintaining 
patients’ level of participation in daily life and related QoL for a longer period, despite 
the progression of the disease.  
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Abstract 
Impairments in executive functions (EF) are the core cognitive impairment in patients 
with Parkinson’s disease (PD). Surprisingly, cognitive rehabilitation is not routinely 
offered to patients with PD. However, in patients with acquired brain injury (ABI), 
cognitive rehabilitation, in particular strategic executive training, is common practice 
and has been shown to be effective. In this study, we determined whether patients 
with PD have different needs and aims with regard to strategic executive training than 
ABI patients, and whether possible differences might be a reason for not offering this 
kind of cognitive rehabilitation programme to patients with PD. Patients’ needs and 
aims were operationalised by individually set goals, which were classified into 
domains of EF and daily life. In addition, patients with PD and ABI were compared on 
their cognitive, in particular EF, profile. Overall, PD patients’ goals and cognitive 
profile were similar to those of patients with ABI. Therefore, based on the findings of 
this study, there is no reason to assume that strategic executive training cannot be 
part of standard therapy in PD. However, when strategic executive training is applied 
in clinical practice, disease-specific characteristics need to be taken into account.  
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Introduction 
Cognitive impairments are frequently documented in patients with Parkinson’s 
disease (PD). In particular impairments of executive functions (EF) are already present 
in mild to moderate stages of PD and can even be observed in newly diagnosed 
patients. Executive dysfunctions are therefore considered a core feature of cognitive 
impairment in PD (Kudlicka et al., 2011; McKinlay et al., 2010; Muslimovic et al., 2005). 
EF are those capacities that enable individuals to adapt to new situations and to 
develop and pursue life goals in a constructive and productive way (Burgess & Simons, 
2005). Impairments in EF can thus lead to a decreased independence in daily life 
functioning.  
Pharmacological treatment, in particular dopaminergic medication, is the 
standard therapy in patients with PD. The literature, however, shows inconsistent 
results regarding whether pharmacological treatment enhances or impairs executive 
functioning (Cools et al., 2001; Cools et al., 2003; Vale, 2008). Nevertheless, it is 
obvious that patients with PD on dopaminergic medication still suffer from 
impairments of EF which they also experience in daily life (Koerts et al., 2011; Koerts 
et al., 2012). However, in clinical practice, admittance to neuropsychological 
rehabilitation programmes is not yet part of standard therapy for patients with PD, 
despite the fact that these programmes have been shown to be effective in other 
patient groups with executive impairments (e.g. in patients with acquired brain injury) 
(Cicerone et al., 2011; Wilson, 2008). This is even more surprising given the fact that 
over the past few years several studies have been conducted that aimed to show the 
effectiveness of cognitive rehabilitation programmes in patients with PD (Edwards et 
al., 2013; Hindle, Petrelli, Clare, & Kalbe, 2013; Mohlman et al., 2010; Mohlman, 
Chazin, & Georgescu, 2011; Naismith, Mowszowski, Diamond, & Lewis, 2013; 
Nombela et al., 2011; Paris et al., 2011; Reuter, Mehnert, Sammer, Oechsner, & 
Engelhardt, 2012; Sammer, Reuter, Hullmann, Kaps, & Vaitl, 2006; Sinforiani, 
Banchieri, Zucchella, Pacchetti, & Sandrini, 2004). Overall, the results of these studies 
lead to the conclusion that cognitive rehabilitation is also a feasible and effective 
treatment option for patients with PD. Especially with regard to impairments of EF, 
one study (Reuter et al., 2012) demonstrated that a multifaceted rehabilitation 
programme consisting of strategy training alongside function and skill training, 
resulted in improvements in daily life functioning and quality of life of patients with 
PD.  
Strategy training of EF aims to teach patients a top-down approach that can 
be adapted flexibly and applies to various executive problems that patients encounter 
in daily life situations, and therefore focuses on improving daily life functioning and 
quality of life of patients with PD (Spikman, J.M. & Fasotti, L., 2012). Cicerone et al. 
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(2011) concluded in their review that cognitive rehabilitation programmes involving 
strategy training have been proven to be the most effective approaches for improving 
EF impairments in patients with ABI, in whom impairments of EF are frequently found 
(Bouwens, van Heugten, & Verhey, 2009; Ertzgaard, Ward, Wissel, & Borg, 2011; 
Evans, 2012). For example, Spikman et al. (2010) showed that patients with ABI who 
received executive strategy training resumed their previous roles in daily life and 
accomplished their individual goals significantly better than patients who received 
computer training. Also, patients with ABI who received executive strategy training 
showed more improvement with regard to setting realistic goals, planning, initiative 
and regulation compared to patients who received computer training.  
Since impairments of EF are common in PD and strategy training has proven 
effective in other patient groups with EF impairments, this raised the question why it 
is not yet common practice to offer strategy training to patients with PD. One of the 
reasons might be that therapists do not consider this as an appropriate treatment 
option because they believe that disease-specific characteristics, such as motor 
impairments, fatigue and the progressive, neurodegenerative nature of the disease, 
might hamper patients with PD to profit from profiting from these rehabilitation 
programmes. Another possibility is that, despite the fact that executive impairments 
are common in patients with PD, it might be that these patients want to accomplish 
different goals and show a substantially different cognitive, in particular EF profile 
than patients with ABI who are admitted to rehabilitation programmes. This might 
lead therapists to believe that cognitive rehabilitation is not a suitable option for 
patients with PD. 
To increase insight into whether this latter possibility is legitimate, it was 
determined whether patients with PD have different individual needs and aims for 
cognitive rehabilitation than a heterogeneous group of patients with ABI, e.g., 
traumatic brain injury (TBI), stroke and other neurological conditions, who 
successfully completed a strategy training. If we find that there are no substantial 
differences between these two groups regarding these aspects, this might lower the 
threshold for offering strategy training to patients with PD. Patients’ needs and aims 
were operationalised by individual goals that patients specified within the context of 
executive strategy training. In addition, to what extent patients with PD show a 
different cognitive, in particular EF, profile than patients with ABI was also examined. 
The heterogeneous group of patients with ABI was chosen as a control group since (1) 
impairments of EF belong to the core cognitive impairments in all these subgroups of 
patients with ABI and (2) because strategic executive training has already been shown 
to be effective in this mixed group of patients with ABI (Spikman et al., 2010).  
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Methods 
Ethics statement 
This study was approved by the medical ethical committee of the University Medical 
Centre Groningen, the Netherlands. All patients voluntarily agreed to participate by 
means of written informed consent and were treated according to the declaration of 
Helsinki.  
Patients 
Original descriptions of rehabilitation goals were available for 73 patients with ABI 
who participated in the study of Spikman and colleagues (2010). These 73 patients 
with ABI (31 with TBI, 31 with stroke, and 11 with other neurological conditions, such 
as cerebral tumours and encephalitis) were included in order to re-analyse their data 
for the purpose of the current study. All patients had been treated in an outpatient 
rehabilitation centre. For a more detailed description of the ABI patients, please see 
Spikman et al. (2010).  
In addition, 26 idiopathic patients with PD were included. These patients 
were either recruited in the Netherlands from the departments of neurology of the 
University Medical Centre Groningen, Maastricht University Medical Centre, or the 
hospital Nij Smellinghe in Drachten. Patients were diagnosed according to the UK 
Parkinson’s Disease Brain Bank Criteria and were assessed while on regular 
dopaminergic medication. A levodopa equivalent daily dose (LEDD) was calculated for 
all patients with PD (Esselink et al., 2004). The severity of the motor symptoms of 
patients with PD was examined using the Unified Parkinson’s Disease Rating Scale part 
three (Fahn & Elton, 1987) and the Hoehn and Yahr (H&Y) scale (Hoehn & Yahr, 1967). 
Patients in H&Y stage 4 (severe disability, still able to walk or stand unassisted) and 
stage 5 (wheelchair bound or bedridden unless aided) were not included. Patients 
with PD were significantly older than patients with ABI (t = -8.30, p<0.001). Groups did 
not differ with regard to gender (χ2 = 0.07, p = 0.796) or level of education (Mann-
Whitney U = 796.50, p = 0.208). Table 1 shows descriptive variables and disease 
characteristics of both patient groups. 
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Table 1. Means (SDs) of descriptive and disease characteristics of ABI (n=73) and PD 
(n=26) patients. 
Patients with ABI Patients with PD 
M (SD) range M (SD) Range 
Age in years 42.7 (13.9) 17 - 65 62.0 (8.6) 48 - 79 
Education 5.0 (1.1) 2 - 7 5.3 (1.3) 2 - 7 
Sex M/F (%) 47/26 (64.4/35.6) - 16/10 (61.5/38.5) - 
UPDRS, part III - - 24.8 (11.4) 10 - 59 
H&Y - - 2.4 (0.4) 1.5 - 3 
LEDD - - 771.0 (400.8) 160 - 1670 
Note. Educational level was classified based on a 7-point scale; 1 ≤ 6 years primary 
school and 7=university degree. Severity of motor symptoms in PD was measured by the 
UPDRS motor part; range 0-108 max. H&Y = Hoehn and Yahr scale (range 0-5). LEDD = 
levodopa equivalent daily dose. UPDRS = Unified Parkinson’s Disease Rating Scale. Please 
see Spikman et al. (2010) for a more detailed description of patients with ABI. 
Study design and procedure 
Both patient groups were assessed within randomised controlled trials (RCT). In the 
study of Spikman et al. (2010), patients with ABI were included if they (1) had a 
minimal post-onset time of 3 months, (2) were aged between 17 and 70 years, (3) 
lived at home, (4) had a history of daily life problems related to impairments in EF 
reported by themselves or their proxies, (5) experienced these impairments as 
burdensome, and (6) were motivated to participate in a cognitive rehabilitation 
programme. Consistent with these criteria, patients with PD or their proxies had to 
complain about problems related to executive dysfunctioning in daily life, had to 
experience these problems as burdensome, and had to be motivated to take part in a 
cognitive rehabilitation programme. Neurological and severe psychiatric comorbidity 
were exclusion criteria in both groups. In addition, severe cognitive comorbidity 
(including screening for dementia) was an exclusion criterion in both groups. The 
other inclusion and exclusion criteria were checked during a semi-structured interview 
with the patient and his or her proxy and on the basis of patients’ medical files. 
Patients with ABI and PD who met the abovementioned criteria underwent 
an extensive neuropsychological assessment, which consisted of several 
neuropsychological tests and a questionnaire. Additional inclusion criteria were a 
standard age score on the Behavioural Assessment of the Dysexecutive Syndrome 
(Wilson et al., 1996a) categorised as “low average” or lower, or a discrepancy 
between this standard age score and premorbid IQ measured by the Dutch Groninger 
Intelligence Test short version (Luteijn & van der Ploeg, 1983) of 15 points, and 
standard scores of 2 or lower on the BADS Six Elements Test or Zoo Map subtests. A 
total score of at least 18 points on the Dysexecutive Questionnaire (Burgess, Wilson, 
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Evans, & Emslie, 1996) was a final inclusion criterion (Spikman et al., 2010). There is a 
more detailed description of these tests and questionnaire below. If patients showed 
impairments on these subjective and/or objective measures of EF, they were 
randomly assigned to the experimental or control rehabilitation group. In both 
conditions, patients were asked to set three individual rehabilitation goals. The 
current study only focuses on these rehabilitation goals.  
Goal descriptions of patients with ABI were retrieved from original patient 
files. Of the patients with ABI, four had only two written goal descriptions in the 
original files and one had five goal descriptions all of which were included for analysis. 
All patients with PD specified three goals, which were also retrieved from their files.  
Neuropsychological measures of executive and general cognitive 
functions  
The following neuropsychological tests and questionnaire were administered in order 
to describe the cognitive and EF profile of patients with ABI and PD.  
Executive functions 
All subtests of the BADS (Wilson et al., 1996a) were administered. The sum of profile 
scores resulted in a standard age score and a related clinical classification. Results of 
the subtests Zoo Map (total score part 1) and Six Elements were further analysed in 
order to study planning behaviour. The ratio B/A in the Trail Making Test (Reitan, 1958) 
was used to measure cognitive flexibility. Patients’ ability to inhibit responses was 
measured by means of the ratio Color-Word card/Word card of the Stroop Color Word 
Test (Stroop, 1935).  
The total score of the DEX questionnaire (Burgess et al., 1996) was used to 
measure subjective complaints related to problems with executive functioning in daily 
life. This questionnaire was completed by patients and their proxies. The difference of 
scores (patient total score-proxy total score) was used as a measure of self-awareness 
(Spikman et al., 2013). In the case of three patients with ABI, a therapist instead of a 
partner or family member completed the proxy version of the DEX.  
General cognitive functions 
The Rey Auditory Verbal Learning Test (Dutch version; RAVLT; (Deelman et al., 1980) 
was administered to study the immediate and delayed recall of unrelated verbal 
information. The total score of the Digit Span forward and backward of the Wechsler 
Adult Intelligence Scale (WAIS; (Wechsler, 1987) was used to evaluate short-term 
verbal memory. Psychomotor speed was measured with the Trail Making Test (TMT; 
(Reitan, 1958) part A and the Word card of the Stroop Color Word Test (Stroop, 1935).  
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Goal classifications  
In order to compare patients’ aims and needs, we classified rehabilitation goals of 
patients with PD and ABI twice: first into domains of EF and subsequently into 
domains of daily life activities. The classification of EF was based on Ylvisaker’s (1998) 
definition and contained the following EF domains; (1) Planning, (2) Regulation, (3) 
Time management, (4) Initiative, (5) Self-Awareness, (6) Other EF (i.e. a goal which 
was related to EF but could not be classified into one of the other domains) and (7) 
Other (i.e. a goal that was not related to EF at all). Regulation included self-monitoring, 
inhibiting irrelevant behaviours, and cognitive flexibility. The category “time 
management” was added to the original definition of Ylvisaker, based on literature 
supporting the idea that a conscious awareness or sense of time is required for goal-
directed behaviour and is therefore a legitimate aspect of EF (Barkley, 2011). Table 2 
presents a detailed description of the classification. 
Table 2. Classification of domains of executive functions.  
Domains of EF Definition 
(1) Planning Goals that are related to mental processes preceding the execution of a task.   
(2) Regulation Goals that apply to the actual process of execution of a task. 
(3) Time management Goals that are explicitly related to deficits in estimating time. 
(4) Initiative Goals that apply to motivating oneself to actually start activities and/or goals 
that are aiming for a positive change compared to the current level of 
activities, such as implementing more different activities or accomplishing 
certain activities more often. 
(5) Self-awareness  Goals that are related to a lack of awareness associated with disease-specific 
deficits.   
(6) General EF Goals that contain 2 or more domains of EF. However, if it is explicitly stated 
which domain has most priority, than the goal can be classified into one of the 
former categories.  
(7) Other Goals that are not related to EF. 
 
The World Health Organization’s International Classification of Functioning, Disability, 
and Health (2002) was used for defining a classification of basic functioning and daily 
life domains (Heerkens et al., 2002). This led to a classification consisting of the 
following domains: (1) Cognitive functioning (non-EF), (2) Executive functioning, (3) 
Physical functioning, (4) Mental functioning and emotion regulation, (5) Self-care, (6) 
Occupation and education, (7) Housekeeping and gardening, (8) Finances and 
administration, (9) Leisure and community life, (10) Mobility, (11) Social relations, and 
(12) Communication. Table 3 shows this classification system in more detail. 
The classification systems were developed in several steps. Three 
independent raters (T.T.V., J.M.S and J.K) classified all rehabilitation goals into 
domains of EF and subsequently into domains of basic functioning and daily life during 
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a first classification round. Since the inter-rater reliability was not sufficient, 
adjustments were made to the definition of domains in both classifications, leading to 
the classification systems as shown in Tables 2 and 3. Subsequently, all goals were 
classified again, a process that resulted in reliable ratings. These final classification 
systems were used by a fourth independent rater (H.T.D.) to classify all rehabilitation 
goals again. The ratings of H.T.D. were reliable when compared to the ratings of T.T.V. 
(see below for information about the inter-rater reliability). The ratings of T.T.V. were 
eventually used for further analyses.  
Table 3. Classification of domains of basic functioning, daily life activities and participation. 
Domains Examples 
1)   Cognitive functioning (non EF) Memory, reaction speed, visual perception, information processing 
2)   Executive functioning Planning, regulation, initiative, attention  
3)   Physical functioning Fatigue, fitness, energy, motor functions  
4)  Mental functioning and emotion 
      regulation 
Self-esteem, self-confidence, nervousness, specific emotions  
5)   Self-care Bathing, shaving, getting dressed, eating and drinking 
6)   Occupation and education Work-day planning, homework, teaching, organising files  
7)   Housekeeping and gardening Cleaning, cooking, mowing, repairs  
8)   Finances and administration Payments, overview income and expenses, use of ATM machine, 
sorting bills 
9)   Leisure & community life Hobbies, holiday, politics, religion  
10) Mobility Driving, public transport, taxi, biking  
11) Social relations Friends/acquaintances, family, partner/children, colleagues  
12) Communication Conversations, phoning, reading, e-mailing   
 
Statistical analyses 
In order to assess the quality of the goal classifications, the inter-rater agreement of 
both classifications (EF and daily life domains) was calculated by using Cohen’s Kappa. 
Furthermore, χ2 tests were performed to compare distributions of EF goals and daily 
life goals between patient groups. Because all statistical assumptions were met, the 
cognitive and EF profiles of patients with PD and ABI were compared using ANCOVAs. 
As patient groups differed significantly with regard to age, this variable was used as a 
covariate in the model. The alpha level of 0.05 was adjusted for multiple comparisons 
using the Bonferroni correction, resulting in an alpha level of 0.004. Furthermore, 
Cohen’s d was calculated for all neuropsychological tests and questionnaire 
comparisons between patients with PD and ABI. An effect size of <0.2 was labelled as 
marginal, 0.2 as small, 0.5 as medium, and 0.8 as large (Cohen, 1992). Paired samples 
t-tests were used to compare ratings of patients with PD and ABI to ratings of their 
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proxies on the DEX questionnaire. Since the ABI group consisted of TBI patients, 
stroke patients, and patients with other neurological conditions, ratings of patients 
and proxies on the DEX questionnaire were also analysed for each subgroup 
independently with paired samples t-tests. Results of neuropsychological tests were 
also analysed from a clinical perspective. Therefore, test results of the RAVLT, Digit 
Span, and Trail Making Test were compared to normative data. Performances that fell 
within the lowest 10% of the normative samples were considered to be impaired 
(Lezak et al., 2004). The BADS total score was transformed in a standardised scaled 
age score, which can be interpreted as a clinical score ranging from impaired, 
borderline, low-average, average, above average, high to very high. These descriptive 
data are reported and compared between groups by means of percentages. 
Results 
Classifications: Inter-rater reliability  
The classification of goals into domains of EF resulted in a Cohen’s Kappa of 0.71. The 
agreement between raters regarding the classification of goals in domains of daily life 
functioning was 0.86. According to the classification proposed by Landis & Koch (1977), 
the inter-rater reliability or agreement between ratings ranged from substantial to 
almost perfect.  
Classifications of EF and daily life domains: Comparisons 
between patients with PD and ABI 
The group of 73 patients with ABI formulated 217 goals and the group of 26 patients 
with PD specified a total of 78 goals. Figure 1 shows the classification of goals into 
domains of EF for both patient groups. The percentage of goals that were set on 
“Time management” was significantly higher in patients with PD than in patients with 
ABI (χ2 = 15.57, p<0.001), whereas patients with ABI set a significantly higher 
percentage of goals on cognitive domains that were not related to EF when compared 
to patients with PD (χ2 = 6.13, p = 0.013). Furthermore, in both groups the majority of 
goals were set on the “Regulation” domain, including goals related to self-monitoring, 
inhibition of irrelevant behaviours and cognitive flexibility. Patients with ABI came up 
with only two goals in the domain of “Self-awareness”, whereas patients with PD set 
no goals at all in this domain. For patients with ABI, the top three domains of EF in 
which most goals were set, were, respectively “Regulation”, “Initiative” and 
“Planning”. For patients with PD the top three were: “Regulation”, “Planning” and 
“Initiative”.  
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Figure 1. Rehabilitation goals of patients with PD and ABI classified into domains of EF 
(percentage of total number of goals set within patient groups). χ2 test: *p<.05, **p<0.01. 
 
When goals were classified into domains of daily life, a significant difference was 
found between our patient groups for “Housekeeping and gardening” (χ2 = 12.95, 
p<0.001). Figure 2 shows that patients with PD set a considerable higher percentage 
of goals within this domain than did patients with ABI. There were no significant 
differences found between groups with regard to the other domains. The majority of 
goals of both patients with PD and ABI were classified in the domain of “Executive 
functions”, indicating that these goals were not focused on specific daily life domains. 
Remarkably, none of patients with PD formulated goals that fell into the domain of 
“Physical functioning”, whereas in patients with ABI the lowest number of goals was 
set on “Self-care”. Patients with ABI set most goals within the following three domains: 
“Executive functioning”, “Leisure and community life”, “Social relations” and 
“Cognitive functioning” (in the latter two domains the same number of goals was 
formulated). For patients with PD, the top three were as follows: “Executive 
functioning”, “Housekeeping and gardening” and “Communication”.  
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Figure 2. Rehabilitation goals of patients with PD and ABI classified into domains of basic 
cognitive functions and daily life activities and participation (percentage of total number of 
goals set within patient groups). χ2 test: **p<0.01. 
General cognitive and EF profile of patients with PD and ABI 
Patients with PD and ABI showed only a minor difference in performance on tests of 
memory which did not reach significance (see Table 4). It was found that 42.3% of 
patients with PD and 43.8% of patients with ABI showed an impaired performance on 
the immediate recall of the RAVLT. The performance on the delayed recall of the 
RAVLT was labelled as clinically impaired in 3.9% of patients with PD in contrast to 
13.7% of the ABI group. With regard to short-term verbal memory a higher 
percentage of patients with ABI were impaired when compared to patients with PD 
(respectively 26.4% and 11.5%). No differences were found between patient groups 
on measures of psychomotor speed (see Table 4), even though 26.9% of patients with 
PD were considered to be clinically impaired in psychomotor speed compared to more 
than half of patients with ABI (50.7%).  
Likewise, no significant differences were found between patients with PD and 
ABI on several measures of EF, such as cognitive flexibility, inhibition and planning 
(see Table 4), which is consistent with the marginal to medium effect sizes. On the 
TMT ratio 28.0 % of patients with PD and 21.9% of patients with ABI were impaired on 
the TMT ratio. Also, the standardised age score of the BADS was labelled as “low 
average” or “impaired” in 30.8% of patients with PD compared to 42.5% of patients 
529605-L-sub01-bw-Vlagsma
Processed on: 11-3-2019 PDF page: 65
Parkinson’s patients’ executive profile and goals they set for improvement: why is cognitive  
rehabilitation not common practice? 
 
65 
4 
with ABI. No significant differences were found between patients with PD and ABI 
regarding the number of problems with executive functioning in daily life as reported 
on the DEX questionnaire. Moreover, there was no significant difference between 
proxies of patients with PD and ABI with respect to the reported number of problems 
on the DEX questionnaire. When ratings for both groups of patients were compared 
to ratings of their proxies, no significant differences were found (paired samples t-test 
ABI: t = 0.49, p = 0.626; PD: t = 0.91, p = 0.374). The same was true when these ratings 
were independently compared for each subgroup of patients with ABI (TBI: t = -1.07, p 
= 0.294; stroke: t = 0.56, p = 0.580; other: t = -1.05, p = 0.317). Furthermore, there was 
no significant difference between patient groups when difference scores (DEX self–
DEX proxy) of the DEX questionnaire were compared (see Table 4).  
Table 4. Performance of ABI and patients with PD on neuropsychological measures of general 
cognitive, executive functions and the DEX questionnaire. 
  
ABI (n=73) PD (n=26) ANCOVA Effect size 
M (SD) M (SD) F p d 
Memory 
     RAVLT IR  39.72 (10.61) 35.00 (10.08) 0.20 0.657 0.45 
     RAVLT DR  8.00 (3.37) 7.65 (2.83) 0.19 0.662 0.11 
     Digit Span total score 13.26 (3.65) 14.65 (3.11) 3.61 0.060 0.40 
Psychomotor speed 
     TMT A  47.65 (22.59) 46.81 (15.76) 0.38 0.537 0.04 
     Stroop Word card 57.88 (17.55) 60.27 (28.62) 0.55 0.459 0.11 
Executive Functions 
     TMT B/A ratio 2.19 (0.86) 2.54 (0.88) 0.82 0.367 0.40 
     Stroop ratio 1.62 (0.30) 2.09 (2.47) 2.53 0.115 0.37 
     BADS  Zoo Map total score  0.86 (3.96) -0.42 (4.40) 0.04 0.950 0.31 
     BADS Six Elements  5.05 (1.35) 5.40 (1.08) 0.42 0.516 0.27 
     BADS  Standardised age score 89.21 (13.64) 94.00 (15.45) 0.67 0.417 0.34 
     DEX    Self 31.37 (13.00) 25.46 (9.88) 1.64 0.203 0.48 
     DEX    Proxy 32.11 (14.66) 23.35 (11.73) 1.82 0.181 0.63 
     DEX    Δ -0.74 (12.90) 2.12 (11.91) 0.05 0.819 0.23 
Note. ANCOVA = univariate analysis of covariance; IR = immediate recall score; DR = delayed 
recall score; TMT = Trailmaking test; BADS = Behavioural Assessment of the Dysexecutive 
Syndrome; Zoo map total score part 1; Significance p <.004, Bonferroni corrected alpha. 
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Discussion 
The results suggest that strategic executive training might be applied as a standard 
therapy for patients with PD, since their goals for cognitive rehabilitation of EF 
impairments, reflecting their needs and aims, as well as their EF profile are 
comparable to those of a mixed group of patients with ABI for whom strategic 
executive training has already been shown to be effective.  
When patients’ goals were classified into domains of EF, it was found that 
patients with PD and ABI set a comparable number of goals for the majority of EF 
domains (i.e. planning, regulation, initiative, self-awareness and general EF). Patients 
with PD did, however, set significantly more goals in the domain of “Time 
management” than patients with ABI. Since cognitive slowness is common in both 
patient groups (Broeders et al., 2013; Dikmen et al., 2009; Muslimovic et al., 2005; 
Rasquin et al., 2004; Spikman et al., 1996), it is more likely that this finding is due to 
slowness of movement (bradykinesia), the single most important diagnostic criterion 
of PD (Bloem et al., 2010). Patients with PD indeed frequently reported that they do 
not take their motor problems sufficiently into account and therefore need more time 
for activities than expected. From a neuro-anatomical perspective the fronto-striatal 
network plays a dominant role in time estimation. Evidence suggests that difficulties 
in time estimation in patients with PD are related to dysfunctions of this dopaminergic 
fronto-striatal network (Perbal-Hatif, 2012).  
Patients with ABI set a significantly higher percentage of goals that was not 
related to EF at all than patients with PD. When analysing these goals in more detail, it 
was found that they were mainly related to problems in the regulation of social 
behaviour, including emotion perception, and to problems with regard to lowered 
self-esteem, memory, visuo-perception, and fatigue. However, since impairments in 
social cognition, memory, visuo-perception, and fatigue are also reported in patients 
with PD, the finding that patients with ABI set more goals related to these aspects 
than patients with PD is difficult to explain (Goldman, Weis, Stebbins, Bernard, & 
Goetz, 2012; Herrera, Cuetos, & Rodríguez-Ferreiro, 2011; McDonald, 2013; Millis et 
al., 2001; Ponsford et al., 2012; Solla et al., 2013; Spikman et al., 2013). Possibly, 
patients with ABI experience deficits in these domains as more restricting in daily life 
than do patients with PD.  
Both patient groups set the smallest number of goals on “Self-awareness” 
and the largest number within the domain of “Regulation”. This indicates that patients 
experience most problems when executing daily activities. Again, these findings 
underline the similarity between patients with PD and ABI concerning specific 
impairments of EF experienced as most restricting in daily life.  
529605-L-sub01-bw-Vlagsma
Processed on: 11-3-2019 PDF page: 67
Parkinson’s patients’ executive profile and goals they set for improvement: why is cognitive  
rehabilitation not common practice? 
 
67 
4 
Patients’ goals were also classified into the domains of basic functioning, 
daily life activities, and participation. The most important finding here is that in almost 
all domains (11 out of 12 domains), no significant differences between patients with 
PD and ABI were found. Both groups are thus highly comparable with regard to 
problems experienced in these three domains. Patients with PD only set a significantly 
higher number of goals within the domain of “Housekeeping and gardening” 
compared to patients with ABI, indicating that patients with PD experience more 
problems with EF when preparing and executing tasks around the house. A possible 
explanation for this finding is the fact that patients with PD were significantly older 
than patients with ABI and therefore a higher number of them had retired. This 
usually means that people spend more time at home. However, other explanations 
are also possible. By far, most goals of patients with PD and ABI were classified in the 
domain of “Executive functioning”, which was defined as one of the basic functioning 
domains. This might indicate that problems with EF do not hinder patients in specific 
daily life domains, but have an impact on daily life functioning in general. This is in line 
with previous studies stating that impairments in EF exert a negative influence on 
everyday life and lead to an overall reduced level of participation (Erez, Rothschild, 
Katz, Tuchner, & Hartman-Maeir, 2009; Perna, Loughan, & Talka, 2012). 
It is worth noting that even though PD is characterised by motor symptoms, 
patients with PD did not set goals to improve their “Physical functioning”. This is in 
line with the idea that patients with PD find cognitive impairments in daily life more 
restricting than motor impairments (Cahn et al., 1998; Klepac et al., 2008).  
In addition to these comparisons, we performed a between groups 
comparison of specified goals falling into the top three domains of basic functioning, 
daily life activities, and participation. Results of this comparison showed that patients 
with ABI set more goals in domains that are related to “Social relations”, “Leisure and 
community” activities, and “Cognitive functioning” than patients with PD. On the 
other hand, patients with PD set more goals related to “Household activities” and 
‘Communication’. It thus seems that patients with PD aim at improving activities they 
undertake (around the house), whereas patients with ABI intend to improve their 
(social) activities. However, the finding that patients with PD set more 
“Communication” goals could possibly also be explained as a disease-specific 
characteristic. Some studies have found problems with production and 
comprehension of language to be common in PD and to be related to impairments in 
EF (Colman et al., 2009; Colman, Koerts, Stowe, Leenders, & Bastiaanse, 2011).  
With regard to comparisons on neuropsychological measures, it was found 
that general cognitive and in particular EF profiles of patients with PD and ABI are 
comparable. No significant differences between groups were found concerning their 
performances on neuropsychological tests for memory, psychomotor speed and EF, 
and the number of problems with EF experienced in daily life. When results were 
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interpreted from a clinical perspective, a large number of patients with PD as well as 
patients with ABI showed a clinically impaired performance (ranging from at least 20 
to 67% for most target measures) with respect to memory, psychomotor speed, and 
EF. This is in agreement with results of previously conducted studies (Elliott, 2003; 
Godefroy et al., 2010) and the fact that ABI and PD are characterised by a 
dysfunctioning of the (pre)frontal cortex due, respectively, to direct injury of brain 
tissue or a dopaminergic dysfunctioning of the fronto-striatal circuits. When 
comparing the ratings of patients and their proxies regarding the number of problems 
with EF in daily life, no significant difference was found between patients with ABI and 
their relatives. The same result was found in patients with PD and their relatives. The 
agreement between patients and their proxies can be interpreted as an indicator of 
intact self-awareness, since patients with impaired self-awareness tend to 
underestimate their impairments when compared to their proxies’ perspective (Hart, 
Sherer, Whyte, Polansky, & Novack, 2004; Spikman & van der Naalt, 2010). In other 
words, EF impairments reported by patients with PD and ABI are reliable and must be 
taken seriously.  
Even though results seem promising with regard to introducing strategic 
executive training as standard therapy, the study is also marked by a number of 
shortcomings. One limitation is that we were not able to retrieve information 
regarding the underlying pathology and severity of patients with ABI. This was 
because patients were recruited from an outpatient rehabilitation setting and that in 
the majority of cases their hospital files were not obtainable. A second limitation of 
this study was that the group of patients with PD was relatively small. The calculated 
effect sizes for the differences in performance on neuropsychological tests, however, 
ranged from small to medium, indicating that a larger sample size of patients with PD 
would not have resulted in different conclusions. Moreover, when analysing 
differences regarding goals and cognitive profiles between patients with ABI and PD, 
disease severity within the group of patients with PD was not taken into account. This 
can be considered a limitation, since increasing disease severity possibly influences 
patients’ goals and cognitive profiles. This would be an interesting question to answer 
in future studies. A final limitation of this study is the heterogeneity of the ABI group. 
Therefore a comparison between patients with PD and a group of patients with 
another neurodegenerative disease would have been desirable. However, according 
to our knowledge, strategic executive training is not offered to any other 
neurodegenerative patient group as standard therapy procedure. Moreover, in the 
context of the current study, this limitation can also be considered as a strength. 
Despite the great diversity of disease-specific characteristics within the group of 
patients with ABI, we still found that patients with PD were highly comparable to this 
group regarding their goals and the EF profile. This means that from a clinical 
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perspective the heterogeneity of the ABI group makes our conclusions even stronger 
than if we had only included a homogeneous TBI group.  
In conclusion, based on our findings, we have no reason to assume that 
strategic executive training could not be offered as standard therapy to patients with 
PD. Results showed that patients with PD and ABI were not only comparable in terms 
of the rehabilitation goals they set, which reflect patients’ needs and aims for 
cognitive rehabilitation, but were also comparable with regard to their cognitive and 
in particular EF profile. When considering the application of strategic executive 
training as standard therapy in patients with PD, neuropsychologists need to be aware, 
however, of disease-specific characteristics such as motor impairments and fatigue. In 
addition, for patients with PD the focus of strategic executive training should possibly 
be more on improving time management and functioning around the house. Future 
studies need to determine whether strategic executive training is actually effective in 
patients with PD, meaning that it results in improving patients’ daily life functioning 
and quality of life. Furthermore, because of the neurodegenerative nature of PD, 
future studies should determine at which stage of the disease this treatment is 
suitable and for how long patients will benefit.  
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Abstract 
In this review we included nine studies (2004-2013) that investigated cognitive 
rehabilitation in patients with Parkinson’s disease (PD), with a focus on improvement 
of executive functions (EF) as a result of the cognitive treatment protocols described. 
Of each individual cognitive treatment protocol the methodological criteria and 
effectiveness were evaluated. Consequently, all cognitive treatment protocols were 
classified based on the operational level of treatment that had been applied: function 
training, skills training and/or strategy training. Furthermore, the outcome measures 
that had been chosen were classified into three ICF levels: function level, 
activity/participation level and psychosocial level. Our findings show that the studies 
conducted so far lead to an improvement of cognitive functions on 
neuropsychological tests only. No transfer of training to daily life has been studied nor 
found. Furthermore, we found that the majority of included studies are of good 
methodological quality. Remarkably, most cognitive treatment protocols were limited 
to applying function training and measuring effect at function level. Given that 
impairments in EF can be considered central in PD, very little studies specifically 
aimed to improve executive functioning. Based on the current review, cognitive 
treatment protocols are proven to be feasible and beneficial for patients with PD, but 
there is a need for developing treatment protocols for executive problems that have 
impact on everyday life functioning, that is societal participation and quality of life 
(QoL). 
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Introduction 
Cognitive dysfunctions are reported in patients with PD in a variety of domains, such 
as attention, memory, visual-spatial functions and executive functions (EF) (Zgaljardic 
et al., 2003). Impairments in EF are predominant and can already be present in the 
early stages of PD (Kudlicka et al., 2011). EF are required for independent functioning 
in everyday life, since these functions enable us to set and achieve realistic life goals 
and to anticipate to unforeseen circumstances (Burgess & Simons, 2005). Therefore, 
impairments in EF have a negative influence on PD patients’ everyday life functioning 
and quality of life (QoL) (Kudlicka et al., 2014).  
Even though motor impairments are the core symptoms of PD, patients seem 
to experience cognitive impairments as even more restricting in everyday life 
functioning than motor symptoms (Klepac et al., 2008). Surprisingly, cognitive 
rehabilitation is not yet part of standard therapy for patients with PD. This raises the 
question to what extent effects of cognitive rehabilitation in PD have been studied so 
far. Therefore the current study gives an overview of the studies that have been 
conducted to investigate the effectiveness of cognitive rehabilitation in patients with 
PD. Specific attention will be given to whether these protocols addressed impairments 
in EF.  
For each study that we included the methodological quality (e.g. the use of 
randomisation, control groups and sample sizes), type of training and the type of 
outcome measures were evaluated. Cognitive treatment protocols can be categorised 
as protocols based on function training, skills training or strategy training (Spikman & 
Fasotti, 2012).  
Function training aims at improving cognitive impairments by stimulating the 
underlying cognitive functions. Repeated, mostly computer based, execution of tasks 
addressing this specific cognitive function is the key element of function training. The 
advantage of function training is that these protocols are basically self-supporting, 
implying that personal support by a therapist can be reduced to a minimum. This 
means that function training is a relatively low-cost form of cognitive rehabilitation. 
To date, however, the effect of function training in terms of improvement in everyday 
life functioning is still debated (van Heugten et al., 2016). Skills training aims to reduce 
the consequences of cognitive impairments in everyday life by practicing and 
improving the execution of specific everyday life activities in which patients 
experience these cognitive impairments. Strategy training aims to achieve the same 
goal by teaching patients cognitive strategies, which they can apply to those individual 
everyday life situations in which they experience cognitive impairments. The 
fundamental principle of strategy training is thus to help patients compensate for 
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their cognitive impairments in everyday life instead of restoring the cognitive 
functions itself.  
The outcome measures that were used in the included studies were classified 
into different categories related to the levels of the International Classification of 
Functioning, Disability and Health (ICF): (1) function level: i.e. performance on 
neuropsychological tests, (2) activity/participation level: i.e. measures related to 
functioning in everyday life activities and participation in societal domains such as 
work, social relations, leisure activities and mobility, (3) personal aspects: measures 
related to well-being, mood, coping and QoL (WHO: Heerkens e.a., 2002). The primary 
aim of this review is to increase our insight into whether cognitive rehabilitation is 
feasible and effective for patients with PD and for which cognitive domains. We were 
specifically interested in cognitive treatment protocols that aim to improve executive 
functioning.  
Methods 
The database PubMed was used to conduct a literature search on studies that 
evaluated cognitive treatment protocols in non-demented patients with PD. The 
following (combination of) search terms were used: “Parkinson’s disease” and 
“cognitive training”, “Parkinson’s disease” and “cognitive rehabilitation”, “Parkinson’s 
disease” and “training”, “Parkinson’s disease” and “executive rehabilitation”, 
“Parkinson’s disease” and “computer training”, “Parkinson’s disease” and “attention 
training” and “Parkinson’s disease” and “memory training”. Abstracts were included 
when they described studies that investigated the effectiveness of cognitive 
rehabilitation or training in patients with PD, including a baseline and post-treatment 
measurement. Abstracts were excluded when: 1) no cognitive treatment/training was 
described, 2) the described treatment/training focused on improving motor 
symptoms in patients with PD, 3) they concerned review studies, 4) cognitive 
treatment/training was investigated in other patient groups than PD and 5) they 
concerned theoretical studies on cognitive rehabilitation. The literature search 
resulted in 9 studies that were included. Subsequently, these studies were categorised 
following the methodological criteria of Cicerone e.a. (2000). Class I studies are of 
highest methodological quality and involve prospective, randomised controlled trials, 
Class II-studies are prospective cohort studies, retrospective studies, case-control 
studies or clinical series with well-designed controls, Class III studies were defined as 
clinical series without controls or case studies.  
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Results 
Class I studies 
So far, five Class I studies have been conducted on the effectiveness of cognitive 
rehabilitation in patients with PD (Table 1). Sammer et al. (2006) investigated the 
effectiveness of a function training aimed to improve EF. The training protocol 
consisted of repeated practise of neuropsychological tests of EF, such as the subtests 
‘Zoo map’ and ‘Key search’ of the Behavioural Assessment of the Dysexecutive 
Syndrome (BADS). Furthermore, patients were asked to tell short stories in order to 
stimulate their speech production. The control treatment included occupational 
therapy, physiotherapy and physical treatment. Post-treatment, patients in the 
experimental condition showed a significant better performance on the subtests 
‘Ruleshift’ and ‘6-Elements’ of the BADS, which were not part of the training tasks, 
when compared to baseline.  The control group did not show an improvement in test 
performance after treatment.  
The study of Sammer et al. (2006) showed that function training for EF can 
lead to a better test performance on tests for EF in patients with PD. However, the 
outcome measures assessed only some specific aspects of EF and attention. Whether 
the function training also had an effect on other aspects of EF remains unclear. 
Moreover, the small sample sizes are considered a limitation of this study.  
In 2011 París et al. performed a study on the effectiveness of function 
training on general cognitive functioning and QoL. The training consisted of 
computerised tasks for attention, (working) memory, speed of information 
processing, EF, visuospatial abilities and non-specific cognitive exercises (e.g. related 
to language and simple calculations). In addition, patients received 20 cognitive 
homework assignments weekly. These assignments are not described in detail in the 
paper. The control group received speech therapy in groups. When compared to the 
control group, patients who received the experimental treatment demonstrated 
significantly improved performance on at least one test of attention, information 
processing speed, memory, visuospatial and visuoconstructive abilities, semantic 
verbal fluency or EF. However, the experimental training showed no effect on 
measures of QoL, mood and cognitive problems in everyday life, indicating that this 
function training did not lead to improvement on the levels of personal aspects and 
activities/participation. Since París et al. (2011) do not describe the training tasks in 
detail, it is unclear which specific aspects of EF were trained. Another limitation of this 
study are the small sample sizes of patients with PD that were included.  
Reuter et al. (2012) investigated a multimodal treatment protocol aimed to 
improve general cognitive functioning in PD. The experimental treatment included: (1) 
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function training: repeated practise of ‘paper-and-pencil tasks’ and computerised 
tasks mainly for EF and memory, (2) skill training for concentration, planning 
strategies, orientation and making use of mnemonics in everyday life activities, and 
(3) (psycho)motor training. The multimodal treatment protocol was compared to two 
control treatments: one control group received (1) function training and (2) 
skill/strategy training, whereas the other control group received only (1) function 
training. In addition, these control groups followed relaxation and vocational training 
to compensate for the extra time that was spend on training during the multimodal 
treatment. Patients and their relatives were instructed to continue practicing the 
exercises at home. When looking into more detail at patients’ treatment goals, results 
showed that the majority of their goals focused on improving aspects of EF, which is in 
line with the assumption that patients with PD are hindered by impairments in EF in 
everyday life. Patients in the multimodal treatment group showed a significant greater 
improvement than both control groups on two screening measures of cognitive 
functioning (i.e. the Alzheimer Assessment Scale Cognition (ADAS) and Scales for 
Outcome of Parkinson’s Disease Cognition (Scopa-Cog)) and on neuropsychological 
tests of EF. In addition, patients receiving the multimodal treatment reported a higher 
QoL post-treatment and achieved their treatment goals significantly more frequent 
than patients in the control groups. Furthermore, the multimodal treatment group 
developed a more active life style and reported to feel more confident when 
executing everyday life activities than the control groups. Also, a higher percentage of 
patients in the experimental group had continued exercising at home compared to the 
control groups. The treatment effects in favor of the multimodal treatment were still 
present at six months post-treatment. Based on these results, it can be concluded that 
the multimodal treatment showed positive effects on function level, as well as 
activity/participation level and level of personal aspects. The findings are robust given 
the large sample sizes that were included. A minor limitation related to the sample 
sizes is that the reason for the exclusion of 18 patients is not described.  
The study of Edwards et al. (2013) evaluated the effectiveness and 
generalizability of a function training for speed of information processing. In addition, 
the authors were also interested in predictors of treatment success. The experimental 
treatment was a self-supporting computer training (called Insight) aimed to train 
speed of information processing in a visual realistic context. Patients had access to the 
computer training at home. The control group was formed by patients that were put 
on a waiting list receiving no treatment. Post-treatment both groups showed faster 
reaction times on a neuropsychological test for visual attention (Useful Field of View 
test, UFOV). In comparison with patients in the waiting-list-condition, the 
experimental group showed even greater improvement on this test in terms of faster 
reaction times. With regard to cognitive self-perception and depressive symptoms, no 
differences were found between baseline and post-treatment assessment. Thus, only  
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on function level a treatment effect was found. A longer disease duration, younger 
age at diagnosis and a higher Levodopa daily dose appeared to be predictors of 
treatment success. A limitation of this study is that measures of EF were not included, 
while the authors do suggest that improving speed of information processing might 
result in better executive functioning.  
In a recent study of Naismith et al. (2013), a neuropsychological treatment 
was evaluated that aimed at improving patients’ performance on neuropsychological 
tests for memory and cognitive functioning in general. The cognitive training consisted 
of two one-hour sessions: one hour psychoeducation related to PD followed by one 
hour of computer training (function level). Patients in a waiting list condition formed 
the control group. Results showed that the cognitive training group improved 
significantly more on a neuropsychological test for memory (‘Logical memory’, subtest 
of Wechsler Memory Scale-III) than patients in the waiting list condition. On tests for 
speed of information processing, cognitive flexibility and verbal fluency no differences 
between the groups were found. Unfortunately, the effect of psychoeducation on 
patients’ knowledge about PD did not reach significance. Therefore, the effect of 
treatment was limited and only found on function level. Furthermore, it is hard to 
disentangle whether the improved performance on the memory test can be 
interpreted as an effect of the cognitive training only or can also (partly) be explained 
by an effect of psychoeducation. EF was not targeted specifically in the training and 
the outcome measures for EF showed no improvement post-treatment. Nevertheless, 
this is a valuable study since it is the first study that investigated and demonstrated 
the effectiveness of a memory training in patients with PD. 
Overall, it is remarkable that all studies evaluated a treatment protocol that 
consisted at least partly of function training and that four out of five studies (París et 
al. (2010) did not define a primary outcome measure) also chose to use a primary 
outcome measure on function level (i.e. a neuropsychological test). This means that 
the evaluation of effectiveness was primarily focused on whether or not a cognitive 
treatment protocol leads to improved test performance. Three studies included also 
secondary outcome measures pertaining to functioning on activity level, participation 
and personal factors in addition to a primary outcome measure on function level.  
However, only Reuter et al. (2012) showed that the effect of treatment generalized to 
better functioning in everyday life. This study was also the only study that evaluated a 
cognitive treatment protocol which included skill training in addition to function 
training. This study concluded that function training alone did not lead to 
improvement in everyday life functioning, whereas the multimodal treatment did. 
Furthermore, the study of Reuter et al. was the only study that included a follow-up 
measurement. The other studies do not provide follow-up measurements that can 
lead to conclusions about the eventual long term effects of the evaluated cognitive 
treatment protocols, which can be considered a limitation.  
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Table 1. Methodological ratings, descriptions and main findings of included studies.  
Authors 
(year) 
Class I/II/III 
PD 
N 
H&Y Controls 
N 
M age (Sd)  Training content Level cognitive 
training 
Length of treatment  
Sammer e.a. 
(2006) 
Class I 
12 2-3 14 PD Exp. 70.8 (7.9) 
Cont. 68.5(9.0) 
Exp.: 
Neuropsychological 
pencil-and-paper tasks 
and speech 
reproduction tasks 
Cont.:  
Occupational therapy, 
physiotherapy and 
physical treatment 
Function training 10 sessions of 30 min 
in 3-4 weeks 
 
París e.a. 
(2011) 
Class I 
16 1-3 12 PD Exp. 64.75 (9.19) 
Cont. 65.42 (9.60)  
Exp.:  
Computer training and 
pencil-and-paper tasks: 
related to language or 
calculation skills 
Cont.:  
Speech therapy 
 
Function training 12 sessions of 45 min 
in 4 weeks 
 
Reuter e.a. 
(2012) 
Class I 
222 2-4 71 PD 
76 PD  
75 PD 
64.0 (4.0) Exp.: 
1)Computer training 
and 
neuropsychological 
pencil-and-paper tasks. 
2)Skills training 
3)Psychomotor training 
Cont. 1: 1 and 2 
Cont. 2: 1 
Function training 
Skills training 
1) 14 one-hour 
sessions, 4 per week  
2) 10 sessions of 
90min, 3 per week 
3) 10-12 one-hour 
sessions at home: 
1) 45 min, 3 per 
week 
2)2 per week  
3)2 per week  
 
Edwards e.a. 
(2013) 
Class I 
32 1-3 42 PD Exp.  69.38 (7.81) 
Cont. 68.17 (8.38)  
Exp.: Computer 
training  
Cont.:  
Waiting list  
 
Function training min. 20 one-hour 
sessions, 3 per week  
 
Naismith 
e.a. (2013) 
Class I  
35 1-3 15 PD Exp.  68.5 (7.1) 
Cont. 64.9 (6.5) 
Exp.: Computer 
training and psycho-
education 
Cont.: Waiting list  
Function training  14 sessions of 2 
hours,  
twice a week 
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 Targets 
 
 
Outcome measures Level outcome 
measures 
Measurements Results 
 EF BADS; Rule shift, 6-
Elements test, TMT, 
FNL, AKT 
Primary: 
Function 
Baseline and 
post-treatment 
The experimental group showed post-
treatment a significant improved test 
performance on the 6-Elements and Rule-
shift. The control group showed no 
significant improvements.  
With regard to working memory, attention 
and well-being, no effects of treatment nor 
differences between groups were found.  
 
 Attention, WM, 
SIP, memory, 
EF, visuospatial 
skills.  QoL, 
mood and ADL 
MMSE, ACE, WAIS-III; 
Digit Span,  VLGT, 
SDMT, TMT, Stroop 
interference, WMS- III; 
Logical Memory I, II, 
CVLT-II, RBANS, Letter 
fluency, Semantic 
(animal)fluency, TOL, 
PDQ-39, GDS-15, CDS 
Function 
Activity/ 
Participation 
Personal factors 
Baseline and 
post-treatment 
The experimental group showed post-
treatment a significant better test 
performance that the control group on the 
Digit Span forward, Stroop interference, 
ROCFT, semantic fluency, TMT B and TOL. 
No differences were found on the PDQ-39, 
GDS-15 and CDS.  
 EF and everyday 
life functioning 
Primary: ADAS-COG 
Secondary: SCOPA-
COG, GAS, PASAT, 
BADS, MWT-B,  PDQ-
39, HADS 
Primary:  
Function 
Secondary: Activity, 
participation and 
personal factors  
Baseline, post-
treatment and 
follow-up at 6 
months 
The experimental multimodal group showed 
post-treatment significant better 
performances on the primary and 
secondary outcome measures, compared to 
both control groups. A higher % of patients 
in the multimodal group continued their 
training at home and this group experienced 
a greater improvement of QoL than the 
control groups. These findings remained at 
follow-up.  
 Speed of 
information 
processing 
Primary: UFOV 
Secondary: Cognitive 
Self-Report 
Questionnaire, CES-D 
Primary: Function 
Secondary: 
Activity/participatio
n and personal 
factors  
Baseline and 3 
months post-
treatment 
The experimental group performed post-
treatment significantly better on the UFOV 
than controls. The control group performed 
post-treatment significantly better on the 
UFOV than at baseline.  
 Memory Primary: WMS-III; 
Logical memory 
Secondary: TMT, 
Letter fluency, 
Psychoeducation 
questionnaire 
Primary: Function 
Secondary: Function 
and personal factors  
Baseline and 
post-treatment  
Post-treatment the experimental group 
showed a significant better performance on 
the Logic memory test (learning and 
retention) than controls. On secondary 
outcome measures no differences were 
found.  
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Table 1 (continued). Methodological ratings, descriptions and main findings of included studies.  
Authors 
(year) 
Class I/II/III 
PD 
N 
H&Y Controls 
N 
M age (Sd)  Training content Level cognitive 
training 
Length of treatment  
Nombela 
e.a. (2011) 
II 
10  
5 trea-
ted 
2-3 10 HC Exp. 60.1 (3.04) 
Untrained. 61.2 
(4.14) 
Cont. 59.6 (4.47) 
Exp.: Pencil- and paper 
tasks: i.e. Sudoku 
puzzles.  
Function training 1 Sudoku a day 
during 6 months  
 
Sinforiani 
e.a. (2004) 
Class III 
20 1,5 
+/- 
0,6 
- 68.9 (7.1) Exp.: Computertraining Function training 12 one-hour 
sessions, twice a 
week  
 
Mohlman 
e.a. (2010) 
Class III 
1 2 - 74 Exp.: everyday life 
activities and cognitive 
behavioural therapy 
Function training  10 sessions of 90- 
120 min 
 
Mohlman 
e.a. (2011) 
Class III 
14 - - 62.71 (7.32) Exp.: everyday life 
activities 
Function training 4 sessions of 90 min, 
1 per week 
 
 
Note. H&Y= Hoehn and Yahr scale for determining the severity of PD (range 0-5). Outcome measures; 
BADS= Behavioural Assessment of the Dysexecutive Syndrome; TMT: Trail Making Test; FNL: Face 
Name Learning Test; AKT: Alters Konzentrations Test;  ADL: Activities of Daily Living; MMSE: Mini 
Mental State Examination; ACE: Addenbrooke Cognitive Examination; WAIS II: Wechsler Adult 
Intelligence Scale; CVLTII: California Verbal Learning Test; SDMT: Symbol Digit Modalities Test; WMS-
III: Wechsler Memory Scale; ROCFT: Rey Osterrieth Complex Figure Test;  RBANS: Repeatable Battery 
for the Assessment of Neuropsychological Status; TOL: Tower of London; PDQ-39: Parkinson’s Disease 
Quality of Life Questionnaire; GDS-15: Geriatric Depression Scale; CDS: Cognitive Difficulties Scale; 
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 Targets 
 
 
Outcome measures Level outcome 
measures 
Measurements Results 
 Working 
memory and 
attention 
Stroop; alternative 
version, Sudoku 
puzzles, FMRI  
Function: including 
brain activity - fMRI 
Baseline and 
post-treatment 
The experimental group showed post-
treatment significant better performances 
on the Stroop: reaction time↓, correct 
responses↑ and omissions ↓. Post-
treatment, untrained patients needed more 
time to solve a Sudoku than the 
experimental group and controls. On FMRI 
the experimental group showed decreased 
cortical activation, which was comparable 
to the activation of healthy controls.  
 Attention, 
abstract 
reasoning, 
visual-spatial 
capacities  
Babcock's story, Letter 
fluency, Raven’s 
matrices, MMSE, 
WAIS-III; Digit Span, 
Corsi-test, WCST, 
Stroop 
Function Baseline, post-
treatment and 6 
months follow-
up  
At post-treatment patients performed 
significantly better on the Babcock’s story, 
Letter fluency and Raven matrices 
compared to baseline. This finding 
remained at 6 months follow-up. On 
secondary measures no differences were 
found.  
 Executive skills 
and anxiety  
PSWQ, BAI, STAI, HAM-
A en D,BDI, Attention 
Control Scale, MMSE, 
Boston Naming Test, 
WAIS-III; Digit Span, 
Letter fluency, Stroop, 
TMT, WAIS-III; 
Similarities and Digit 
symbol  
Personal factors and 
function  
Baseline, second 
baseline at 1 
month, post-
treatment, 
follow-up at 1 
and 3 months 
post-treatment 
Post-treatment the patient reported a 
reduction of anxiety symptoms, which 
remained stable on the long term. With 
regard to test performance, no effect of 
treatment was found.  
 Executive skills Primary: ATP practise 
log sheet: fatigue, 
effort, progress, 
enjoyment 
Secondary: WAIS-III; 
Digit Span, Stroop, 
TMT, Letter fluency 
Primary:  Personal 
factors 
Secondary: Function 
Baseline and 
post-treatment. 
Primary outcome 
measure each 
session.  
Patients experienced the training as feasible 
and enjoyable. Post-treatment patients 
reported a significant improvement in 
selective attention and switching of 
attention. Also a significant improvement 
was found compared to baseline on the 
Digit Span backwards, Stroop, TMT and 
COWAT.  
 
ADAS-COG: Alzheimer Assessment Scale Cognition; SCOPA-COG: Scales for Outcome of 
Parkinson’s Disease-Cognition; GAS: Goal Attainment Scaling; PASAT: Paced Auditory Serial 
Addition Test; MWT-B: Mehrfach Wortschatz Test; HADS: Hospital Anxiety and Depression 
Scale; UFOV: Useful Field of View Test; CES-D: The Centre for Epidemiological Studies 
Depression Scale; fMRI: Functional Magnetic Resonance Imaging; WCST: Wisconsin Card Sorting 
Test; PSQW: Penn State Worry Questionnaire; BAI: Beck Anxiety Inventory; STAI: State-Trait 
Anxiety Inventory; HAM-A and D: Hamilton Scale for Anxiety and Depression; BDI: Beck 
Depression Inventory. 
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Class II studies 
Only one study could be classified as a Class II study (Table 1). Nombela et al. (2011) 
investigated whether a function training for working memory and attention would 
improve PD patients’ performance on neuropsychological tests for working memory 
and attention and whether receiving training was related to patterns of functional 
brain activity, as measured with fMRI. Patients who received training were compared 
to a group of untrained patients and to a group of healthy controls. The cognitive 
training involved solving one Sudoku puzzle per day, during six months. Once a week a 
psychologist checked these puzzles and made corrections if necessary, which were 
also explained to patients. At baseline and post-treatment a modified version of the 
Stroop test was administered to patients while they were in the fMRI scanner. 
Compared to healthy controls, patients with PD needed significantly more time to 
solve a Sudoku puzzle and showed a significant longer reaction time on the alternative 
version of the Stroop test at baseline. When post-treatment comparisons were made 
between untrained patients with PD, trained patients with PD and healthy controls, 
results showed that untrained patients needed significantly more time to solve a 
Sudoku puzzle than the other groups. Furthermore, the patients in the training group 
showed a significant reduction of cortical activation when compared to untrained 
patients, which was comparable to the patterns of activation observed in healthy 
controls. This study has a few limitations that need to be mentioned. First, the 
included sample sizes were very small and Nombela et al. (2011) do not describe how 
patients were allocated to the different conditions. Moreover, the function training 
was limited in the sense that it included only Sudoku puzzles. Furthermore, since one 
outcome measure on function level was used, the authors were not able to draw 
reliable conclusions about possible effects of training on the domains of working 
memory and attention in general or effects on everyday life functioning and QoL.  
Class III-studies 
Three studies were classified as Class III-studies (Table 1). In the study of Sinforiani et 
al. (2004) a treatment protocol was evaluated that consisted of both cognitive and 
motor training. The cognitive training involved a computer training that aimed to 
improve prefrontal regulated cognitive functions, by training aspects of attention, 
logic reasoning and visuo-spatial capacities. Directly after treatment and at six months 
follow-up, patients showed a significant improved performance on the Babcock’s 
story, Fonologic fluency and Raven’s matrices (which are considered tests for frontal 
functions). The authors conclude that the combination of cognitive and motor training 
leads to improved cognitive functioning, in particular to improved frontal cognitive 
functions. However, a remark that must be made is that the cognitive training did not 
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involve training of EF, EF being frontally regulated functions. Also, there was no effect 
of training found on the Wisconsin Card Sorting Test (WCST), which is surprising since 
this is considered an EF test that is sensitive to frontal dysfunction. The small sample 
sizes and the lack of a control group are considered methodological shortcomings. 
Another limitation is that effects on the level of activities/participation and personal 
factors were not studied, because the training as well as the outcome measures only 
aimed at training and improvements on function level.  
Mohlman et al. (2010) described a case study of a PD patient that followed a 
cognitive rehabilitation protocol aimed at reducing symptoms of anxiety and 
improving EF. Half of the training protocol included cognitive behavioural therapy 
(CBT) and the other half focused on function training in the form of Attention Process 
Training-II (APT-II). The APT-II is a self-supporting training that trains different aspects 
of attention and logic reasoning. It uses audio discs that instruct patients to 
repeatedly practise activities in their home environment that rely heavily on 
attentional processes (e.g. divided attention: talking on the phone while cooking). 
After treatment, the symptoms of anxiety were evidently reduced and remained 
stable over time. However, no significant effect of training was found in terms of 
improvement on neuropsychological test performance. This finding was explained by 
the fact that the patient showed already (above) average performances on the 
majority of tests at baseline and by the presence of ceiling effects for some tests, 
reducing the possibility of improving test performance. An advantage of the APT-II is 
that it comprises tasks that are trained in everyday life situations. On the other hand, 
given that the primary aim of this study was to improve EF, it is surprising that the 
APT-II as well as the outcome measures focus primarily on aspects of attention 
(function level). Ecologically valid outcome measures related to EF in everyday life or 
QoL were not included (e.g. Behavioural Assessment of the Dysexecutive Syndrome). 
Furthermore, there were some methodological limitations: only one questionnaire 
was administered twice at three months follow-up, there were no statistical analyses 
performed and since the training protocol comprised CBT as well as APT-II it is hard to 
distinguish to which of these training elements the reduction of anxiety symptoms can 
be attributed. 
In another study of Mohlman et al. (2011) the feasibility and patients’ 
acceptance of the APT-II training was studied into more detail. In this study Mohlman 
et al. defined EF as attentional control and self-monitoring of behaviour. APT training 
sessions were led by doctoral psychology students that were experienced in giving 
APT training. In addition patients made assignments at home. Results showed that 
patients with PD reported to experience the training as feasible and acceptable. With 
regard to aspects of attention, patients reported significantly more improvement on 
selective attention and switching of attention that on other attentional aspects. 
Furthermore, patients’ performance on tests for EF improved after training. However, 
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given that the main goal of this study was to determine whether APT-II training is 
feasible for patients with PD, the results would have been statistically more robust 
when a control group had been included and a follow-up measurement had been 
carried out. Besides, the inclusion of ecological valid measures of EF could have added 
relevant information.  
Discussion 
The current review shows that up until 2014 a relatively small number of studies have 
been conducted on the effectiveness of cognitive rehabilitation in PD. To our 
knowledge the first study dates from 2004 (Sinforiani et al., 2004). Given that the 
studies that were included in this review reported a low percentage of drop-outs, we 
tentatively conclude that cognitive treatment protocols seem to be feasible for 
patients with PD. 
The reviewed studies were classified according to their methodological 
characteristics. The majority of these studies (five out of nine) was of good 
methodological quality. In these studies patients were randomly allocated to a 
treatment condition and a control group was included (i.e. control treatment or 
waiting list condition). However, except for one study (Reuter et al., 2012: n>200) the 
sample sizes were small. In two third of the studies, the sample sizes did not exceed a 
number of 20 patients, which indicates that significant results must be interpreted 
with caution. Another important limitation for the majority of studies was the lack of a 
follow-up measurement. Therefore, it remains unclear whether effects of treatment 
that are found, would have lasted over time. This would be relevant information for 
clinical practice but also from a societal perspective, since this can increase our insight 
into the cost-efficiency of treating patients with PD. 
With regard to the content of the cognitive treatment protocols, it is 
remarkable that all studies included, aimed to improve cognitive functioning by using 
function training. Thus, cognitive functions were trained by repeated practise of 
‘paper-and-pencil tasks’ and computerised tasks. Only Mohlman et al. (2010; 2011) 
explicitly made a translation to everyday life functioning by stimulating patients to 
train aspects of attention by executing specific tasks in their home environment. 
However, the content of this training protocol must still be considered as a function 
training, since it was limited to repeated practise of specific tasks. Only Reuter et al. 
(2012) evaluated a multimodal treatment that consisted of skill training in addition to 
function training.  
Except for the study of Mohlman et al. (2010), all studies led to the 
conclusion that function training is effective in patients with PD, meaning that training 
resulted in improved performance on neuropsychological tests. Remarkably, the 
primary outcome measures for the majority of studies were limited to measures on 
529605-L-sub01-bw-Vlagsma
Processed on: 11-3-2019 PDF page: 91
 
Cognitive rehabilitation in patients with Parkinson’s disease: an overview 
 
91 
5 
function level (i.e. neuropsychological tests), with the exception of the studies of 
Mohlman et al. where primary outcome measures aimed to reflect improved 
functioning related to personal factors. Only the studies of París et al. (2011), Reuter 
et al. (2012) and Edward et al. (2013) evaluated the effectiveness of a cognitive 
training protocol on patients’ functioning in everyday life activities and on their level 
of participation. The multimodal treatment of Reuter et al. (2012) was the only 
treatment that resulted in improvements in everyday life functioning and QoL of 
patients with PD.  
Only four studies aimed specifically at improving EF. However, when looking 
into detail at these treatment protocols, it is questionable whether these studies 
actually trained EF. For instance, patients in the studies of Mohlman et al. (2010;2011) 
received an attention training (APT-II) and París et al. (2011) did not clarify which 
specific aspects of EF were trained. Moreover, the outcome measures related to EF 
consisted of basic and standard tests of EF instead of more complex and ecologically 
valid tests such as the BADS. The other five studies focused on improving speed of 
information processing, memory, attention, abstract reasoning or visuo-spatial 
functions. Given that EF are predominantly impaired in PD, it is surprising that only 
four studies aimed specifically on improving executive functioning.  
Based on the conducted studies on cognitive rehabilitation in PD so far, it can 
be concluded that cognitive treatment protocols are feasible for patients with PD. 
Also, findings show that cognitive rehabilitation is effective in terms of improving 
cognitive functioning in PD. However, the most important limitation is that the 
majority of treatment protocols included only function training and measured the 
effectiveness of a training protocol only on function level as well. Therefore, the 
effectiveness of cognitive treatment on everyday life functioning in patients with PD 
remains unclear. This would be a highly interesting question to answer, since PD is a 
neurodegenerative disease and leads to an increasing reduction of patients’ 
independence in everyday life. For patients with traumatic brain injury or stroke, 
cognitive rehabilitation has already been found to be effective in improving everyday 
life functioning (Krasny-Pacini et al., 2014). Spikman et al. (2010) showed that patients 
who received a multimodal strategy training for dysfunctions in EF, resumed to a 
significantly higher extent their previous (i.e. prior to the TBI or stroke) roles in society 
(work, social relations, leisure and mobility) than patients who merely received a 
computer training. Finally, based on the current review it can be concluded that in 
future research more attention should be paid to cognitive treatment protocols 
specifically aimed to improve EF and to evaluating the effects of such treatments on 
activity/participation level and on the level of personal factors.  
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Abstract 
In this multicentre randomised controlled trial (RCT), forty-three patients with 
Parkinson’s disease (PD) were randomly allocated to either the experimental 
condition receiving cognitive rehabilitation including strategy training (ReSET; 
Strategic Executive Treatment, n=24) or to the control condition receiving 
computerised repetitive practise training for attention (Cogniplus, n=16). We 
expected that strategy training (ReSET) would be more effective than cognitive 
training (Cogniplus) in improving patients’ everyday life executive functioning. 
Neuropsychological assessment was administered at baseline, at 2 weeks and 3-5 
months post-treatment. Primary outcome measure was the Role Resumption List 
(RRL). Secondary outcome measures were treatment goal attainment (TGA), 
Dysexecutive Questionnaire (DEX), Parkinson’s Disease Questionnaire (PDQ-39), Zarit 
Burden Interview (ZBI) and neuropsychological tests. No effects of treatment were 
found on the primary outcome measure and on neuropsychological tests, except for 
one test of attention. At two weeks and 3-5 months post-treatment, patients with PD 
in both the ReSET and Cogniplus group reported a significant improvement in 
everyday life executive functioning, as measured with TGA and the DEX-self, with an 
advantage for ReSET only shortly after treatment. Given these results and that 
patients with PD were able to adhere to these treatments despite their motor 
symptoms and fatigue (i.e. the drop-out rate was small), we conclude that both 
strategy training and cognitive training for impairments in EF might be beneficial and 
feasible for patients with PD. 
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Introduction 
Parkinson’s disease (PD) is a neurodegenerative disorder that is characterised by 
motor symptoms. Impairments in cognitive domains such as attention, memory 
visuospatial functions and executive functions (EF) are also common in PD (Elgh et al., 
2009; Muslimovic et al., 2005). In particular, impairments of executive functions (EF) 
are frequently found and can already be present in the early stages of the disease 
(Kudlicka et al., 2011; McKinlay et al., 2010). 
EF are higher order functions that control more basic cognitive processes like 
attention or memory. EF is an umbrella term that incorporates several functions such 
as planning, regulation and initiation of behaviour, time management and self-
awareness (Vlagsma et al., 2015; Ylvisaker, 1998). These functions enable us to 
behave in a goal-directed way in non-routine and complex everyday life tasks and to 
anticipate unforeseen circumstances. Previous studies have shown that impairments 
in EF can lead to reduced independence in everyday life functioning and to a lower 
quality of life (QoL) (Kudlicka et al., 2014; Lawson et al., 2014b). 
In neurological populations other than PD, e.g. acquired brain injury (ABI), it 
is common practice to offer patients neuropsychological rehabilitation programmes 
for impairments in executive functioning (Krasny-Pacini et al., 2013). For patients with 
PD, neuropsychological rehabilitation is not part of standard therapy. This is surprising 
as the profile of executive dysfunctions and reported needs and aims regarding 
neuropsychological rehabilitation of patients with PD are comparable to patients with 
ABI (Vlagsma et al., 2015). Moreover, because patients with PD report that their 
impairments in EF are at least as restrictive as their motor symptoms (Klepac et al., 
2008) and since they have to cope with these impairments for a large part of their life, 
neuropsychological rehabilitation for impairments in EF could be particularly valuable 
to maintain patients’ independence in everyday life for as long as possible.  
In the last decade an increasing number of studies were conducted on 
neuropsychological rehabilitation in PD. However, to date only four studies 
investigated the effectiveness of cognitive interventions that specifically aimed to 
improve impairments in EF in patients with PD (Mohlman et al., 2010; Mohlman et al., 
2011; Reuter et al., 2012; Sammer et al., 2006). These studies focused primarily on 
cognitive training, which involves repetitive practise of (computerised) tasks aimed at 
enhancing underlying cognitive functions. Importantly, these studies unanimously 
concluded that cognitive training for deficits in EF is feasible and beneficial for 
patients with PD (Calleo et al., 2012). Another five RCT studies were conducted on 
cognitive training in PD. These more general studies targeted a  broader range of 
cognitive functions including EF (Cerasa et al., 2014; Paris et al., 2011; Pena et al., 
2014; Petrelli et al., 2014; Zimmermann et al., 2014). The results of these randomised 
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controlled trials showed that cognitive training led to an overall significant 
improvement of PD patients’ performance on neuropsychological test measures for 
EF. However, no evidence was found for generalisation of improvement to patients’ 
everyday life functioning (Calleo et al., 2012; Leung et al., 2015). In two recent studies 
of Pena et al. (2014) and Reuter et al. (2012) patients with PD received a skill training 
in addition to cognitive training. The skill training involved guided and repetitive 
practise of specific activities in everyday life. Only Reuter et al. (2012) included in 
addition to neuropsychological test measures, outcome measures that were related 
to functioning in everyday life. They found that after treatment, patients with PD had 
improved in terms of their QoL, functioning on treatment goals, self-confidence and 
employment of a more active life style. For patients with TBI, the use of cognitive 
rehabilitation programmes that are based on strategy training is highly recommended 
for improving impairments in EF in everyday life, whereas cognitive training solely 
based on repetitive practise is not (Cicerone et al., 2011). Strategy training aims at 
teaching patients cognitive strategies that help them compensate the cognitive 
impairments they encounter in their everyday life activities. A large number of studies 
found solid evidence for the effectiveness of such intervention programmes, even in 
the long term (Tate et al., 2014). For example, Spikman et al. (2010) showed 
effectiveness of EF strategy training that lasted at least 6 months post-treatment. 
They found that ABI patients who received strategy training resumed their previous 
roles in everyday life more often, showed more improvement with regard to setting 
and accomplishing realistic goals and showed better planning and regulation abilities 
than patients who received computerised cognitive training. However, patients in 
both groups showed no improvement on neuropsychological tests for EF or attention, 
which led the authors to conclude that although these tests may be sensitive to 
impairments, they are not sensitive to changes due to treatment. Recently, Foster and 
colleagues (2017) investigated the feasibility of an individualized cognitive strategy 
training in a case series of seven non-demented patients with PD. Patients evaluated 
this intervention as being acceptable and engaging, corroborating its feasibility. 
Although this study did not aim to evaluate the effectiveness of the intervention, 
patients also reported improvement on a scale for performance and satisfaction of 
everyday life tasks, which is promising. However, the cognitive targets for treatment 
were not specified in this study. Given that strategy training has a positive effect on 
indications of everyday life EF in ABI patients and the findings of the study of Foster et 
al. (2017) in patients with PD, it is surprising that the effect of strategy training on 
everyday life executive impairments has not yet been examined in patients with PD. 
Therefore, the main goal of the present study was to investigate the effectiveness of a 
cognitive rehabilitation programme based on strategy training (ReSET; Strategic 
Executive Treatment) on everyday life executive functioning, level of participation and 
QoL in patients with PD, both immediately after treatment and in the longer term. In a 
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RCT design we compared this cognitive rehabilitation programme based on strategy 
training to a computerised cognitive training for attention and working memory 
(Cogniplus). Attention and working memory are basic cognitive functions, which are 
also necessary when performing complex executive tasks. We hypothesise that 
Cogniplus may lead to improved performance on neuropsychological tests for aspects 
of EF, but will not translate into improved executive functioning in everyday life. This 
is in contrast to ReSET of which we expect that it will lead to improvement in everyday 
life executive functioning. A second goal was to investigate whether cognitive 
rehabilitation based on strategy training was feasible for patients with PD. When 
compared to ABI patients, motor impairments and fatigue might have a stronger 
negative impact on their abilities to follow out-patient treatment and to practise with 
assignments at home. 
Methods 
Study design and procedure  
This study was conducted in three medical centres in the Netherlands: University 
Medical Centre Groningen (UMCG), Maastricht University Medical Centre (MUMC) 
and Nij Smellinghe Drachten. The study was approved by the ethics review board 
(ERB) of the UMCG and was conducted in accordance with the declaration of Helsinki.  
Patients were eligible for participation in this study when they were aged 
between 18 and 80 years, diagnosed with PD according to the UK Parkinson’s Disease 
Brain Bank Criteria and had a disease severity ≤ Hoehn & Yahr (H&Y: (Hoehn & Yahr, 
1967)) stage 3, i.e. patients had to be mobile in order to visit one of the medical 
centres on a weekly basis for at least three months. Furthermore, patients had to be 
(1) motivated for treatment, (2) had to report problems with EF in everyday life they 
experienced as burdensome (based on semi-structured interview and/or a total score 
of ≥18 on the Dysexecutive Questionnaire (DEX: (Burgess et al., 1996)); and/or (3) had 
impairments on objective neuropsychological tests of EF. Impairments were defined 
as: a standard score of ≤2 on the subtests Zoo Map Test or Six Elements Test of the 
Behavioural Assessment of the Dysexecutive Syndrome (BADS: (Burgess et al., 1996)) 
and/or  a standard age total score on the BADS categorised as ‘low average” or lower 
and/or a discrepancy of 15 points between standard age score and premorbid IQ as 
measured with the short version of the Dutch Groninger Intelligence Test (Luteijn & 
van der Ploeg, 1983). Exclusion criteria were severe neurological and psychiatric 
comorbidity including dementia (i.e. SCales for Outcomes in PArkinson’s disease-
COGnition scale score ≤17 (Verbaan et al., 2011)). The above-mentioned tests and 
questionnaires were part of an extensive neuropsychological assessment. Results of 
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this assessment were used as the baseline measurement (T0) when patients were 
found to be eligible for participation in accordance with the inclusion criteria.  
Eligible patients were randomly assigned to either the experimental (ReSET) 
or control (Cogniplus) treatment by drawing lots. In order to balance the allocation of 
patients to both treatment conditions, lots were drawn per 4 patients (i.e. 2 
experimental and 2 control condition). A coworker who was not actively involved in 
the study was responsible for the drawing of lots.  
Both ReSET and Cogniplus consisted of 14 one hour sessions; once a week or 
if possible twice a week. Patients were assessed with a neuropsychological test 
battery (i.e. interview, tests and questionnaires) at three time points: baseline (T0), 2 
weeks post-treatment (T1) and 3-5 months after the last treatment session (T2). Well-
trained test assistants, who were blind for the treatment condition, administered the 
tests.  
Participants 
Forty-nine patients with PD were included (UMCG: n=33, MUMC: n=8,Nij Smellinghe: 
n=8). Six patients dropped out during the treatment period: 2 because of physical 
disabilities and 4 patients because of loss of motivation. Therefore, 43 patients 
(ReSET: n=24, Cogniplus: n=19) completed the treatment and post-treatment 
assessment (T1; Figure 1). Another 4 patients dropped out to 3-5 months post-
treatment assessment (T2): one patient had developed severe psychiatric 
comorbidity, one patient stated after four sessions that he considered himself to be 
sufficiently improved as he had no complaints anymore and therefore felt no 
necessity to continue the treatment and 2 patients could not complete assessment 
because of logistic reasons. Thirty-nine patients thus completed the study protocol 
(Figure 1).  
Disease severity was determined with the Unified Parkinson’s Disease Rating 
Scale motor part (UPDRS-III) and H&Y scale. A Levodopa equivalent daily dose (LEDD; 
(Esselink et al., 2004)) score was calculated for all patients who were on dopaminergic 
treatment. Three patients were not on dopaminergic treatment, for 2 patients 
medication use was not reported and 4 patients received Deep Brain Stimulation 
(DBS) in addition to dopaminergic treatment. Surgery was performed at least one year 
prior to study inclusion. Patients on dopaminergic treatment were in the on phase 
during treatment and neuropsychological assessment. Table 1 presents descriptive 
variables and disease characteristics of both treatment groups. No differences were 
found between treatment groups regarding age, disease duration and disease 
severity.  
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Furthermore, a healthy control group (n=90) was included to determine whether the 
patients with PD showed impairments in EF at baseline compared to healthy controls. 
Table 2 shows that both groups were comparable as there were no differences with 
regard to age, gender, premorbid IQ and level of education. However, at baseline 
patients with PD reported significantly more symptoms of anxiety and depression on 
the Hospital Anxiety and Depression Scale (HADS:(Zigmond & Snaith, 1983) than 
healthy controls.  
 
 
 
 
 
 
Figure 1. Flow chart of the inclusion process.  
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Experimental treatment ReSET: strategic executive treatment 
ReSET is an individual treatment, given by experienced neuropsychologists. The aim is 
to improve or stabilise the level of independence and QoL, by teaching patients 
strategies to compensate for impairments in EF in everyday life situations. These 
strategies allow patients to tackle everyday life situations in a systematic and 
structured way, by formulating their intentions and actions explicitly in terms of goals 
and sub goals (planning) and effectively executing these plans, while monitoring their 
behaviour.  
The content of the treatment protocol is based on the “Multifaceted 
treatment programme” of Spikman et al. (2010) and targets several aspects of EF as 
defined by Ylvisaker et al. (1998): self-awareness, goal setting, planning, initiation and 
monitoring of behaviour, flexibility and strategic behaviour. Adjustments were made 
to the protocol of Spikman et al. (2010) in order to make it more feasible for patients 
with PD. The number of sessions was reduced from 24 to 14. There were also fewer 
exercises per session as PD patients’ psychomotor tempo is often reduced (Vlagsma et 
al., 2016).   
The ReSET protocol consisted of 14 one-hour sessions that were grouped into 
three modules. The first module ‘Information and awareness’ consisted of three 
sessions aimed at increasing patients’ insight into their executive dysfunctions and the 
consequences of these dysfunctions in everyday life. This was achieved by giving 
psycho-education to patients and their relatives and evaluating patients’ strengths 
and weaknesses based on their performance on the neuropsychological assessment. 
In the third session, patients were asked to formulate three individual goals related to 
executive functioning that could be improved through the treatment (Vlagsma et al., 
2015) and were asked to rate their level of functioning regarding these goals.  
The second module ‘Goal setting and planning’ consisted of six sessions 
based on the General Planning Approach (GPA: Spikman et al., 2010). The GPA 
teaches patients to structure the planning and execution of activities by formulating a 
concrete goal and explicitly describing the actions that need to be carried out in order 
to achieve the goal in a step-by-step manner, the estimated time per action and the 
materials needed for accomplishing the goal. Furthermore, patients were taught to 
make a realistic and energy balanced day-to-day and week planning and learned to 
adjust their planning to their individual fluctuating energy level. Also they were taught 
how to use an organiser properly. Therapists’ assistance was gradually reduced over 
sessions. Homework involved mostly the execution of activities that were planned 
during the session. The homework assignments were evaluated at the beginning of 
each session. 
The third module ‘Initiative, execution and regulation’ consisted of five 
sessions. While in the second module the emphasis lay on the planning process, this 
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module focused more on the execution of the plan. During these sessions, Goal 
Management Training (GMT; (Levine et al., 2000) plays a central role in which patients 
are taught to build in a self-control mechanism that helps them to ‘keep on track’ and 
actually achieve their goals as planned. Furthermore, attention was given to making 
the initiation of a plan easier by using, external aids (e.g. organiser, alarm).  
Control treatment Cogniplus 
The training protocol of Cogniplus (Schuhfried, 2007) consisted of 14 one-hour 
sessions. Within these sessions six subtests of the computer training program 
Cogniplus (Schuhfried, 2007)(Schuhfried, 2007) were individually administered to 
patients. Five subtests aimed at training aspects of attention (i.e. alertness, selective 
attention, divided attention and vigilance) and one subtest aimed at training working 
memory. For the rest of this paper, the control treatment is referred to as ‘Cogniplus’. 
The program is basically self-supporting; however, a psychological test assistant was 
present to provide technical support if necessary. Each aspect of attention and 
working memory was trained with a separate task. During each session, patients 
performed three different tasks and trained different aspects of attention and 
working memory. This ensured that sessions remained challenging. Patients who 
received the computer training were also asked to formulate three individual 
executive goals during the third session and were asked to rate their level of 
functioning regarding their goals at baseline and post-treatment assessments. 
Measures 
All measures were administered at baseline, 2 weeks and 3-5months post-treatment, 
with exception of the Rey Auditory Learning Test (RAVLT: (Deelman, Brouwer, van 
Zomeren, & Saan, 1980)), which was only used at baseline.  
Primary outcome measure  
INTERVIEW 
The Role Resumption list (RRL: Spikman et al., 2010) is a semi-structured interview 
that measures patients’ level of participation in different societal domains (i.e. work, 
social relations, leisure activities and mobility; max. score=16). At all time-points 
patients were asked to compare their current level of participation to their 
participation level before diagnosis. A higher score reflects a lower level of 
participation.  
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Other outcome measures 
NEUROPSYCHOLOGICAL TEST MEASURES  
Executive functions 
EF were assessed with the Trail Making Test B/A ratio (TMT B/A: (Reitan, 1958)), the 
Visual Elevator subtest of the Test of Everyday Attention (TEA; number correct: 
(Robertson, Ward, & Ridgeway, V. & Nimmo-Smith, I., 1994)) and the Behavioural 
Assessment of the Dysexecutive Syndrome (BADS; age score: (Wilson, Alderman, 
Burgess, Emslie, & Evans, 1996)). Of the BADS subtests, the complex Zoo map subtest 
(total score) was also independently analysed.  
Attention and memory functions 
The Trail Making Test A (TMT A: Reitan, 1985) was used to measure selective 
attention and the RAVLT ((Deelman et al., 1980), a verbal memory test, measured 
immediate recall (IR) and delayed recall (DR).  
RATING OF GOAL ATTAINMENT 
Treatment goal attainment (TGA; Spikman et al., 2010) was used to measure 
treatment effectiveness as experienced by the patients. During the third session of 
each treatment, patients had formulated three personal goals which were related to 
executive dysfunctions in everyday life. Pre- and post-treatment, patients rated their 
level of functioning on these goals on a ten point scale (10=max., per assessment the 
mean score of three goals was used). At both post-treatment assessments, patients 
rated their level of functioning again (TGA: per assessment the mean score of three 
goals).  
QUESTIONNAIRES 
The Dysexecutive Questionnaire (DEX; total score: (Burgess et al., 1996) was used to 
assess problems in executive functioning in everyday life. The questionnaire was 
completed by participants (i.e. self-version) and patients’ significant others (i.e. proxy 
version). Healthy controls completed only the self-version of the DEX. A higher score 
reflects more problems with executive functioning in everyday life. 
The Brock Adaptive Functioning Questionnaire (BAFQ: (Dywan, 1996)) was 
used to measure aspects of adaptive functioning. Both a self and a proxy version were 
used. For the purpose of this study, only the scales related to EF were used (i.e. 
‘Planning’, ‘Initiative’, ‘Flexibility’, ‘Excess caution’ and ‘Impulsivity’). A mean total 
score of these subscales was calculated. A higher score represented more complaints.  
In order to assess patients’ health-related QoL, the Parkinson Disease 
Questionnaire (PDQ-39; total score (Jenkinson, Fitzpatrick, Peto, Greenhall, & Hyman, 
1997)) was used. A higher score indicated a lower level of QoL. 
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Caregiver burden was assessed with the short form of the Zarit Burden 
Interview (ZBI; total score: (Zarit, Orr, & Zarit, 1985)), which was completed by 
patients’ significant others. A higher score was related to a higher caregiver burden.  
Statistical analyses 
IBM Statistical Package for the Social Sciences version 22 was used for data analyses. 
Independent samples t-tests and non-parametric tests were used to compare 
descriptive and disease characteristics between patients with PD and controls and 
between treatment groups. Independent samples t-tests were also used to compare 
performances on neuropsychological tests of (1) patients with PD in the experimental 
condition and patients in the control condition at T0 and (2) patients with PD and 
healthy controls at T0. Treatment effects were analysed with repeated measures 
ANOVAs. This univariate analysis was chosen in order to minimise data loss due to 
missing values. The dependent variables were the RRL, TGA, DEX-self, DEX-proxy, 
BAFQ EF-self, BAFQ EF-proxy, TMT B/A, BADS age score, TEA visual elevator, TMT A, 
PDQ-39 and ZBI. Possible time and interaction effects of the treatment conditions 
with respect to these outcome measures were analysed in two steps: T1 versus T0 
and T2 versus T0. In addition, the effect sizes (partial-eta-squared) were calculated. An 
effect size of 0.01 was labelled as small, 0.06 as medium and 0.14 as large (Fritz, 
Morris, & Richler, 2012). For statistical analyses an alpha of 0.05 was applied. At T2 
the percentage of missing values was 15.4% for the primary outcome measure (RRL), 
17.9% for the ZBI, 15.4% for the TEA map search, 10.3% for the BAFQ proxy version 
and 2.6% at maximum for the other outcome measures. This was mainly due to 
logistic reasons within one of the participating centres.  
Results 
Comparisons at baseline 
Table 2 shows that Patients with PD reported significantly more problems at baseline 
(T0) with executive functioning in everyday life than healthy controls. Furthermore, it 
was found that PD patients’ performance was significantly lower on objective tests of 
EF and attention compared to healthy controls.  
Tables 1 and 3 show that there were no significant differences at T0 between 
the experimental (ReSET) and control (Cogniplus) group with regard to descriptive and 
disease characteristics, global level of cognitive functioning (SCOPA-COG), symptoms 
of anxiety and depression and any of the outcome measures.  
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Table 3. Baseline performance of patients with PD in both treatment conditions on primary 
and secondary outcome measures. 
ReSET (n=24) Cogniplus (n=19)  
 M (SD) M (SD) t p 
Primary outcome       
     RRL total 4.77 (2.00) 4.67 (2.72) 0.14 0.888 
Neuropsychological tests       
     EF       
          TMT B/A 2.52 (1.05) 2.65 (0.86) -0.43 0.672 
          Zoo-map total score 7.88 (5.62) 5.79 (6.28) 1.15 0.258 
          BADS age score 97.17 (15.73) 99.63 (9.56) -0.60 0.552 
          TEA visual elevator 7.14 (2.21) 7.87 (2.70) -0.90 0.373 
     Attention & memory       
          TMT A 46.38 (13.25) 40.37 (14.07) 1.44 0.158 
          RAVLT IR 38.08 (11.59) 37.42 (10.53) 0.19 0.847 
          RAVLT DR 7.50 (3.34) 8.32 (2.98) -0.83 0.409 
Questionnaires       
     EF       
          TGA 4.50 (1.04) 4.23 (1.37) 0.74 0.465 
          DEX self 24.08 (10.66) 24.79 (10.89) -1.17 0.252 
          DEX proxy 20.74 (14.75) 22.26 (10.98) -1.80 0.087 
          BAFQ-EF self 2.27 (0.55) 2.40 (0.48) -0.79 0.437 
          BAFQ-EF proxy 2.11 (0.71) 2.36 (0.59) -1.14 0.264 
     QoL & caregiver burden       
          PDQ-39 44.50 (21.43) 52.74 (21.28) -1.26 0.216 
          ZBI 10.32 (7.68) 10.21 (9.57) 0.04 0.968 
Note. RRL = Role Resumption List; TMT B/A = Trail Making Test B/A ratio; BADS age score = 
Behavioural Assessment of the Dysexecutive Syndrome total standard age score; TEA = Test of 
Everyday Attention; TMT A = Trail Making Test A; RAVLT IR = Rey Auditory Verbal Learning Test 
immediate recall; DR = delayed recall; TGA = Treatment goal attainment; DEX = Dysexecutive 
Questionnaire; BAFQ-EF = Brock Adaptive Functioning Questionnaire: sum of executive function 
scales; PDQ-39 = Parkinson’s  Disease Questionnaire; ZBI = Zarit Burden Interview.  
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Effects of treatment  
Table 4 shows the results of the repeated measures analyses of T1 versus T0. No 
difference was found between T0 and T1 or between groups on the primary outcome 
measure (RRL). Also, small effect sizes were found for these comparisons. Patients in 
both treatment conditions reported a significant improvement of functioning related 
to their treatment goals (TGA) at T1, with patients in the ReSET condition showing a 
significantly greater improvement than patients in the Cogniplus condition (large to 
medium effect sizes respectively). Furthermore, at T1 both treatment groups showed 
a significant reduction of problems on the DEX-self compared with T0, with patients in 
the ReSET condition showing a significantly larger reduction than patients in the 
control condition (medium effect size). In both groups at T1, patients’ significant 
others did not report a reduction of problems on the DEX-proxy compared with T0. No 
differences were found regarding the performances on the neuropsychological tests, 
BAFQ-self and proxy version, PDQ-39 and Zarit.  
Table 5 shows the results of the repeated measures analyses of T2 versus T0. 
No difference was found between T0 and T2 and between groups on the RRL (medium 
and small effect sizes, respectively). Furthermore, patients in both treatment 
conditions still reported a significant improvement at T2 of TGA compared with T0 
(large effect sizes). However, there is no difference between the groups (medium 
effect size). At T2 the number of problems reported on the DEX-self in both treatment 
groups was also significantly reduced compared with T0, but there was no significant 
difference between the groups (large to small effect sizes, respectively). In both 
groups, patients’ significant others did not report a reduction of the problems on the 
DEX-proxy at T2 compared with T0 (medium effect size). Regarding the performances 
on neuropsychological tests, only a significant interaction was found for the Visual 
elevator. For both treatment groups no time or interaction effects were found on the 
BAFQ-self and proxy version, PDQ-39 and Zarit at T2. 
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Discussion 
This is the first RCT that studied the effectiveness of a strategy training (ReSET) for 
improving EF in everyday life, level of participation and QoL in patients with PD. 
Recent studies concluded that cognitive training is feasible and beneficial for patients 
with PD with EF deficits. However, these studies evaluated protocols that were 
primarily based on cognitive training (i.e. repetitive practise of (computerised) tasks in 
order to strengthen EF) but restricted their measurement of treatment outcome to 
performances on neuropsychological tests. Hence, it remained unclear whether there 
was an effect of treatment on everyday life executive functioning of patients with PD 
and whether this lasted over time. Foster et al. (2017) recently showed that also 
strategy training is feasible for patients with PD; however, the effectiveness of their 
intervention was not investigated. The primary aim of the current study was to 
investigate whether a strategy training for EF, called Reset, would improve PD 
patients’ functioning in everyday life more than a cognitive training (Cogniplus) and 
whether this effect would last over time.  
Unfortunately, ReSET did not lead to overall improvement on measures of 
everyday life executive functioning in the long term. However, immediately after 
treatment patients in the strategy training group (ReSET) reported to have attained 
their goals to a larger extent and to have experienced fewer executive complaints 
than patients in the control condition receiving cognitive computerised training 
(Cogniplus). At follow up this group difference had disappeared although both patient 
groups still reported improvement compared to pre-treatment functioning on both, 
relatively subjective measures (i.e. goals and DEX questionnaire). We found no 
changes on other measures of everyday life executive functioning or on 
neuropsychological tests for EF for both treatment groups after treatment. The drop-
out rate during treatment was relatively small (n=6), showing that the majority of 
patients with PD with a relatively mild disease severity (H&Y I-III) were able to 
complete the treatment programmes in an outpatient setting. This underlines the 
finding of Foster et al. (2017) that, as with cognitive training, also cognitive 
rehabilitation programmes based on strategy training can be feasible for patients with 
PD  
We did not find significant effects of ReSET and Cogniplus on the primary 
outcome measure, the RRL. This measure was chosen because it had been proved to 
be a valid measure of the effectiveness of EF strategy training on participation level of 
ABI patients in a previous study (Spikman et al., 2010). In the present study, however, 
patients with PD showed no improvement with regard to their level of participation 
(work, social relations, leisure and mobility) irrespective of the type of treatment they 
received. There are several explanations for this lack of result. First, the RRL assesses 
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participation by requiring patients to compare their current participation level to a 
previous level in the period prior to the diagnosis of PD. In contrast to patients with 
ABI, for patients with PD the moment of onset of the disease is not always clear cut 
since the majority of patients were diagnosed after a long period (sometimes years) of 
having gradually progressing symptoms. Furthermore, for many patients reporting a 
decreased participation with regard to work, social activities, leisure or mobility this 
was not always clearly related to cognitive dysfunction; patients indicated that motor 
impairments and fatigue had a significant negative influence as well. In addition, the 
majority of patients were already unemployed pre-treatment, either because they 
had already reached their retirement age (the patients with PD were on average older 
than the ABI group in the study of Spikman et al., 2010) or because they had quit their 
job before retirement age because of Parkinson related symptoms. For these patients, 
functioning on the work-subscale of the RRL could not be rated, narrowing the score 
range substantially. For these reasons, we deem the RRL far less suitable and less 
sensitive to measure changes in participation in patients with PD than had been the 
case for ABI patients.  
At baseline, the patients with PD showed impairments on all 
neuropsychological tests for EF and attention, when compared to healthy controls. 
Patients with PD also reported significantly more problems with executive functioning 
in everyday life (DEX) than healthy controls. Furthermore, at baseline the ReSET and 
Cogniplus group did not differ with regard to demographic and disease characteristics, 
performance on objective neuropsychological tests and the number of problems with 
EF in everyday life, level of participation and QoL. Thus, prior to treatment both 
treatment groups did not differ from each other, which indicates that differences 
between groups found after treatment cannot be explained by differences between 
the groups at baseline.  
The finding that patients in both treatment groups reported some 
improvement on two subjective indications of executive functioning, with a slight 
advantage for the ReSET group directly after treatment but that disappeared at follow 
up, strongly suggests that patients subjectively experienced some benefit of 
treatment. However, for both groups the significant others of the patients with PD did 
not report to have observed a reduction of the EF problems that patients exhibit in 
everyday life. This contrast suggests that the reduction of problems that patients 
experience is not visible to others and may indicate merely that patients have attained 
a higher level of control and self-efficacy, i.e. that they have gained more confidence 
in their ability to plan and execute everyday life tasks, regardless of whether this is 
actually the case. Since previous studies have demonstrated that perceived self-
control and self-efficacy matter when it comes to dealing with a chronic illness such as 
PD in relation to well-being, we deem this a relevant finding (Kuijer & De Ridder, 2003; 
Rosqvist et al., 2016; Thombs, Kwakkenbos, Riehm, Saadat, & Fedoruk, 2017). 
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Nevertheless, we could not demonstrate that ReSET or Cogniplus resulted in 
significant improvement of PD patients’ QoL or in a decrease of their caregivers’ 
burden. Given that PD patients’ functioning will gradually deteriorate over time 
because of the neurodegenerative character, one could also argue that finding no 
change in QoL and caregivers’ burden over time is in fact a positive outcome. An 
additional explanation for lack of change regarding caregiver burden may be that the 
average caregivers’ reported burden before treatment was already rather low 
(M=8.92-11.00; max. 48), which reduces the possibility to find improvement on this 
measure.  
With regard to neuropsychological tests for EF, a significant interaction effect 
was found at 3-5 months post-treatment on the TEA Visual elevator test. Contrary to 
our expectation, patients who received ReSET showed a slightly better performance 
than at baseline, whereas the performance of the control group had worsened. This 
finding is hard to explain, because if improvement on such a task was expected this 
would be the case for those patients who received the attention training in the 
Cogniplus protocol. Furthermore, for both treatment groups we did not find improved 
performance after treatment on the other neuropsychological tests for EF and 
attention. Previous studies that examined cognitive training in PD sometimes showed 
improvement on neuropsychological tests (Calleo et al., 2012; Leung et al., 2015). 
However, it has been demonstrated that cognitive training that primarily aims at 
improving specific cognitive functions only leads to improvement on 
neuropsychological measures that bear great resemblance to the tasks that were used 
in the treatment (near-effects), whereas only rarely has improvement been found on 
other neuropsychological tests or on measures for everyday life functioning (far-
effects) (Cicerone et al., 2011). However, the primary aim of ReSET in this study was to 
teach patients compensatory strategies in order to better cope with their impairments 
in EF in everyday life. Hence, we expected not to find changes on neuropsychological 
tests for EF. Even more so, these tests are considered to be less sensitive to changes in 
functioning because they have to be complex and new to require the use of EF, which 
will not be the case when used for repeated assessment.  
The current study has some limitations that need to be mentioned. First, only 
patients with a mild to moderate disease severity (H&Y stage 1 to 3) were included. 
However, in more severely impaired patients (H&Y stage 4 and 5) it is very likely that 
cognitive impairments will become more frequent and more severe, and that the 
percentage of patients who develop dementia will increase. We expect that cognitive 
rehabilitation aimed to learn and apply a strategy will be too demanding for the 
cognitive capacities of this subgroup. Possibly, these patients can still benefit from 
skill training (i.e. training of specific activities), which offers more structure. This is an 
interesting topic for future studies. In general, the sample size was small, which had a 
negative influence on the power. However, compared to previous studies on 
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neuropsychological rehabilitation in patients with PD, the sample sizes are relatively 
large. Another limitation is that at T2 the percentage of missing values was 
unfortunately high for some outcome measures. Consequently, it might be that 
significant results were not found due to a lack of power. Furthermore, another 
limitation pertaining to the amount of time spent on training was not equal for both 
conditions. Even though both ReSET and Cogniplus consisted of 14 one-hour sessions, 
patients in the ReSET group had to spend additional time because practising the 
planning and execution of everyday activities in their home environment was an 
important element of the strategy training, whereas patients in the Cogniplus group 
could only practise during the session itself. 
In conclusion, this study demonstrates that patients with PD with a mild 
disease severity (H&Y ≤ 3) were able to adhere to a neuropsychological rehabilitation 
programme, despite of their motor symptoms and fatigue, as indicated by the low 
drop-out rate. This indicates that participating in the treatment programmes ReSET, 
and Cogniplus, is feasible for this group of patients with PD. With regard to the 
effectiveness of both treatment programmes, the results of the present study show 
that both cognitive rehabilitation including strategy training (ReSET) and cognitive 
training (Cogniplus) lead to some self-reported subjective improvement of executive 
functioning in everyday life, with a slight advantage of ReSET directly after treatment 
compared to the Cogniplus. This suggests that patients subjectively experienced some 
benefit of neuropsychological rehabilitation in general (i.e. may seem to have attained 
a higher level of control and self-efficacy regarding executive functioning in everyday 
life), even though this was not visible to their significant others. 
 Because of the neurodegenerative character of PD, future research should 
focus on determining up to which point in the progression of the disease patients are 
actually able to learn and benefit from cognitive rehabilitation programmes based on 
strategy training. A large number of patients will eventually develop a dementia 
(Vasconcellos & Pereira, 2015), which means that providing external structure will 
become more and more important when the disease progresses. Therefore, we deem 
it worthwhile to involve caregivers more intensively during treatment sessions, so 
they can gradually increase their assistance in structuring patients’ everyday life 
activities over time. Furthermore, because of the heterogeneity and complexity of the 
disease, it is highly important to tailor treatment programmes to patients’ individual 
needs for use in clinical practice. Finally, because of the progressive character of PD, 
which leads to deterioration of patients’ physical and cognitive functioning in 
everyday life, not only improvement of PD patient’ level of everyday life functioning 
should be considered a desirable outcome of neuropsychological rehabilitation, but 
also a stabilization of their level of functioning for a longer time period than would be 
the case for patients who do not receive treatment would be advantageous.  
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Geolocation information 
This study was conducted in three medical centres in the Netherlands: 1) the 
University Medical Centre Groningen located in Groningen, the Netherlands; 2) Nij 
Smellinghe a medical centre located in Drachten, the Netherlands; and 3) Maastricht 
University Medical Centre located in Maastricht, the Netherlands.  
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Summary 
In chapter one a general introduction is given on Parkinson’s disease, executive 
functions (EF) and neuropsychological assessment of EF. Furthermore, the principles 
of neuropsychological rehabilitation and cognitive training are illustrated. The general 
introduction closes with the thesis aim and outline. The aim of this thesis was to 
characterize EF related to its assessment and to evaluate a strategic training in 
patients with PD.  
The primary aim of our study as described in chapter two, was to determine 
whether patients with PD show mental slowness (bradyphrenia) apart from the 
assumed motor slowness (bradykinesia). In this study the use of the term bradykinesia 
primarily refers to the aspect of motor slowness. Patients with PD were assumed to 
show motor slowness and to a certain extent mental slowness in comparison with 
healthy controls. In addition the study hypothesised that particularly mental slowness, 
if found, would have a negative influence on patients´ neuropsychological test 
performance. This was investigated with a simple reaction time task (Vienna Test 
System) that offered the possibility to distinguish between a mental component (i.e. 
reaction time) and a motor component of the response (i.e. motor time). Surprisingly, 
no significant differences were found when the motor times of patients with PD were 
compared to the motor times of healthy controls. Patients with PD showed however 
significantly slower reaction times than healthy controls. We therefore concluded that 
patients with PD show mental slowness apart from motor slowness. Reaction and 
motor times of patients with PD were not related to clinical measures of disease 
severity (i.e. H&Y and UPDRS-III). Mental speed was not a predictor of 
neuropsychological test performance, however motor times were a significant 
predictor of performance on two tests of attention (TMT A and Stroop Color-
Word/Color card ratio). This finding implicates that for patients with PD motor 
slowness needs to be taken into account when interpreting results on these tests.  
In chapter three we investigated whether objective measures (i.e. 
neuropsychological tests) and subjective measures (i.e. questionnaires) of EF are 
associated in a group of non-demented patients with PD. Furthermore, it was 
investigated whether impairments in EF measured with tests predict patients’ level of 
participation and QoL. No associations were found between objective and subjective 
measures of EF, indicating that each set of measures represents a unique part of the 
spectrum of EF problems of these patients. Both types of measures, gender and 
disease severity were moderate predictors of participation and/or QoL in patients 
with PD.  
In chapter four we compared the general cognitive and executive profile 
(based on neuropsychological test performance) and needs and aims (as 
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operationalised by individual treatment goals) of patients with PD to a group of ABI 
patients to investigate whether there are structural differences between both groups 
that might justify why cognitive rehabilitation is not yet offered as standard therapy in 
patients with PD. Patients underwent an extensive neuropsychological test battery 
and set three individual goals they wanted to attain by means of the EF treatment. 
These goals were first classified into domains of EF and subsequently into domains of 
basic functioning, daily life activities and participation. We found that PD and ABI 
patients’ neuropsychological profile as well as their goals were highly comparable. 
Interestingly, patients with PD set more goals related to “time management” (aspect 
of EF) and “housekeeping and gardening” (domains of everyday life functioning) than 
ABI patients. In sum, we found no reasons to assume that patients with PD cannot 
benefit from strategic executive training.  
Chapter five presents a review on cognitive rehabilitation in patients with PD. 
Knowing that impairments in EF are predominant in PD, specific attention was given 
to the extent to which the included studies focused on improving impairments in EF. 
Nine studies (2004-2013) were included and evaluated in terms of methodological 
quality and effectiveness. In addition, these rehabilitation programmes were classified 
regarding type of training applied (i.e. function, skill and strategy training) and the 
outcome measures were classified into three ICF levels: function level, 
activity/participation level and psychosocial level. Findings of these studies indicate 
that cognitive rehabilitation is feasible and effective in terms of improving cognitive 
functioning measured with neuropsychological tests. An important limitation of these 
studies is that the majority of treatment programmes included function training only 
and also measured outcome on function level only. Thus, it remains unclear whether 
effects generalize to everyday life functioning for patients with PD. Besides, relatively 
little attention was paid to treatment of impairments in EF. Since strategy training was 
found to be effective for ABI patients, we conclude that future research is needed to 
study the effectiveness of strategy training in improving executive functioning in 
everyday life, participation in societal domains and QoL in patients with PD. 
Chapter six describes the results of the RCT we carried out on the 
effectiveness of ReSET; a Strategic Executive Treatment compared to a computerised 
function training (Cogniplus) in patients with PD. At 2 weeks and 3-5 months post-
treatment, patients in both the ReSET and Cogniplus condition reported an 
improvement in functioning regarding their individual treatment goals and reported a 
decreased number of executive complaints in everyday life functioning. Only at two 
weeks post-treatment this self-reported improvement was significantly greater in the 
ReSET group than in the Cogniplus group. Patients’ significant others in both groups 
did, however, not report a significant decrease of executive problems after treatment. 
Therefore, we suggested that it was mainly patients’ belief of self-efficacy that might 
have been strengthened after treatment, which was apparently not observable for 
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significant others in terms of improved functioning in everyday life activities. Both 
treatments had no effect on patients’ general level of participation and QoL. This 
means that we found insufficient evidence to confirm the hypothesis that, as it was 
found in ABI patients (Spikman et al., 2010), strategy training is more effective than 
function training for improving impairments in EF in everyday life functioning, level of 
participation and QoL in patients with PD. Future research should focus on 
investigating for which specific group of patients with PD which type of treatment is 
most beneficial in terms of improving everyday life functioning and QoL.  
Chapter 7 comprises a general discussion of the preceding chapters, in which 
the most important results are summarized and in particular the clinical relevance of 
these conclusions is described. Furthermore, recommendations for future research 
are made based on the clinical lessons that have been learned from the studies as 
described in the individual chapters.  
General discussion 
In this section we will discuss the main issues related to both the assessment and 
treatment of impairments in EF in patients with PD, based on the studies that were 
summarized in the previous section. 
Slowness in PD: mental versus motor slowness  
Bradykinesia (i.e. slowness and diminished amplitude of movement) is one of the core 
motor symptoms in PD. In addition, bradyphrenia or slowness of information 
processing is believed to be common in patients with PD as well. A long-standing 
research question we tried to answer in this thesis was whether patients with PD 
show mental slowness in addition to motor slowness, or in other words whether 
mental and motor slowness can be distinguished. If so, a subsequent question 
pertains to which type of slowness is dominant in terms of affecting performance on 
neuropsychological tests of attention, memory and EF.  
In our study as described in chapter 2, we used a reaction time task (Vienna 
Test System) to differentiate between a mental speed of information processing 
component (i.e. reaction time= time between presentation of stimulus to lifting the 
index finger from the rest key) and a motor component (i.e. motor time = time 
between lifting the finger from rest key to response key) of the response. We found 
that patients with PD showed slower reaction times than healthy controls, but 
contrary to our expectations, their average motor times were not slower than those 
of healthy controls. An important remark here is that all patients were on dopamine 
medication while tested, which may have interfered with a valid measurement of 
motor slowness. Furthermore, we had expected to find an association between the 
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(on medication) UPDRS-III score and the degree of motor slowness in patients with 
PD. However, no significant correlation was found. A possible explanation for this 
finding could be that in addition to bradykinesia, the UPDRS-III measures a range of 
other motor symptoms (e.g. rigidity and postural balance) and as such lacks 
specificity. To overcome this problem the sum score of the relevant UPDRS-III items 
should be used to operationalize bradykinesia. Unfortunately, in most patients´ 
medical files of our samples only a total score on the UPDRS-III was reported.  
Another interesting explanation refers to the assumption that slow motor 
times reflect bradykinesia and whether this is correct. Given the recent literature (Wu 
et al., 2015), bradykinesia and other motor symptoms of PD are thought to be the 
result of an underlying impaired motor automaticity instead of basic slowness of the 
actual executed movement itself. Because of degeneration of dopamine producing 
neurons in the basal ganglia, especially the function of the sensorimotor striatum 
becomes impaired, which is essential in facilitating automatic motor behaviour in 
healthy people. As a consequence, a higher degree of attentional control provided by 
cortical regions and specifically the associate striatum is needed in order to 
consciously initiate motor behaviour. This indirect route is per definition slower than 
when motor behaviour is generated automatically, since each sub-movement has to 
be initiated in an effortful, conscious manner. Wu et al. (2015) describe that even 
simple repetitive movements as measured with the UPDRS-III (e.g. finger tapping) are 
automatically executed by healthy people, whereas patients with PD have difficulty 
with internally generating these movements. This suggests that the clinically observed 
slowness of movement, defined as bradykinesia, might be interpreted as apathy-
driven slowness. This means that very likely it is caused by an accumulation of 
repeatedly delayed initiation of movements instead of a slow execution of the 
movements itself. This might explain the lack of correlation between motor times and 
the UPDRS-III total score, since the motor times in the reaction task refer to the pure 
motor action, filtering out the initiation of the movement. 
Following this line of arguments, it is plausible that if the slowness in the 
reaction time task is related to an initiation problem, this will likely affect the 
execution of everyday life activities in patients with PD, in which we observed 
difficulties during the ReSET programme. The execution and completion of everyday 
life activities (e.g. cooking) requires the initiation of a series of sub-actions which 
needs to be internally generated. In healthy people daily behavioural routines like 
brushing your teeth or eating breakfast with a spoon are carried out automatically 
(Wu et al., 2015). For patients with PD, because of their automatization problems, 
more attentional control will be required to initiate these sub-actions resulting into a 
delay of the execution of the specific behavioural routine. This is in line with the 
clinical experience that patients with PD especially have difficulty with estimating the 
time necessary to execute their plans (which they are able to make) and with initiating 
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the execution of a task, while they do know how to do it. In terms of Ylvisaker’s (1998) 
classification of aspects of EF, we postulate that apathy-driven ‘initiation’ seems to be 
the aspect that is primarily affected and thus can be considered a core impairment in 
EF in patients with PD.  
Cognitive rehabilitation: what is the merit? 
The question whether patients in PD would benefit from strategy training was a major 
topic in this thesis. Based on the results we can conclude that at two weeks and 3-5 
months post-treatment, patients in both the ReSET and Cogniplus condition reported 
an improvement in functioning on their individual goals and reported a decreased 
number of executive complaints in everyday life functioning (DEX). Two weeks post-
treatment, this self-reported improvement was significantly greater in the ReSET 
group than in the Cogniplus group. Although this improvement was not reported by 
patients’ relatives, we believe that this may be an important and promising finding 
with respect to outcome on a participation level. We could interpret the results as an 
increase in the extent to which patients’ perceived to have control in daily life 
situations that is related to self-efficacy. Self-efficacy in turn has been found to 
positively affect overall well-being and QoL (Bowen et al., 2015). However, in our 
study no effects were found for both treatments on the level of participation and QoL. 
As such, our study did not support a superior effect of strategic training over 
functional training, as was described in ABI patients (Spikman, Boelen, Lamberts, 
Brouwer, & Fasotti, 2010).  
One explanation for this lack of finding is that although ABI and patients with 
PD may have EF impairments in common, there are still differences in terms of 
disease related demographic characteristics and symptomatology. For instance, PD is 
a neurodegenerative disease characterised by a progressive course that leads to 
gradual deterioration of (motor) functioning, independency and level of participation, 
whether the cause of ABI is usually readily apparent with symptoms becoming 
manifest shortly after the injury (more acute type of brain injury). Also, patients with 
ABI and PD are confronted with their impairments in different stages of their lives, 
with ABI patients having a younger mean age at onset than Parkinson’s disease 
(usually onset between 50-60 years). This means that impairments in EF influence the 
level of participation (i.e. work, social relations, leisure activities and mobility) for 
patients with ABI and PD in a different way and to a different extent. For example, a 
majority of the patients with PD was unemployed because they either reached the 
age of retirement or were found to be unable to work because of motor impairments. 
Resumption of work was not a realistic nor desired goal for those patients. Except for 
possible cognitive and executive impairments, participation in the domains of social 
relations, leisure activities and mobility was also frequently limited in patients with PD 
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due to their motor impairments (e.g. bradykinesia, tremor, postural instability) and 
fatigue. For instance patients were less involved in social and leisure activities because 
they felt too tired and became unable to drive a car, which limited their mobility. Daily 
activities in patients with PD are usually much more confined to activities that can be 
done in and around the house than those for ABI patients. Also, when PD progresses, 
mobility of patients decreases further and they become even more home bound. The 
relatively young ABI group in the study of Spikman et al. (2010) was actively 
participating in the mentioned domains until they were suddenly unable to participate 
due to the acute type of brain injury (e.g. unable to work, unable to keep up their 
social relations). Results showed that strategic executive training helped these 
patients to actually resume those societal roles.  
We conclude that for patients with PD it is more important and realistic to 
focus on stabilization rather than improvement of their level of participation in terms 
of increasing activities in societal domains instead of resumption of previous roles. 
Stabilization of the participation level and QoL as long as possible should be 
considered as a beneficial outcome.  
Another explanation for the lack of treatment effects on the participation and 
QoL in patients with PD might be related to the specific clinical characteristics of our 
sample as experienced during treatment. The General Planning Approach has a 
central role within the strategic executive treatment (ReSET). This approach helps 
patients to execute everyday life activities more efficiently by teaching them to 
consciously formulate the goal of the activity, determine the individual steps that 
need to be carried out, put the steps in the right order and describe the materials and 
expected time that will be needed per step. When using this approach, patients are 
provided with a structure which helps them to actually execute and complete the 
intended activity and as such may provide feelings of control. The previous study of 
Spikman et al. (2010) proved that this approach was beneficial for ABI patients, since 
these patients had especially problems to come up with the individual steps and to 
execute these steps in a logical order. For the majority of patients with PD, however, 
we found that formulating the individual steps for a certain activity and putting them 
in the right order was not a major problem. Therefore, the merit of using GPA was 
mainly to obtain a realistic view of the actual time needed for activities and sub-steps. 
It appeared that patients with PD estimated the needed time mostly shorter than the 
actual time investment that was needed. In everyday life, patients with PD seemed to 
insufficiently take into account their apathy driven slowness when planning an 
activity, since they persisted in making the same daily to-do-lists as they were used to 
before their diagnosis. This frequently led to frustrations, because they could not 
complete their daily tasks in the estimated time span. Teaching how to use a diary 
efficiently was therefore another beneficial part of the ReSET protocol. Patients 
learned to routinely use a diary not only for important appointments, but even more 
529605-L-sub01-bw-Vlagsma
Processed on: 11-3-2019 PDF page: 130
 
chapter 7 
 
130 
for planning everyday life activities in and around the house. This helped patients to 
obtain a visual overview of their week programme and to evaluate whether this was a 
realistic planning. Besides, the diary functioned as an external reminder for actually 
initiating activities and getting them done.  
Our clinical experiences that impairments in EF in PD especially involve 
problems with time management are in line with the findings of the study described in 
chapter 5. When treatment goals of PD and ABI patients were classified into domains 
of EF, it appeared that patients with PD set significantly more goals related to time 
management than ABI patients. Thus, it seems that patients with PD are unable to 
adjust their daily schedule to their overall slowed tempo, which they experience as 
burdensome.  
In sum, similarities but also some essential differences were found between 
the PD group described in this thesis and the group of ABI patients described in the 
previous study (Spikman et al., 2010), with regard to the presentation of impairments 
in EF and the extent and way these impairments hinder patients in their everyday life 
functioning. We conclude that in contrast to ABI patients, for patients with PD 
neuropsychological rehabilitation should not be aimed on resumption of roles or 
improvement of executive functioning. Instead the focus should be on maintaining 
their current level of everyday life functioning as long as possible, by providing them 
with tools to execute preferred activities in time.  
Clinical implications with regard to cognitive treatment of EF in 
patients with PD 
One can question whether strategy training is the most preferred type of cognitive 
treatment in this group of patients with PD given our hypothesis that initiation 
problems play a central role in patients with PD. After all, the General Planning 
Approach and Goal Management Training still appeal strongly to patients’ abilities to 
initiate and structure activities when applying these methods in everyday life. We 
suggest that skills training would possibly be a better alternative in patients with PD 
that encounter significant initiation problems. This type of training aims at improving 
the execution of specific everyday life activities by repetitive training of the sub-
actions that are needed to accomplish the activity. In other words, training specific 
routines in order to re-automatize these routines without the purpose that these will 
generalize to other activities. Compared to strategy training, skills training offers more 
structure and depends less on patients’ initiative. Moreover, the trainer is actively 
present when training patients and thus has the possibility to correct errors 
immediately. Errorless learning has a positive influence on the outcome but was not 
possible during our programme because of practical reasons. The execution of plans 
by making use of GPA and GMT could only be verbally evaluated in the following 
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session. For clinical practice, it can be valuable to collaborate with occupational 
therapists who do have the opportunity to train patients in their home environment.  
Improving patients’ feeling of self-efficacy can also be a valuable aim of 
treatment in itself, since a sense of self-efficacy is crucial for well-being and QoL 
(Bowen et al., 2015). Based on the findings of this thesis, computerised function 
training (Cogniplus) is also a good option for this purpose. Starting with such a 
function training gives patients the idea that they are actively working on reducing 
their problems. This may increase their sense of self-efficacy in the first place and 
might also motivate patients for further treatment.  
Is ReSET more suitable for another subgroup of patients with 
PD?  
We still believe that strategic executive training could be a beneficial treatment for a 
specific subgroup of patients with PD. This would concern younger patients with PD 
than those included in this study. Patients, who are in the early stage of disease with 
only mild symptoms (H&Y I) and who are still actively participating within the domains 
of work, social relations, leisure activities and mobility. Strategy treatment would be 
an option if patients experience some burden of their impairments in EF which will 
fuel their motivation to undergo intensive treatment. Such a subgroup would 
probably be more comparable in terms of demographic characteristics to the ABI 
group in the study of Spikman et al. (2010), for whom strategic executive training was 
clearly beneficial.  
Furthermore, we believe that it might be even best to offer patients with PD 
strategic executive training as soon as they report complaints of executive 
impairments in daily life, without having objective impairments, which was an 
inclusion criterion in our study. The main reason for this is that in the early stage of PD 
patients’ memory capacity and attentional functions are largely intact which are 
essential requirements for learning new strategies and usually worsen when the 
disease progresses. Given that patients with PD will develop executive impairments 
somewhere along the course of their disease, it might be advantageous to already 
learn patients effective strategies during the early stages of the disease. Possibly, 
patients benefit longer from using such strategies by the time executive impairments 
worsen. Subjective impairments will probably better motivate patients to start an 
intensive intervention like ReSET, as compared to objective impairments, not (yet) 
experienced as burdensome in everyday life. Furthermore, we would highly 
recommend to actively involving partners or relatives during the treatment 
programmes in future research. When partners or relatives also become familiar with 
the tools and approaches that allow them to compensate for executive impairments 
early-on, it will probably lead to increased understanding of executive impairments. 
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They can use these methods to provide patients with more structure in later stages of 
the disease when patients become increasingly dependent of external structure and 
remind patients to make use of those strategies 
Increasing patients’ awareness of problems with time management and 
offering strategies to improve this seems to be particularly valuable when evaluating 
the treatment goals of patients with PD and the clinical experiences of working with 
the ReSET protocol. So, one could argue that giving patients and their partners or 
relatives psychoeducation on this topic might already be of significant value for 
improving their perceived impairments with EF in everyday life. This is an important 
issue to address in future studies, since it might provide a cost-effective treatment 
alternative for impairments in EF in patients with PD. 
Recommendations for neuropsychological assessment of EF in 
PD 
In several studies as described in this thesis, evidence was found that impairments in 
EF are common in patients with PD. However, the clinical presentation of these 
impairments and the impact on everyday life seems to be different from ABI patients. 
To be able to use this knowledge in clinical practice, it is essential to know how 
problems with EF can be recognized in patients with PD. Or in other words: what is 
needed in neuropsychological assessment for patients with PD to get a realistic view 
on their specific impairments in EF? 
Standard neuropsychological tests (e.g. Trail Making Test or a simple reaction 
time task (Vienna test system)) need to be administered in order to investigate 
whether patients show basal cognitive impairments they need to compensate for, 
such as attentional deficits, slowed speed of information processing or impairments in 
basal aspects of EF. In addition, neuropsychological tests for EF that are more complex 
and having a higher ecological validity (i.e. resembles the use of EF in everyday life to 
a greater extent) are essential to determine which impairments in higher-order EF 
form a problem in everyday life. Neuropsychological tests that provide patients with 
relatively little structure and do not involve high time pressure are suitable to use for 
this purpose. The Behavioural Assessment of the Dysexecutive Syndrome (Wilson et 
al., 1996) is a good example of such a test battery.  
In order to get a more comprehensive view of related restrictions in everyday 
life in terms of complaints and performance, it is essential to add subjective measures 
(Chapter 3). Neuropsychological tests assess patients’ optimal performance, whereas 
subjective measures such as questionnaires ask for patients’ experienced burden of 
impairments in EF and offer the possibility to ask for those aspects of EF that are 
difficult to measure quantitatively such as initiative. To select patients for treatment 
subjective rather than objective measures will be helpful. Many patients with 
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complaints do not necessarily show impairments on the respective tests but 
experience some burden that motivates them for seeking support. Subjective 
questionnaires, such as the DEX questionnaire, that assess whether patients or 
relatives already report complaints about EF in everyday life are more important to 
include patients than impairment based on low scores on tests. In line with previous 
studies, we found no indications for an impaired self-awareness and thus PD patients’ 
self-report on subjective measures must be considered as reliable. 
A clinical interview with patients and their partners or relatives forms also an 
essential subjective element within the diagnostic process of impairments of EF. 
Assuming that loss of initiative is probably the core feature of impairment in EF, it is 
important to explicitly ask patients and their relatives if and how they perceive 
problems with this in everyday life. Subsequently, information can be derived on the 
severity of this initiative problem. For instance, one can ask if patients are still able to 
make a feasible day planning or whether they frequently experience a lack of time in 
everyday life situations. Relevant questions for relatives are whether they experience 
that patients have difficulty starting activities in the first place and whether they have 
to provide the patient with external structure (i.e. give clear instructions) to actually 
get activities done. We believe that the more patients depend in everyday life 
activities on external structure as provided by relatives, the more severe their 
initiative problem. In turn, this gives valuable information about what would be 
realistic goals for treatment and can even determine what kind of cognitive treatment 
programme (i.e. skills training versus strategy training) would be most beneficial.  
With regard to the decision process of what kind of treatment would be most 
beneficial for patients with PD, it is also important to take patients’ individual 
executive goals into account. Individual goals can be seen as a reflection of what 
would contribute to patients’ participation and QoL. When someone is still actively 
participating in societal domains (e.g. work) and able to learn and use strategies, then 
a goal can be to fulfill the societal roles as long as possible. However, a more severely 
affected patient who needs already a lot of external structure would be pleased when, 
given his or her increased dependency, he or she would be able to perform a few 
specific everyday life activities independently. In the first example strategy training 
would be preferred, whether in the second example skills training might be a better 
option.   
Conclusions and future perspectives  
We are convinced that in clinical practice objective (neuropsychological tests) and 
subjective measures (questionnaires and the clinical interview) have mutual added 
value when determining whether and to what extent patients with PD show and 
experience impairments in EF. Disease severity, current level of participation in 
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societal domains and the presence and severity of initiative problems (as core aspect 
of EF in PD) are considered crucial factors for determining what kind of cognitive 
treatment for impairments in EF is most likely to be successful for the individual 
patient. We suggest to provide strategy training for relatively young (<60 years) 
patients in the early stages of PD (or even the novo patients) who are still actively 
participating in societal domains and already report complaints about impairments in 
EF, without the necessity of objective impairments in EF. Older patients with a mild to 
severe disease severity who show evident initiation problems and a low level of 
societal participation might benefit from skills training only. Older patients with a mild 
disease severity and mild initiation problems who are not actively participating in 
societal domains (such as the patient group in this study) may benefit from strategy 
training or function training in terms of improving their self-efficacy.  
This study is the first evaluating strategy treatment for EF deficits in PD and 
can be considered as pioneer work within the broad field of neuropsychological 
rehabilitation in neurodegenerative diseases. Our main finding was that patients with 
PD may benefit from neuropsychological treatment, either strategy or function 
training. Hence, the important message is that cognitive rehabilitation should be 
considered as a valuable treatment option for patients with PD despite the 
progressive course of the disease. Future research is needed to optimize the selection 
criteria for patients with PD most likely benefiting from cognitive rehabilitation. E-
health solutions very likely will improve the availability of cognitive training 
programmes and lower the threshold to participate. Participation of spouses or 
relatives in the cognitive treatments should be considered as a pivotal ingredient of 
these therapies. Teaching relatives will provide optimal external structure, especially if 
patients start to show more EF dysfunction during the course of their disease. Future 
treatment programmes will also benefit from collaboration between all disciplines 
involved in health care for patients with PD, like (neuro)psychologists, 
physiotherapists and occupational therapists) (Sturkenboom et al., 2014). In 
conclusion, the main goal of an effective intervention should be to maintain the 
current level of cognitive functioning as long as possible. 
  
529605-L-sub01-bw-Vlagsma
Processed on: 11-3-2019 PDF page: 135
 
Summary and general discussion 
 
135 
7 
References 
Bowen, P. G., Clay, O. J., Lee, L. T., Vice, J., Ovalle, F., & Crowe, M. (2015). Associations of social 
support and self-efficacy with quality of life in older adults with diabetes. Journal of 
Gerontological Nursing, 41(12), 21-9; quiz 30-1. doi:10.3928/00989134-20151008-44 [doi] 
Spikman, J. M., Boelen, D. H., Lamberts, K. F., Brouwer, W. H., & Fasotti, L. (2010). Effects of a 
multifaceted treatment program for executive dysfunction after acquired brain injury on 
indications of executive functioning in daily life. Journal of the International 
Neuropsychological Society : JINS, 16(1), 118-129. doi:10.1017/S1355617709991020; 
10.1017/S1355617709991020 
Sturkenboom, I. H., Graff, M. J., Hendriks, J. C., Veenhuizen, Y., Munneke, M., Bloem, B. R., . . . OTiP 
study group. (2014). Efficacy of occupational therapy for patients with parkinson's disease: A 
randomised controlled trial. The Lancet.Neurology, 13(6), 557-566. doi:10.1016/S1474-
4422(14)70055-9 [doi] 
Wilson, B. A., Alderman, N., Burgess, P. W., Emslie, H., & Evans, J. J. (1996). Behavioural assessment 
of the dysexecutive syndrome. Bury St. Edmunds: Thames Valley Test Company. 
Wu, T., Hallett, M., & Chan, P. (2015). Motor automaticity in parkinson's disease. Neurobiology of 
Disease, 82, 226-234. doi:S0969-9961(15)00232-6 [pii] 
Ylvisaker, M. (1998). Traumatic brain injury rehabilitation: Children and adolescents. Boston: 
Butterworth Heinemann. 
  
 
 
 
 
529605-L-sub01-bw-Vlagsma
Processed on: 11-3-2019 PDF page: 136
 
 
 
 
 
 
 
 
 
  
529605-L-sub01-bw-Vlagsma
Processed on: 11-3-2019 PDF page: 137
 
 
 
 
 
     

 
 
 
 
529605-L-sub01-bw-Vlagsma
Processed on: 11-3-2019 PDF page: 138
 
    
 
138 
Ziekte van Parkinson 
De idiopathische ziekte van Parkinson (ZvP) is na de ziekte van Alzheimer de meest 
voorkomende neurodegeneratieve ziekte. Het klinische beeld van de ZvP kenmerkt 
zich door motorische symptomen, zoals bradykinesie (traagheid en verminderde 
amplitude van bewegen), akinesie (bewegingsarmoede), rusttremor, rigiditeit en 
houdingsinstabiliteit. Voorts kunnen er zich een variëteit aan niet-motorische 
symptomen voordoen, zoals cognitieve stoornissen, neuropsychiatrische stoornissen 
(bijv. stemmingsstoornissen en hallucinaties), autonome disfuncties (bijv. 
orthostatische hypotensie), slaapstoornissen en vermoeidheid. Deze niet-motorische 
symptomen kunnen het zelfstandig functioneren van patiënten sterk belemmeren, 
evenals hun relatie met naasten. De Parkinsonistische symptomen worden 
hoofdzakelijk veroorzaakt door een progressieve degeneratie van dopamine 
producerende neuronen in de substantia nigra en ventrale tegmentum, welke 
onderdeel uitmaken van de basale ganglia. Daarnaast spelen veranderingen in 
noradrenerge, serotonerge en cholinerge transmittersystemen ook een rol in de 
etiologie van de de ZvP. De substantia nigra en ventrale tegmentum maken deel uit 
van de frontostriatale netwerken, waarin dopamine onmisbaar is. Binnen deze 
netwerken kan men een scheiding aanbrengen tussen het sensomotorische netwerk 
dat vooral van belang is voor motorisch functioneren, het associatieve-cognitieve 
netwerk dat betrokken is bij cognitieve en executieve functies en het limbische 
netwerk dat betrokken is bij het reguleren van emoties en besluitvorming. Wanneer 
bij patiënten met de ZvP de dopamineproductie afneemt zal dit dus niet alleen 
resulteren in problemen op het gebied van motorisch functioneren, maar ook op het 
gebied van cognitief functioneren en gedrag. Hierbij is de cognitieve achteruitgang het 
grootst wanneer er in het brein behalve een afname van dopamine, ook sprake is van 
een niet optimaal functionerend cholinerg systeem. 
Cognitieve stoornissen bij patiënten met de ZvP 
Bij 25% van de patiënten met de ZvP is sprake van milde cognitieve stoornissen, die 
vaker voorkomen naarmate het ziekteproces vordert. Aan de definitie van milde 
cognitieve stoornissen (MCI) wordt volgens de Movement Disorders Task Force 
voldaan als er sprake is van 1) een geleidelijke verslechtering van cognitief 
functioneren, zoals gerapporteerd door de patiënt, naaste of behandelaar, 2) 
objectieve cognitieve stoornissen zoals gemeten met neuropsychologische testen of 
screeninginstrumenten voor algemeen cognitief functioneren en 3) wanneer de 
stoornissen niet substantieel interfereren met het dagelijks functioneren. Verder 
wordt er een onderscheid gemaakt tussen MCI waarbij er stoornissen geobjectiveerd 
worden in een of meerdere cognitieve domeinen (“single versus multiple domain”) en 
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tussen types waarbij er al dan niet sprake is van geheugenstoornissen (“amnestic 
versus non-amnestic”). Uit onderzoek blijkt dat niet-amnestische MCI vaker voorkomt 
dan amnestische MCI binnen de groep patiënten met de ZVP, waarbij stoornissen in 
executieve functies (EF) het meest voorkomen.  
Executieve functies 
Zoals beschreven komen cognitieve stoornissen en in het bijzonder stoornissen in de 
executieve stoornissen vaak voor bij patiënten met de ZvP vanwege toenemend 
disfunctioneren van dopaminerge frontostriatale netwerken in het brein. Executieve 
stoornissen kunnen zich al manifesteren in de beginfases van de ziekte en worden 
soms al vastgesteld op het moment van diagnose.   
EF zijn hogere orde functies die ons in staat stellen om doelgericht te 
handelen, realistische doelen te stellen en ons gedrag aan te passen aan 
veranderende omstandigheden. Vooral in nieuwe, niet-routinematige en complexe 
situaties wordt er een beroep gedaan op EF. In dit proefschrift worden EF als volgt 
gedefinieerd: zelfinzicht, het kunnen stellen van realistische en concrete doelen, 
planning van benodigde deelstappen, initiatiefname, het monitoren van eigen gedrag, 
het kunnen inhiberen van gedrag dat niet tot het doel leidt, flexibiliteit en strategisch 
gedrag ofwel het kunnen generaliseren van succesvol gedrag naar andere, 
soortgelijke situaties.  
Diagnostiek van executieve functies 
Neuropsychologische tests worden veelal gebruikt voor het objectiveren van 
stoornissen in EF. Deze tests worden afgenomen in een gestandaardiseerde setting, 
waarbij mogelijke bronnen van externe afleiding worden geminimaliseerd. Dit 
bemoeilijkt echter het in kaart brengen van EF, omdat er op deze functies juist een 
beroep wordt gedaan in nieuwe, niet-routinematige, complexe en ongestructureerde 
situaties. De ecologische validiteit van standaard neuropsychologische taken (bijv. 
Trailmaking Test en Stroop Kleur-Woord test) wordt daarom laag geschat. Het gebruik 
van de testbatterij Behavioural Assessment of the Dysexecutive Syndrome (BADS) 
wordt daarentegen vanwege een hogere ecologische validiteit aangeraden. 
Vragenlijstonderzoek is een andere, meer subjectieve methode om EF in kaart te 
brengen. Middels vragenlijsten (bijv. Dysexecutive syndrome vragenlijst - DEX) kan 
men de mate en ernst bepalen waarin patiënten en hun naasten executieve 
stoornissen bemerken in het dagelijks leven. Mogelijk wordt op deze manier een meer 
realistische kijk verkregen op executieve problemen dan middels afname van 
neuropsychologische tests, omdat de lijsten rechtstreeks vragen naar de beleving van 
deze problemen in het dagelijks functioneren.  
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EF en de relatie met  dagelijks functioneren en kwaliteit van 
leven  
Uit onderzoek is bekend dat er verscheidene executieve stoornissen voor kunnen 
komen bij patiënten met de ZvP. Problemen met het bewust sturen van de aandacht, 
flexibiliteit, planning, inhibitievermogen, probleemoplossend vermogen, multitasken, 
besluitvormingsprocessen en sociale cognitie worden het meest beschreven. Het zijn 
juist deze functies die essentieel zijn om dagelijkse activiteiten te kunnen plannen, 
organiseren en uit te voeren. Het zelfstandig functioneren van patiënten met de ZvP 
die eveneens kampen met stoornissen in EF wordt daardoor ernstig belemmerd en 
heeft een lagere kwaliteit van leven tot gevolg.  
Neuropsychologische behandeling 
De Wereldgezondheidsorganisatie stelt in haar ICF (International Classification of 
Functioning) model dat een ziekte het functioneren van een patiënt op verschillende 
niveaus beïnvloedt: op functieniveau, activiteitenniveau en participatieniveau. 
Neuropsychologische behandeling helpt patiënten om te gaan met de cognitieve, 
emotionele, sociale en gedragsmatige gevolgen van (niet-aangeboren) hersenletsel en 
waar mogelijk deze gevolgen in te perken. Cognitieve revalidatie is onderdeel van 
neuropsychologische behandeling en bestaat doorgaans uit psycho-educatie, het 
maken van aanpassingen in de leefomgeving van een patiënt en cognitieve training. 
Cognitieve training onderscheidt trainingen op drie niveaus: functietraining (middels 
herhaalde oefening van taken trachten onderliggende functies te verbeteren), 
vaardigheidstraining (herhaalde oefening van specifieke dagelijkse taken met als doel 
de uitvoer van deze specifieke taken te verbeteren) en strategietraining (gebruik 
maken van intacte cognitieve functies om strategieën ter compensatie van cognitieve 
stoornissen aan te leren). Strategietraining overstijgt het niveau van functie- en 
vaardigheidstraining en richt zich van alle typen training het meest op het verbeteren 
van het participatieniveau. In recente literatuur wordt voornamelijk strategietraining 
effectief bevonden en aanbevolen als behandeloptie voor patiënten met niet-
aangeboren hersenletsel en executieve stoornissen. Voor patiënten met de ZvP maakt 
cognitieve revalidatie echter nog geen deel uit van de standaard behandelopties, 
terwijl zij eveneens worden gehinderd door executieve stoornissen in het dagelijks 
leven.  
In het proefschrift dat voor u ligt staan twee hoofdvragen centraal. De eerste 
vraag is diagnostisch van aard: in een groep patiënten met de ZvP wordt onderzocht 
welke stoornissen in EF kenmerkend zijn, op welke manier diagnostiek ingezet kan 
worden om deze stoornissen in kaart te brengen en hoe deze stoornissen interfereren 
in het dagelijks functioneren. Hierbij werd de hypothese gesteld dat de aard van de 
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stoornissen in EF gelijkenis toont met apathie en deels verklaard kan worden door 
onderliggende traagheid van informatieverwerking bij motorische en cognitieve 
processen. De tweede vraag richt zich op behandeling van executieve stoornissen: kan 
cognitieve behandeling tot verbetering leiden ten aanzien van executieve stoornissen 
in het dagelijks leven voor patiënten met de ZvP. Hierbij wordt verwacht dat een 
cognitieve behandeling bestaande uit strategische training (ReSET) effectiever is dan 
een behandeling gericht op training van specifieke cognitieve functies (Cogniplus).  
Het primaire doel van de studie zoals beschreven in hoofdstuk 2 was om te 
onderzoeken of mentale traagheid (bradyfrenie) onderscheiden kan worden van 
motorische traagheid (bradykinesie) bij patiënten met de ZvP. Met het begrip 
bradykinesie wordt in deze studie specifiek de traagheid van bewegen bedoeld (en 
niet: verminderde amplitude). Deze vraag werd onderzocht met gebruik van een 
eenvoudige reactietijdentaak (Vienna Test Systeem), waarbij de respons gescheiden 
werd in een mentale component (reactietijd) en een motorische component 
(motorische tijd). Indien mentale traagheid werd geobjectiveerd, was een tweede 
vraag in hoeverre mentale traagheid bij patiënten met de ZvP een voorspeller is van 
de prestaties op neuropsychologische tests. Verrassend genoeg werden er geen 
significante verschillen gevonden tussen de motorische tijden van patiënten en 
gezonde controles. De reactietijden van patiënten waren wel significant trager dan die 
van de gezonde controles. Op basis van deze uitkomsten concludeerden we dat 
patiënten met de ZvP behalve motorische traagheid inderdaad mentale traagheid 
kunnen vertonen. Verder bleek dat binnen de patiëntengroep reactie- en motorische 
tijden niet correleerden met klinisch maten van ziekte-ernst (H&Y en UPDRS-III). 
Mentale traagheid vormde geen voorspeller voor patiënten hun prestaties op 
neuropsychologische tests. De motorische tijden waren wel een voorspeller voor de 
prestatie op twee aandachtstests (TMT A en Stroop Kleur-Woord/Kleurkaart ratio). Dit 
impliceert dat er voor Parkinsonpatiënten bij de interpretatie van resultaten op deze 
tests rekening gehouden dient te worden met eventuele motorische traagheid, omdat 
dit de resultaten kan vertroebelen. 
In hoofdstuk 3 werd onderzocht in een groep niet dementerende patiënten 
met de ZvP of er een relatie bestaat tussen de uitkomsten van objectieve maten voor 
EF (neuropsychologische tests) en de uitkomsten van subjectieve maten 
(vragenlijsten) voor EF. Daarnaast werd onderzocht of executieve stoornissen 
(gemeten met objectieve dan wel subjectieve maten) een voorspeller zijn voor het 
niveau van participatie en de kwaliteit van leven van patiënten met de ZvP. De 
resultaten lieten zien dat er geen significante correlaties gevonden werden tussen 
uitkomsten van objectieve en subjectieve maten voor EF. Hieruit concludeerden we 
dat beide typen maten informatie verschaffen vanuit een ander perspectief en elkaar 
aanvullen. Bovendien leveren beide typen maten een unieke bijdrage aan het 
voorspellen van het participatieniveau en de kwaliteit van leven van patiënten met de 
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ZvP. Daarnaast kwamen sekse en ernst van de ziekte als matige voorspellers naar 
voren.  
In hoofdstuk 4 werd onderzocht of er legitieme redenen zijn om 
strategietraining niet als standaard behandeloptie aan te bieden voor patiënten met 
de ZvP met executieve stoornissen. Allereerst werd onderzocht of patiënten met de 
ZvP verschillen van patiënten met niet-aangeboren hersenletsel (NAH) in termen van 
hun cognitieve en executieve profiel (prestatie op neuropsychologische tests) en in 
termen van hun behoeften en vragen voor behandeling gericht op executieve 
stoornissen (individuele behandeldoelen). Beiden groepen ondergingen een 
uitgebreid neuropsychologisch onderzoek. Daarnaast werden patiënten hun doelen 
geclassificeerd in domeinen van EF en erna in domeinen van algemeen dagelijks 
functioneren en participatie. Uit de resultaten komt naar voren dat de 
patiëntengroepen een vergelijkbaar cognitief en executief profiel laten zien en 
vergelijkbare doelen stellen. Patiënten met de ZvP stelden meer doelen gerelateerd 
aan “time management” (aspect van EF) en “huishouden en tuinieren” (domeinen 
dagelijks functioneren) dan patiënten met NAH. Verder waren er geen significante 
verschillen tussen beide groepen. Concluderend, werden er geen argumenten 
gevonden voor de aanname dat patiënten met de ZvP niet kunnen profiteren van 
strategietraining voor executieve stoornissen. 
Hoofdstuk 5 beschrijft een review over cognitieve revalidatie bij patiënten 
met de ZvP. Er werden negen studies geschikt bevonden om te includeren, die in de 
periode 2004 tot en met 2013 zijn uitgevoerd. In het bijzonder is er aandacht besteed 
aan de mate waarin de onderzochte cognitieve behandelingen zich richtten op het 
verbeteren van EF, aangezien deze executieve stoornissen bij de ZvP op de voorgrond 
staan. De afzonderlijke studies zijn beoordeeld op basis van methodologische kwaliteit 
en effectiviteit. Daarnaast werden de cognitieve behandelingen geclassificeerd op 
basis van het type training dat centraal stond in de behandeling (functietraining, 
vaardigheids- en/of strategietraining). Ook de uitkomstmaten werden gecategoriseerd 
in drie categorieën, gebaseerd op het ICF model: maten op functieniveau, 
activiteiten/participatieniveau en maten gerelateerd aan persoonlijke factoren. Uit de 
resultaten blijkt dat de meerderheid van de studies van goede methodologische 
kwaliteit is en dat de beschreven behandelingen leiden tot een verbetering van het 
cognitief functioneren in termen van een verbeterde prestatie op 
neuropsychologische tests (functieniveau). Echter, zowel de behandelingen als de 
uitkomstmaten beperken zich in de meeste studies tot meten op functieniveau. Er is 
daarom nog onvoldoende inzicht in de mate waarin de gevonden effecten 
generaliseren naar het dagelijks functioneren. Voorts werd er relatief weinig 
specifieke aandacht gericht op het verbeteren van EF (in het dagelijks leven). Omdat 
strategietraining voor executieve stoornissen effectief is gebleken voor patiënten met 
NAH, stellen we dat toekomstig onderzoek nodig is om uit te zoeken in hoeverre 
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strategietraining ook effectief is voor het verbeteren van executief functioneren in het 
dagelijks leven, participatie in maatschappelijke domeinen en de kwaliteit van leven 
van patiënten met de ZvP.  
Hoofdstuk 6 beschrijft de resultaten van een RCT naar de effectiviteit van 
ReSET; a Strategic Executive Treatment (strategietraining) in vergelijking met een 
gecomputeriseerde functietraining (Cogniplus) bij een groep patiënten met de ZvP. 
Twee weken (nameting) en drie tot vijf maanden (follow-up) na de behandeling, 
rapporteerden patiënten in beide groepen een vooruitgang in de gestelde doelen en 
rapporteerden ze minder klachten omtrent executief functioneren in het dagelijks 
leven. Alleen ten tijde van de nameting was deze subjectief ervaren vooruitgang 
significant groter in de ReSET groep dan voor de patiënten in de Cogniplus groep. De 
naasten van patiënten in beide groepen rapporteerden na de behandeling echter niet 
een ervaren afname van de executieve problemen in het dagelijks functioneren van 
de patiënt. Daarom werd gesteld dat de gerapporteerde vooruitgang van patiënten 
geïnterpreteerd zou kunnen worden als een toename van self-efficacy (vertrouwen 
dat iemand heeft in zijn/haar vermogen om specifiek gedag uit te voeren), dat 
blijkbaar voor diens naasten niet concreet observeerbaar was in het dagelijks 
functioneren. Zowel ReSET als Cogniplus brachten geen veranderingen teweeg op 
participatieniveau en in de kwaliteit van leven. Dit betekent dat, in tegenstelling tot 
voor patiënten met NAH, er onvoldoende bewijs werd gevonden voor de hypothese 
dat strategietraining effectiever is dan functietraining voor het verbeteren van 
executief functioneren in het dagelijks leven, participatieniveau en de kwaliteit van 
leven van patiënten met de ZvP. Voor toekomstig onderzoek is het van belang om 
meer inzicht te krijgen in welke subgroep van patiënten met de ZvP en executieve 
stoornissen het meest profiteert van welk type behandeling, in termen van 
verbetering in het dagelijks functioneren en de kwaliteit van leven. 
Dit proefschrift besluit met een algemene discussie in hoofdstuk 7, waarin de 
nadruk ligt op de implicaties van onze studies voor de klinische praktijk. Voorts 
worden er aanbevelingen beschreven voor toekomstig onderzoek, gebaseerd op de 
klinische inzichten die wij verkregen hebben tijdens de uitvoering van de studies zoals 
beschreven in de afzonderlijke hoofdstukken. 
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Dankwoord 
Jarenlang heb ik uitgekeken naar het moment waarop ik mijn dankwoord mocht gaan 
schrijven, om precies te zijn acht jaren lang. Acht jaren staan gelijk aan de duur van 
een basisschoolperiode, twee wetenschappelijke studies, twee termijnen van een 
Amerikaanse president, vier Olympische spelen en acht keer de vier seizoenen. Voor 
mij waren het acht jaren met vele persoonlijke hoogtepunten, maar ook met moeilijke 
periodes. Tijd om deze periode af te sluiten, maar niet alvorens een heel aantal 
mensen in mijn omgeving te bedanken zonder wie ik niet op dit punt zou zijn 
aanbeland.  
 
Beste Joke, in de eerste plaats ben jij vanaf het begin mijn begeleider geweest, maar 
gaandeweg de jaren is onze band steeds hechter geworden. Het laatste jaar ging dan 
wel gepaard met tegenslag, maar het was waardevol om te ervaren hoe steunend we 
voor elkaar konden zijn. Ik wil je bedanken voor het vertrouwen dat je altijd in mij 
hebt gehouden en hebt getoond! Fijn was het dat ik te allen tijden bij je binnen kon 
lopen voor vragen en daarnaast natuurlijk ook dank voor jouw kritische 
wetenschappelijke blik op mijn stukken en kennis van de neuropsychologie, waar ik 
veel van heb geleerd. Daarnaast heb ik het altijd bewonderd dat je naast het 
gezinsleven een succesvolle carrière hebt, die er tijdens mijn traject toe leidde dat je 
van begeleider promoveerde naar promotor. Hopelijk houden we nog lang contact! 
 
Leden van de leescommissie: prof. dr. M.A.J. de Koning-Tijssen, prof. dr. B.A. Schmand 
en prof. dr. C.M. van Heugten, hartelijk dank voor het lezen en beoordelen van mijn 
proefschrift.   
 
Annelien en Hilde, ik wil jullie bedanken voor alle tijd die jullie hebben geïnvesteerd in 
het werven en behandelen van patiënten met de ziekte van Parkinson van het 
noorden tot zuiden des lands. Waar ik jarenlang vijf dagen per week aandacht kon 
geven aan dit onderzoek, moesten jullie het combineren met alle andere klinische 
werkzaamheden, onderwijs- en andere onderzoekstaken. Ik heb me beseft dat dit 
voor jullie een lastige taak was. Annelien, dank dat je uit het zuiden afreisde om mij bij 
te staan tijdens de moeilijkste anderhalf uur van de afgelopen acht jaren. Dat 
waardeerde ik zeer. Meriam den Ouden en Marly Strijkers, dank voor het 
neuropsychologisch onderzoek dat jullie in het kader van mijn onderzoek hebben 
verricht in Drachten en Maastricht. 
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Teus, met jouw volle agenda was het een uitdaging om daar een gaatje in te vinden. Ik 
heb soms letterlijk voor je deur staan posten, maar de momenten dat je kon 
overleggen waren altijd van toegevoegde waarde. Met jouw jarenlange klinische- en 
onderzoekservaring op het gebied van de ziekte van Parkinson wist je vaak een andere 
invalshoek te belichten, maar ook had je aandacht voor talige details. Voorts wil ik 
graag mijn waardering uitspreken voor jouw morele steun en vertrouwen het 
afgelopen jaar. Tot slot wil ik je bedanken voor het (samen met Martje Drent) werven 
van patiënten op de afdeling neurologie in het UMCG. En natuurlijk voor het feit dat je 
de rol als promotor op je hebt willen nemen. 
 
Harriët Smeding, in de beginfase van het onderzoek ben je betrokken geweest om het 
behandelprotocol vorm te geven. Bedankt voor je klinische blik en ideeën.  
 
Het meest belangrijk om te bedanken zijn de patiënten met de ziekte van Parkinson 
die bereid waren om deel te nemen aan mijn behandelstudie. Zonder hen zou er nu 
geen proefschrift liggen en was het mij niet gelukt om mijn motivatie tot het einde te 
behouden. Met bewondering heb ik al hun persoonlijke verhalen, maar ook die van 
partners en soms andere familieleden aangehoord over wat voor impact de ziekte van 
Parkinson heeft op het alledaagse leven in al zijn facetten. Veel moed, 
doorzettingsvermogen en optimisme is nodig van patiënten en naasten om het leven 
kleur te blijven geven als je (of je naaste) lijdt aan een ziekte die je zelfstandigheid 
stukje bij beetje inbindt. Bedankt voor al jullie openheid en inzet. Partners en 
familieleden, bedankt dat jullie bereid waren om patiënten naar het ziekenhuis te 
brengen voor behandelsessies en testdagen.  
 
Ik wil de Parkinson vereniging graag bedanken voor het verstrekken van een subsidie, 
waarmee reiskosten konden worden vergoed voor patiënten die deel namen aan de 
studie.  
 
In 2014 heb ik me een periode mogen aansluiten als vrijwilliger bij het Parkinson café 
in Groningen, waar patiënten en hun naasten bijeen komen om informatie te krijgen 
van hulpverleners, maar vooral voor het lotgenotencontact en deelname aan sociale 
activiteiten. Miranda van Beveren, Thea de Haan, Vally Hardenberg en Greetje 
Teuben, jullie bevlogenheid en betrokkenheid bij deze doelgroep was zeer 
bewonderenswaardig om van dichtbij mee te maken. Ik vond het heel mooi om te 
zien hoe jullie, naast je rol als hulpverlener, ook als mens een steentje bijdroegen aan 
het welbevinden van patiënten en hun omgeving. Het was voor mij een leerzame 
ervaring om bij jullie te mogen aansluiten en bovenal ongedwongen gezellig! 
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Tijdens het onderzoek had ik ook niet zonder de hulp van verscheidene 
psychologiestudenten gekund, die verantwoordelijk waren voor het afnemen van 
neuropsychologische tests en vragenlijsten bij patiënten en gezonde proefpersonen. 
Inmiddels zullen jullie allen zelf al enige tijd werkzaam zijn als psycholoog, maar 
Brenda Goldhoorn, Loes Keur, Tessa Jansen, Anneroos Dekker, Lars Röben, Iris 
Bergman, Diniek Kanis, Annemarie Slim, Annemiek Breshamer en Ruben Bakker 
bedankt!  
 
De eerste helft van mijn promotietraject maakte ik actief deel uit van de vakgroep 
Clinical and Developmental neuropsychology van de faculteit Gedrags- en 
Maatschappijwetenschappen aan de Rijksuniversiteit Groningen. In het bijzonder wil 
ik de secretaresses Josje de Roo en Jolanda Polling bedanken voor de ondersteunende 
taken die zij hebben verricht gedurende mijn onderzoek. Verder wil ik José Heesink, 
Kees Aarts en Anke Bouma, dank voor jullie luisterend oor en steun in verschillende 
vormen.  
 
Mijn onderzoek werd mede gefinancierd door het Nationaal Initiatief Hersenen en 
Cognitie (NIHC) van NWO en maakte in dat kader deel uit van het landelijke 
consortium cognitieve revalidatie. In het bijzonder wil ik Carolien van Heugten 
bedanken als projectleider van het consortium. Ieke, Hileen, Marieke en Dirk, het 
contact met jullie als medeonderzoekers heb ik al die jaren erg waardevol gevonden. 
Niet alleen voor een stukje lotgenotencontact, maar vooral vanwege de gezellige 
borrels, etentjes en congressen waar we over onze persoonlijke levens bijkletsten. In 
de periode dat jullie de onderzoeken afrondden, liet mijn promotiefeest nog op zich 
wachten. Ik zette daar wel een trouwfeest tegenover waar jullie goed 
vertegenwoordigd waren. Super leuk dat jullie toen naar Ezinge in het hoge noorden 
zijn afgereisd!  
 
De meeste uren in ruim vier jaar heb ik zitten zwoegen in kamer 214 van het UMCG, 
maar gelukkig niet alleen. Mandy, Gera en Marjon, jullie hebben mij vanaf het eerste 
uur vergezeld. Mandy: OFF, do you still know me? ;). Thanks for all the moments of 
laughter and for your sarcasm, which put all our serious research stuff in perspective. 
Gera, goede herinneringen heb ik aan het congres in Bergen waar wij samen met 
Marjon een kamer deelden. Die 10 artikelen waar we het geregeld over hadden heb jij 
inmiddels ook echt geschreven. Marjon, wij zijn tot op de dag van vandaag partners in 
crime. Wat hebben we veel met elkaar gedeeld, niet alleen zaten we in hetzelfde 
schuitje dat RCT onderzoek heet, maar ook hebben we beide op persoonlijk vlak heel 
wat life events doorgemaakt. Waar we bij start van het onderzoek nog nagenoeg 
buren waren, zijn we inmiddels beiden verhuisd. We zijn beiden getrouwd. Jij kreeg  
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twee prachtige zoons en ook op dat vlak is de achtervolging ingezet. Het 10- jaren 
project waar we vaak grappend voor vreesden is het niet geworden, want ook voor 
jou staat de promotie op de planning. Dank voor alle inhoudelijke overlegmomenten 
en persoonlijke steun! Ons contact eindigt niet na de promoties; maar snel weer 
borrelen bij de Dame…of ergens anders ;). Buunk en Scheenen, jullie waren de tweede 
lichting kamergenootjes met wie ik in diezelfde kamer 214 zat. Jullie humor was een 
zeer prettige afleiding. 
 
Lieve collega’s van het MCL, sinds 2015 maak ik deel uit van de vakgroep Medische 
psychologie. Jullie hebben mij de gelegenheid gegeven om me verder te ontwikkelen 
als diagnosticus en behandelaar in de klinische praktijk. Zeker de afgelopen twee jaren 
waarin ik de kans kreeg om de GZ-opleiding te volgen. Mijn passie voor het vak is 
eigenlijk alleen maar toegenomen, door de prettige leeromgeving die jullie bieden, 
maar ook omdat ik me ontzettend tussen jullie thuis voel als persoon. Jullie steun 
afgelopen jaar was echt hartverwarmend en heeft me erg geholpen. Gerdien, Wytske 
en Jo-Anneke, ik wil jullie in het bijzonder bedanken voor jullie grote betrokkenheid, 
het aanhoren van mijn verhalen en bovenal de wijze levenslessen die ik van jullie heb 
geleerd. Ik hoop nog lang deel uit te maken van onze vakgroep!  
 
Ik had het vooraf nooit zo kunnen bedenken, maar een dag na de promotie zal ik het 
theoretische deel van mijn GZ-opleiding afronden. Mede GéZetters, bedankt voor al 
jullie klinische ervaring waar ik veel van heb geleerd én alle keren dat jullie oprecht 
geïnteresseerd waren in hoe het stond met ‘het onderzoek’. Linda, Rik, Linda S. en 
Zeljka, jullie lieve woorden (of unicorns en sterretjes Zeljka) op de juiste momenten 
hebben me heel goed gedaan, maar zeker ook de relativerende humor. Hopelijk 
houden we nog lang contact! 
 
Henk Albert en Thea, Mirjam Esther en Gerard, Anne Femke en Twan: ook al zijn we 
door onze drukke levens niet vaak bij elkaar, onze band is er niet minder om. Ook 
jullie toonden afgelopen jaar allemaal op je eigen manier betrokkenheid, dankjewel! 
Anne Fem, jij in het bijzonder bedankt voor het maken van de prachtige kaft (ook al 
heeft dat zo’n 10 bossen tulpen gekost)! Jij hebt die creatieve genen waarvan ik er 
geen enkele bezit, geweldig. Jaap Jan en Betty, Annemiek en Sander, oma Mienie, 
Pieter en Jeanette, Gert, Johan en Wessel: bedankt voor die Blumen en jullie voelbare 
steun! Ik voel me volledig onderdeel van de familie, ook al ben ik Fries en van de 
´koude kant´ (net als Pieter). 
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Leave heit en mem, doorzettingsvermogen, een sterk rechtvaardigheidsgevoel en 
eerlijkheid zijn eigenschappen die ik zonder twijfel van jullie heb meegekregen in het 
leven en zonder welke ik dit traject niet tot een goed einde had kunnen brengen. 
Ontzettend bedankt voor jullie onvoorwaardelijke steun, liefde en vertrouwen door 
de jaren heen. Vanaf nu is er weer één zorg minder.  
 
Renske en Jelle, Marion en Gerard, Boukje & Maryam, Jan-Willem en Nelleke, Cor en 
Linda, Klaas en Marion, Chris en Cindy, Rudy en Marloes, Jochem en Hanna, Anton en 
Jacquelien, Femke: bedankt voor alle ontspannende momenten tijdens de afgelopen 
jaren. Daarmee doel ik op wijntjes drinken, Japanner-etentjes met Japannerkoek en 
vliegende eieren, alle andere niet-Japanse etentjes, Chris zijn culinaire bbq 
uitspattingen, festivals, concerten, pubquizzen, wandelingen etc. Laten we deze 
vriendschappen nog jaren in standhouden! Renske en Marion, heel fijn dat jullie mij 
op het moment suprême bij willen staan als paranimfen.  
 
Dan rest er nog één iemand om te bedanken, aan wie ik minstens een pagina had 
kunnen wijden. Allerliefste Tjibbe, zo lang wij elkaar kennen ben ik bezig met dit 
promotieonderzoek. Jij bent het beste wat me in die jaren is overkomen en zonder jou 
was ik er zeker weten niet in geslaagd om het onderzoek af te ronden. Jij was er altijd 
voor me op de momenten dat het tegenzat. Mijn mentale veerkracht is door jouw 
onuitputtelijke positivisme en relativeringsvermogen exponentieel toegenomen door 
de jaren. Daarnaast was je mijn discussiepartner over inhoudelijke stof, vraagbaak 
over het maken van tabellen en Excel, mijn metgezel in het vieren van alle 
hoogtepunten (helaas de komende tijd geen publicatiedinertjes meer voor je) en 
data-entry medewerker haha. Ik ben je dankbaar voor de lay-out die er door jou zo 
netjes uit ziet. Ik hou van je en heb ontzettend veel zin om samen de nieuwe uitdaging 
in ons leven aan te gaan die over een paar maanden op ons wacht! 
 
En dan is het nu tijd om een punt te zetten achter deze leerzame tijd.   ● 
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Curriculum Vitae 
In het kleine watersportdorp Heeg in Friesland werd Thialda Teakje Vlagsma geboren op 
15 april 1987. Na haar Vwo-opleiding op Bogerman in Sneek, koos Thialda in 2005 voor 
de studie Psychologie aan de Rijksuniversiteit Groningen. Het studentenleven van 
Thialda was gevuld met gezelligheid, vrienden, sport, Grey’s Anatomy  en natuurlijk hard 
studeren voor de vele enerverende vakken die de studie Psychologie rijk was. Welke van 
deze factoren heeft geleid tot haar interesse in neuropsychologie is onduidelijk, maar 
het succesvol afronden van haar bacheloropleiding vloeide logischerwijs voort in een 
keuze voor de master Hersenen en Gedrag. Tijdens een klinische stage in 2009 in het 
UMCG gedurende deze master, maakte Thialda kennis met het doen van 
neuropsychologisch onderzoek bij diverse patiëntgroepen. In diezelfde periode voerde 
zij een onderzoeksproject uit bij jongvolwassenen die als kind waren behandeld voor 
een hersentumor naar de effecten van behandeling op arbeidsparticipatie en sociale 
cognitie. Ook werkte Thialda mee aan een normeringsonderzoek van de Nepsy-2. Een 
stageadres als het UMCG prikkelde haar leergierigheid en leidde tot een promotieplaats 
over cognitieve behandeling voor patiënten met de ziekte van Parkinson. Deze periode 
van promoveren bracht Thialda op vele bijzondere plekken. Presentaties over haar 
onderzoek werden gegeven op congressen in onder andere Finland, Oostenrijk, 
Zwitserland, Noorwegen en op Cyprus. Op laatstgenoemde twee locaties leidde dit zelfs 
tot indrukwekkende prijzen: een ‘Highly recommended award’ en een ‘Best datablitz 
award’. Ook heeft Thialda zich tijdens haar promotie ingezet als vrijwilliger voor het 
Parkinson Café en voor de organisatie van een symposium voor de sectie 
Neuropsychologie van het NIP. Haar ervaring en expertise heeft ze vervolgens toegepast 
bij Revalidatie Friesland in Beetsterzwaag, waar ze patiënten met niet-aangeboren 
hersenletsel heeft behandeld. Sinds 2015 werkt Thialda als psycholoog in het Medisch 
Centrum Leeuwarden op de afdeling Medische Psychologie. Hier verricht zij diagnostiek 
en behandelt zij verscheidene interessante patiëntgroepen en heeft ze haar klinische 
ervaring verder verbreed, onder andere door middel van haar (bijna afgeronde) GZ-
opleiding. 
 
Als metgezel van Thialda gedurende haar lagere school, middelbare school en 
studieperiode kan ik met volle overtuiging stellen dat Thialda een perfecte gespreks- en 
samenwerkingspartner is. Ik ben ontzettend trots dat ik zo veel jaren naast haar heb 
mogen zitten in klaslokalen en collegezalen in het noorden des lands en natuurlijk op 
het feit dat ze met het afronden van dit proefschrift zichzelf doctor mag noemen.  
 
Renske Zuurveen  
